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The prevalence of the haematological malignancies enumerates those currently 
living with past diagnosis of this class of diseases, and provides insights regarding 
survivor populations and their burden. However, there is a lack of accurate 
information regarding the prevalence of the haematological malignancies. This is 
partly because of changing disease classifications and the fact that the current 
methods available to estimate total prevalence have not always been appropriate 
due to the characteristics of the disease including age at diagnosis and the 
introduction of novel treatments that have altered outcomes.  
 
Using data from the Haematological Malignancy Research Network (HMRN) a 
method was developed to estimate the prevalence of the haematological 
malignancies, according to current disease classification, in HMRN region and for 
the UK as a whole. The method used a mathematical model and flexible statistical 
methods to estimate the total prevalence on 31st, August, 2011. 
 
Total prevalence estimates that about 19,700 cases in HMRN area are living with 
a prior diagnosis of haematological malignancy on the index date. Among them, 
about 9,600 living cases were diagnosed before the establishment of HMRN 
registry. Using observed prevalence, it was estimated that in the UK there are 
165,841 cases of haematological malignancies; however, total prevalence 
estimates 327,818 cases.  Subtypes showed different disease burdens due to their 
own characteristics. 
 
This thesis is the first study to calculate the prevalence of haematological 
malignancies using current disease classification (ICD-O-3). It provides indicators 
of real burden of haematological malignancies for each of the subtypes in HMRN 
area; these can then be extrapolated to the UK as a whole.  
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The prevalence of a disease in a population is the proportion of people who have 
received a diagnosis of that disease in the past and that are alive on a specified 
date, which is called the index date.  Unlike incidence, which can provide 
information on disease prevalence for diseases of short duration (the patient died 
or was cured), prevalence is more informative for diseases of relatively long 
duration. It helps to measure the burden of disease in a population and is an 
important measure for health and social care planning. Conceptually, it seems 
straightforward to obtain the prevalence of disease by counting the number of 
survivors of the disease alive at any point in time. There are, however, many 
methodological challenges associated with estimating disease prevalence and 
these will be discussed in the following chapter.   
 
1.1.1.1 Cancer registration 
 
This thesis is concerned with the prevalence of cancer. Obtaining accurate 
estimates of cancer prevalence requires either broad sampling by surveillance or 
estimates based on available registry data. For survey-based reporting, recall bias 
may lead to over or under reporting of diseases. The accuracy of self-reported 
data may vary by disease type, and the likelihood of misreporting is different 
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among subgroups of patients. Therefore, it is common and convenient to estimate 
cancer prevalence using data from cancer registries. 
  
Here, the term ―cancer registry‖ usually refers to a population-based cancer 
registry, which collects data on cancer occurring in a well-defined population. 
Information for these registries usually comes from treatment facilities, such as 
hospitals and private clinics, and diagnostic services, such as pathology 
departments, radiology departments and death certificates. Data can be actively 
obtained by personnel visiting different departments or passively by heath care 
workers notifying cancer registries. More recently, there is electronic capture of 
data, which may integrate cancer registration into the patient administrative 
systems (Gjerstorff, 2011). The data items collected are determined by the aims of 
the registry. These usually, but not only, include personal identification (such as 
name, sex, and date of birth), demographics (such as address and ethnicity), the 
cancer and its investigations (such as diagnosis, classification), treatment, and 
follow-up (Silva, 1999). Reporting of cancer cases to a registry may be voluntary, 
or compulsory by legislation or administrative order. Confidentiality should be 
taken into account to protect individual privacy (Jensen, et al., 1991).  
 
From registry data, information regarding patients‘ gender, age at diagnosis, 
cancer sites, and status at last follow-up can be obtained relatively easily. In terms 
of cancer registration it is generally assumed that once a patient has been 
diagnosed with cancer, they remain a prevalent case until death (Silva 1999). 
Within a registry, for example, the prevalence of a disease diagnosed within a 
limited duration can be captured conveniently from the available data. However, 
although it is relatively simple to calculate, this measurement may potentially lead 
to an underestimate of actual prevalence for diseases which have longer survival 
periods than spans the time period a registry has been in existence.  
 
When the registry has been in operation for many years, the prevalent cases may 
simply be enumerated from registry data. Therefore, within a cancer registry 
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observation period, such direct methods simply exploit incidence and life status to 
count the number of cancer patients living at a certain time in the population. 
However, this numerical direct method can only provide prevalence for L years 
(where L is the length of registry period). This is known as observed prevalence, 
which covers all patients diagnosed after the start of the registry. n-year 
prevalence measures the proportion of the population alive on the index date that 
have received a diagnosis of the disease in the period of n years before the index 
date. For example, 5-year prevalence is based on the most recent 5 years of 
available registry data. Both of these measure prevalence in limited durations, and 
may provide biased estimates of the total prevalence of the disease in the 
population. Developments of a method to estimate such a total prevalence (that 
is, the proportion of the population alive on the index date who have ever received 
a diagnosis of the disease), can correct for this bias and provide better guidance 
for the planning of health care services. (All definitions are described in section 
1.2.) 
 
The population-based cancer registry used in this thesis is the Haematological 
Malignancy Research Network (HMRN), and is further described in Chapter 
Three. 
 
1.1.1.2 Motivation for this work 
 
Despite many reports in the literature on the incidence, mortality and survival of 
cancer, relatively few studies exist describing prevalence (Merrill, et al., 2000; 
Capocaccia, et al., 2002; Verdecchia, et al., 2002; Forman, et al., 2003; Lutz, et al., 
2003; Möller, et al., 2003). n-year prevalence, which is  abstracted simply from 
registry data,  is the usual way that cancer prevalence is reported in the literature; 
such as 1-year prevalence, 5-year prevalence, and 10-year prevalence. Observed 
prevalence is highly related to the length of registry. Therefore, measures of 
observed prevalence are not comparable among different registries. Estimates 
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based on total prevalence are rarely reported, possibly reflecting the challenges 
associated with calculating prevalence using this method.  
 
The primary information gained from total prevalence is an understanding of the 
proportion of people in a given population on the index date who remain alive 
after having received a diagnosis of the certain diseases. As a vital indicator, 
cancer prevalence is a measure of the number of cancer patients who require 
health and social services resources, and can be used to adequately plan future 
allocation of such resources. It should be useful for government to make health 
care planning, and for doctors to know the cost for diseases (such as treatment 
cost and cost of monitoring activities). This study focuses on estimating 
prevalence for haematological malignancies based on registry data from HMRN. 
There is rare report about haematological malignancies due to the difficulties in 
classification and methodology. Additionally, the heterogeneity of the 
haematological malignancies and their treatments make it useful to estimate 
prevalence for subtypes.  For example, some of the subtypes such as myeloma can 
be treated as chronic disease (Barlogie et al., 2004).  So a patient may undergo 
treatment for their rest of their lives.  This is in contrast to other cancers, or other 
haematological malignancies such as diffuse large B- cell lymphoma where 
patients may be cured after first line treatment Sehn et al., 2005).  For subtypes 
such as monoclonal gammopathy of undetermined significance and monoclonal 
B-cell lymphocytosis, the patients are usually asymptomatic, and do not require 
treatment. However, the monitoring is needed for them for relatively long time 
(Marti et al., 2005; Shanafelt et al., 2010). In other words, the estimation of 
prevalence for different subtypes of haematological malignancy helps to make 







1.1.2 Haematological malignancies 
 
1.1.2.1 What are haematological malignancies? 
 
Haematological malignancies are a group of cancers associated with the blood, 
bone marrow, and lymph systems. It is useful to recall some basic facts about the 
operation of the blood and lymph systems. Blood cells are divided from stem cells. 
There are two main stem lineages: myeloid and lymphoid. Myeloid stem cells 
produce red cells, platelets and some types of white cell. Lymphoid stem cells 
produce two types of white cell: T-cells and B-cells (Hoffbrand, et al., 2006; 
Howard and Hamilton, 2007) (see Figure 1-1).  
 
                                                                        T-cells 
                               Lymphoid progenitor       B-cells              Plasma cells 
Hematopoietic                                              Neutrophils 
Stem cell                                                       Eosinophils 
                              Myeloid progenitor        Basophils 
                                                                     Monocytes 
                                                                     Platelets 
                                                                     Red cells 
Figure 1- 1 Haematopoiesis map of blood cells 
 
Haematopoiesis occurs in the bone marrow, and blood cells are released to the 
blood stream when they are mature enough. (Hoffbrand, et al., 2006; Howard and 
Hamilton, 2007). If something goes wrong in this process, especially during the 
various stages of differentiation, haematological diseases may occur. Generally, 
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from an anatomical perspective, if immature white blood cells fill up the bone 
marrow, preventing normal blood cells from being made, leukaemia occurs. 
Myeloma is associated with blood plasma, which is developed from B-
lymphocytes. Abnormal plasma cells accumulating in the bone marrow will 
interfere with the production of normal blood cells, destroying normal bone tissue 
and causing pain. Lymphoma results when a lymphocyte (either a B or T 
lymphocyte) undergoes a malignant change and multiplies out of control. 
Eventually, healthy cells are crowded out and malignant lymphocytes amass in 
the lymph nodes, liver, spleen or other sites in the body. Unlike other 
haematological malignancies lymphoma usually present as a solid tumour of 
lymphoid cells. (Hoffbrand, et al., 2006; Howard and Hamilton, 2007). 
Classification of haematological malignancies not only depends on the place and 
stage that errors have occurred, but is also related to other clinical factors such as 
immunophenotype and genetic abnormalities (HMRN, 2011). This classification 
is explored in more detail in the next section. 
 
1.1.2.2 Classification of haematological malignancy 
 
The classification of haematological malignancies is complex, and has changed 
over time as knowledge about the disease has developed. For lymphomas, the 
Rappaport classification developed in the mid- 1950s was purely based on 
morphology (Rappaport, 1966). In 1982, the Working Formulation (Rosenberg, et 
al., 1982) based on morphology and clinical prognosis became the standard 
classification in the U.S. During the same time period, a different classification 
called Kiel was being used in Europe (Lennert, 1978), which was based on cell 
lineage and lymphocyte differentiation. This lack of consensus on lymphoma 
classification made effective comparison between the U.S. and Europe almost 
impossible. Thus, the Revised European- American Lymphoma (REAL) 
classification that was published in 1994 by the International Lymphoma Study 
Group (ILSG) rapidly became the standard in all countries of the world (Harris, et 
al., 2000a). For leukaemia, the classification made by the French, American, and 
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British Cooperative Group (FAB) in 1976 was a milestone. This was based on 
morphology, cytochemistry, and immunophenotype (Bennett, et al., 1976).  
 
In 1995, the European Association of Pathologists and the Society for 
Haematopathology developed a new classification of haematological 
malignancies (Harris, et al., 2000b). In 2001, the World Health Organization 
(WHO) adopted the REAL classification for lymphomas and expanded the 
principle of REAL to the classification of myeloid malignancies, producing an 
international classification (known as the WHO classification) of haematological 
malignancies based on morphology, immunophenotype, genetic abnormalities and 
clinical features (Harris, et al., 2000a). This classification is incorporated into the 
International Classification of Diseases for Oncology (ICD-O-3) (Fritz, 2000), 
which codes tumours or cancers with site, morphology, behaviour, and grading of 
neoplasms.  
 
Although the WHO classification of haematological malignancies has been 
widely used in clinical practice around the world (Smith, et al., 2010), many 
population-based cancer registries still report under the broader classification 
definitions of ICD-10 (WHO, 1994). This is because, compared with other 
cancers, the complex data required to classify using ICD-O-3 is difficult for 
registries to access systematically and it is difficult to bridge code between 
classifications (Roman and Smith, 2011). In the literature, data on haematological 
malignancies are traditionally presented using the conventional groupings of 
leukaemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma (Ferlay, 
et al., 2010; NORDCAN, 2010; NCIN, 2012; SEER, 2012). However, there may 
be diversities within one traditional category, for example different prognoses and 
age distributions. Furthermore, one category may contain a mix of lineage. The 
broad category of leukaemia contains both myeloid and lymphoid leukaemias 
(Figure 1- 2). In addition, it includes both precursor and mature B-cell and T-cell 
subtypes which again are of considerable significance for the interpretation of 
epidemiological data.  Myelodyplastic syndromes (MDS) and myeloproliferative 
neoplasms (MPN) are classified as D codes (classified as neoplasms of uncertain 
27 
 
behaviour) in ICD-10, but in fact, they have been clinically recognized as 
malignancies for at least a decade (Fritz, 2000). Presentation of haematological 
malignancies in this traditional broad way may be of little value for health 
resource allocation and for making comparisons of outcomes due to the high level 
of diversity among the subtypes contained within each of the traditional groupings 
(Smith, et al., 2010). For example, mantle cell lymphoma and follicular 
lymphoma appear to have little in common in incidence and survival, therefore 
there may be doubts about of the usefulness of epidemiological studies that do not 






                                 Myeloid                                                                                                             Lymphoid 
 
              
                Other                Leukaemia    Myeloma                 Leukaemia                   Non-Hodgkin lymphoma       Hodgkin lymphoma                                 Other 
 
                                                                               
         MPN   MDS    AML CMML  CML                   Hairy cell   CLL      ALL  T-cell                                                                MBL       MGUS     LPDs NOS 
                                                                                                                                                                                                    
                                APML                     Plasmacytoma     Precursor B    Precursor T   Mature B       Mature T        Mixed cellularity classical Hodgkin lymphoma 
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                                                                                                                                                                Lymphocyte-rich classical Hodgkin lymphoma 
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Figure 1- 2 The lineage of subtypes of haematological malignancies (Harris, et al., 2000b) (MPN: myeloproliferative neoplasms, MDS: myelodysplastic syndromes, CML: 
chronic myelogenous leukaemia, CMML: chronic myelomonocytic leukaemia, AML: acute myeloid leukaemia, ALL: acute lymphoblastic leukaemia, CLL: chronic 
lymphocytic leukaemia, MBL: monoclonal B-cell lymphocytosis, MGUS: monoclonal gammopathy of undetermined significance, LPDs NOS: lymphoproliferative disorder 
not otherwise specified, APML: acute promyelocytic myeloid leukaemia, MZL: marginal zone lymphoma, MCL: mantle cell lymphoma, DLBCL: diffuse large B-cell 
lymphoma, FL: follicular lymphoma[further classification and subtypes can be found in Section 3.1.2])
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1.1.2.3 Transformation of haematological malignancies 
 
Haematological malignancies have the ability to transform in to more aggressive 
subtypes. Within the myelodysplastic syndromes, for example, a general 
progression to more aggressive disease, acute myeloid leukaemia, is a relatively 
common pathway (Shi et al., 2004). Normally, immature cells known as ―blasts‖ 
make up less than five per cent of all cells in the marrow. In myelodysplastic 
syndromes, blasts often constitute more than five per cent of the cells, whilst the 
more aggressive subtype--acute myeloid leukaemia, has more than 20 per cent 
blasts in the marrow (Hoffbrand, et al., 2006; Howard and Hamilton, 2007). 
 
Lower grade subtypes may grow slowly, and remain stable for a long time (for 
example, follicular lymphoma) (Horning and Rosenberg, 1984). On the other 
hand, more aggressive subtypes have cancerous cells that multiply quickly (for 
example, diffuse large B-cell lymphoma) (Davies et al., 2007; Lossos et al., 2002). 
The designations ―indolent‖ and ―aggressive‖ are often applied to subtypes of 
non-Hodgkin lymphomas (Figure 1-3). The cells in indolent subtypes do not die 
off within their normal lifespan, and can sustain additional damage over time. 
This usually causes the cells to begin to grow rapidly, and makes the lower grade 
subtypes transform in to higher-grade subtypes. When a transformation occurs, 
there is a mix of indolent and aggressive cells, and the lower and higher grade 
diseases often coexist within the same patient. (Horning and Rosenberg, 1984; 
Kyle et al., 2010; Landgren et al., 2009; Lossos et al., 2002; Shanafelt et al., 
2010).  
 
 Indolent                                                                                      Aggressive  
 
 
Figure 1- 3 Examples of indolent and aggressive B-cell lymphoma 




Transformations tend to follow well-known pathways, for example, follicular 
lymphoma, which can transform into the more aggressive lymphoma called 
diffuse large B-cell lymphoma (Davies et al., 2007; Lossos et al., 2002). 
Myelodysplastic syndromes have a general progression to acute myeloid 
leukaemia (Shi et al., 2004). Monoclonal B-cell lymphocytosis can transform in 
to chronic lymphocytic leukaemia (Shanafelt et al., 2010), and monoclonal 
gammopathy of undetermined significance can transform in to myeloma (Kyle et 
al., 2010; Landgren et al., 2009). Monoclonal B-cell lymphocytosis is a precursor 
condition that resembles chronic lymphocytic leukaemia, but the total B-cell 
count is below the threshold for diagnosis of chronic lymphocytic leukaemia 
(<5.0 x 10
9
 cells/L) (Marti et al., 2005; Rawstron et al., 2008). Monoclonal 
gammopathy of undetermined significance is the precursor condition for myeloma 
and is similarly characterised by the presence of a paraprotein, but at a lower level, 
and the patient is usually asymptomatic, and does not require treatment (Smith et 
al. 2010). 
 
1.1.2.4 Challenges in estimating prevalence of haematological malignancies 
 
Estimating prevalence for some subtypes of hematological malignancies is 
hampered by both the difficulty in obtaining data and complexity in developing 
methods: 
 
I. Difficulty in obtaining data of haematological malignancies under WHO 
classification 
 
This difficulty in calculating prevalence of haematological malignancies lies in 
their diagnostic complexity and classification (Smith, et al., 2010). The diagnostic 
parameters of haematological malignancies include a combination of histology, 
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cytology, immunophenotype, cytogenetics, imaging and clinical data.  This range 
of diagnostic criteria usually results in difficulty in making an integrated 
diagnosis of disease. The broad ICD-10 classification is still used to report 
national data, for example by the National Cancer Intelligence Network (NCIN, 
2012) in the UK, the Surveillance Epidemiology and End Results Program 
(SEER, 2012)  in the U.S., and the International Agency for Research on Cancer 
(IARC, 2012) (the reports are discussed in Chapter Two). 
 
Furthermore, the WHO classification for haematological malignancies was only 
established in 2001. Therefore, for some datasets, cases diagnosed prior to the 
WHO classification may be classified according to various older schemes, 
however there is no standard for translating from these historical classifications 
(Morton, et al., 2007). Indeed, it is difficult to ‗bridge‘ code diagnoses classified 
to ICD-10 to current WHO classification. 
 
The above barriers make estimating the prevalence of haematological 
malignancies more challenging than for other cancers. 
 
II. Haematological malignancies have characteristics that are different from 
other common cancers 
 
Haematological malignancies can be diagnosed at any age, and show different 
survival patterns between childhood and adulthood (further discussion about this 
is given in Chapter Three). This is another reason why it is challenging to 
calculate the prevalence of haematological malignancies. The methods used in the 
literature to estimate total prevalence estimation may not be suitable for 
haematological malignancies (since most cancers tend to occur in later 
adulthood), and it is necessary to make some adaptations to the model, using more 
flexible statistical tools. Furthermore, some subtypes of haematological 
malignancy show uncommon age distributions, such as Hodgkin lymphoma 
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which has a bimodal incidence curve. The log linear model used in the literature 
will fail to fit data for them, so it is necessary to develop a flexible model to make 
descriptions and estimations. 
 
 The total prevalence of haematological malignancies is estimated by modeling 
the mathematical relationship among prevalence, incidence, survival, and general 
mortality. The model is easy to understand, since prevalent cases are actually the 
patients who were diagnosed with the particular disease in the past (incidence of 
disease), and who keep being patients (survival) without dying (mortality). To 
make the calculation simple and practical, some assumptions are made. (The 
methods of calculation and the assumptions made are discussed in Chapter 
Three.) Since total prevalence figures are unavailable until the registry is 
sufficiently mature to capture all patients ever diagnosed with a cancer, the aim of 
this study is to try and demonstrate the burden of haematological malignancies by 
estimating its prevalence from limited length registry data - HMRN.  
 
1.2 Aims and objectives of this thesis 
 
The aim of this thesis is to estimate the prevalence of haematological 
malignancies, under the WHO classification, using data from the Haematological 
Malignancy Research Network (HMRN). The main objectives are summarized as 
follows: 
 
1. To demonstrate n-year prevalence using HMRN data for subtypes of 
haematological malignancies under the latest disease classification.  
2. To develop a general method to estimate total prevalence. 
3. To calculate total prevalence for all subtypes using the method in this 
study. 
4. To find a suitable method to calculate total prevalence for subtypes where 
survival has changed significantly in the past. 
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5. To estimate prevalence in the UK and make suggestions for the burden of 
haematological malignancies. 
  
This is the first time that the prevalence of haematological malignancies has been 
estimated under WHO classification. High quality data from HMRN that 
overcomes the difficulties in diagnosis and classification of haematological 
malignancies makes these estimates possible. Although HMRN has a limitation of 
a relatively short follow-up period for some subtypes with longer survival, the 
statistical models used help to achieve the final goal of estimating total 
prevalence. 
 
Total prevalence estimates can be used to show the real burden of subtypes of 
haematological malignancies, and to suggest reasonable health resource 
allocation. Besides total prevalence, 1-year and 5-year prevalence estimates, as 
supplementary information, are calculated in this study by simply counting the 
number of prevalent cases on the index date. Furthermore, suggestions for making 
prevalence estimates for the diseases in which there have been significant survival 




1.3.1 General notations in this thesis 
 
The following notation will be used throughout this study. 
 
Let t be the age at diagnosis (in years). 
Let x be the current age on the index date (in years).  
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Let u be the age at death (in years). 
Let Y be a calendar year. 
Let d be duration of disease (in years). 
Let D be the number of deaths in a period of time. 
Let V(d) be the number of patients who survive for d years from diagnosis. 
Let U be the number of patients lost to follow-up within the registry period of 
time. 
Let I(t) denote the probability that an individual will be diagnosed with a 
specified cancer at the age of t (age t years means between t and t+1 years old). 
Let C(t) denote the number of new patients (or diagnosis) at age t. 
Let G(u) denote the probability of an individual in the background population 
dying at age u (age u years means between u and u+1 years old). 
Let S(t, d) denote the probability that an individual, who has a confirmed cancer 
diagnosis at the age of t, survives for time d after diagnosis (age t years means 
between t and t+1 years old) . 
Let N(x) denote the number of patients (or diagnoses) alive on the index date at 
age x who had a diagnosis of cancer in the past. 
Let P(x) denote the probability that an arbitrary person of age x in the population 
has received a diagnosis of cancer in the past (age x years means between x and 
x+1 years old). 
  
For a patient, she or he is considered to be disease-free before age t (age at 
diagnosis), which means the patient does not have the disease of interest in the 
study.  After age t, the patient becomes a prevalent case until age u (age at death), 
which means between age t and age u the patient survives with the disease. At any 
particular time, all diagnosed patients who have not previously died are prevalent 
cases at that time, and their age at that time is x. In other words, ―cure‖ is not 
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considered in this study, and once the patient is diagnosed with cancer, he or she 
is considered a prevalent case for all the rest of his/her life (we discuss this 
assumption in Chapter Five). 
 
The length of registry is L years (for example, HMRN has 𝐿 = 7 from 2004 to 
2011). The observations under study are cases with registry information. P(x) is 
the prevalence rate at age x, and N(x) is the number of prevalent cases at age x. 
 
1.3.2 Prevalence, incidence, and survival 
 
In epidemiology, the prevalence of a disease in a population can be given as a 
count or as a proportion. It is defined either as the total number of cases in the 
population at a given time, or the total number of cases in the population, divided 
by the number of individuals in the population at that time. In this thesis, 
proportion is used as the default meaning for prevalence and it will be specified 
explicitly when it means count. 
 
 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒 =
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
 (1. 1) 
 
Point prevalence is a measure of the proportion of people in a population who 
have a disease at a particular time, such as on a particular date. This date is called 
the index date. Point prevalence is like a snap shot of the disease at a particular 
time.  
 
 𝑝𝑜𝑖𝑛𝑡 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑥𝑖𝑠𝑡𝑖𝑛𝑔 𝑐𝑎𝑠𝑒𝑠 𝑜𝑛 𝑎 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑑𝑎𝑡𝑒
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑜𝑛 𝑡𝑕𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑑𝑎𝑡𝑒




Prevalence at a certain age is age-specific prevalence, and it can be understood 
as: 
 
 𝒂𝒈𝒆 − 𝒔𝒑𝒆𝒄𝒊𝒇𝒊𝒄 𝒑𝒓𝒆𝒗𝒂𝒍𝒆𝒏𝒄𝒆 =
𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒄𝒂𝒔𝒆𝒔 𝒘𝒉𝒐 𝒂𝒓𝒆 𝒂𝒕 𝒂𝒈𝒆 𝒙
𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒑𝒐𝒑𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝒘𝒉𝒐 𝒂𝒓𝒆 𝒂𝒕 𝒂𝒈𝒆 𝒙
 (1. 3) 
 
Age-specific prevalence focuses on current age x (x years means between x and 
x+1 years old.) rather than diagnosed age t. It counts patients of a certain age on 
the index date, no matter when they were diagnosed. 
 
These measures of prevalence can be estimated by counting the number of people 
found to have the disease in question and by comparing this with the total number 
of people studied. In order to estimate the number of observed patients in a 
registry and unobserved patients diagnosed before the start of the registry, 
prevalence considered as a proportion can also be considered as a probability. At 
this point, prevalence can be estimated as the probability of being found at a 
particular time, having had present a previous diagnosis of the disease in question.  
 
Prevalence, working as a proportion, summarizes the observations. Within the 
registry, it shows the real phenomenon — number of live patients who can be 
observed in the data. Conversely, probability is a measure of the expectation of 
people being found at a certain time, as having had present or past diagnosis for 
the disease. Here, practically, proportion of an event can be considered as its 
probability, with observable proportions being used as the expected probabilities 
in the calculation.   
 
Prevalence can tell us how widespread a disease is in a given population. It 
depends on both the frequency of cancer and its survival characteristics. In other 
words, it is related to incidence and survival duration. For example, for a disease 
with good survival characteristics and high incidence prior to and in year Y1 but 
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with low incidence by and after year Y2, we will find both high incidence and 
prevalence in year Y1, but after year Y2 the incidence will decrease, while the 
decrease in prevalence will show a significant time lag due to the long survival. 
Conversely, a disease that has a short duration might spread widely during Y1 but 
is likely to have a low prevalence in Y2 (due to its short duration).  
 
Incidence is a measure of the risk of developing a disease within a specified 
period of time. It is the number of newly diagnosed cases during a specific time 
period. When expressed as a rate, it is the number of new cases per standard unit 
of population during the time period. It is often expressed as, for example, a 
number per 100, 000 per year or number per 100, 000 per age group. It is 
calculated as: 
 
 𝒊𝒏𝒄𝒊𝒅𝒆𝒏𝒄𝒆 𝒓𝒂𝒕𝒆 =
𝒕𝒉𝒆 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒏𝒆𝒘 𝒄𝒂𝒔𝒆𝒔 𝒘𝒊𝒉𝒊𝒏 𝒂 𝒔𝒑𝒆𝒄𝒊𝒇𝒊𝒆𝒅 𝒕𝒊𝒎𝒆 𝒑𝒆𝒓𝒊𝒐𝒅
𝒑𝒆𝒓𝒔𝒐𝒏−𝒕𝒊𝒎𝒆 𝒐𝒇 𝒕𝒉𝒆 𝒂𝒕 𝒓𝒊𝒔𝒌 𝒑𝒐𝒑𝒖𝒍𝒂𝒕𝒊𝒐𝒏
 (1. 4) 
 
In equation 1.4, the ―at risk population‖ is the population minus the number of 
people who already have a certain disease at the beginning of that period of time. 
Since the number of patients with haematological malignancies is small compared 
to the population, the size of population in the study area is considered to be equal 
to the size of the population initially at risk. 
 
It is assumed that incidence is constant for the registry period. This assumption is 
extended to ―the incidence is constant over the period of interest‖ (details are 
shown in Chapter Three) in the total prevalence estimates.  
 
Incidence rates can also be calculated based on a number of factors, such as age 




        
 𝒂𝒈𝒆 − 𝒔𝒑𝒆𝒄𝒊𝒇𝒊𝒄 𝒊𝒏𝒄𝒊𝒅𝒆𝒏𝒄𝒆 𝒓𝒂𝒕𝒆 =
                                         
𝒕𝒉𝒆 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒏𝒆𝒘 𝒄𝒂𝒔𝒆𝒔 𝒅𝒊𝒂𝒈𝒏𝒐𝒔𝒆𝒅 𝒂𝒕 𝒂 𝒄𝒆𝒓𝒕𝒂𝒊𝒏 𝒂𝒈𝒆 
 𝒑𝒐𝒑𝒖𝒍𝒂𝒕𝒊𝒐𝒏 𝒂𝒕 𝒂 𝒄𝒆𝒓𝒕𝒂𝒊𝒏 𝒂𝒈𝒆
  (1. 5) 
 
Prevalence is a measure taken at a certain point in time and is cross-sectional, 
whilst incidence is longitudinal, looking at the occurrence of the disease of 
interest. Therefore, unlike age-specific prevalence which focuses on a patient‘s 
current age x on the index date, age-specific incidence refers to the age at 
diagnosis t.  
 
Incidence rates can be used as expected probabilities. If t is the age at diagnosis of 
a patient, then the incidence rate at age t can be interpreted as being the 
probability that an arbitrary person in the population will be diagnosed at age t. 
For example, if the incidence of acute myeloid leukaemia (AML) in age 0-4 years 
is 1.3 per 100,000, it can be also considered as a probability of receiving a 
diagnosis of acute myeloid leukaemia in the age rage 0-4 years of 1.3 ∗ 10−5 in 
the area of study. The notation 𝐼(𝑡) indicates the incidence at age t in the 
following calculations. 
 
Similar to the definitions of incidence as rates or probabilities, the survival rate 
indicates the percentage of people in a study who are alive for a given period of 
time d after diagnosis. For an individual it is defined as the probability, 𝑆(𝑑) , that 
an individual survives longer than d (Cleves, et al., 2010). 
 
 𝑺(𝒅) = 𝑷𝒓(𝒂𝒏 𝒊𝒏𝒅𝒊𝒗𝒊𝒅𝒖𝒂𝒍 𝒔𝒖𝒓𝒗𝒊𝒗𝒆𝒔 𝒍𝒐𝒏𝒈𝒆𝒓 𝒕𝒉𝒂𝒏 𝒅)  (1. 6) 
 𝑺(𝒅) = 𝟏 − 𝑷𝒓(𝒂𝒏 𝒊𝒏𝒅𝒊𝒗𝒊𝒅𝒖𝒂𝒍 𝒅𝒊𝒆𝒔 𝒃𝒆𝒇𝒐𝒓𝒆 𝒅)  (1. 7) 
 
In medical research, survival may also be considered as a function of the age at 
diagnosis or of other explanatory variables. 𝑆(𝑡, 𝑑) is the proportion of people 
diagnosed at age t  who survive for d years after diagnosis. It can be also 
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considered as the probability that a patient who is diagnosed at age t is still alive 
after d years. The probability of death during a very small time interval is an 
instantaneous death rate, called the hazard function (Cleves, et al., 2010). 
 
However, this definition of survival refers to overall survival. As a measure, it 
does not take into account what the subject actually dies from. Other causes of 
death can be understood as ―die of another cause but with the disease present‖ 
(Ederer, Axtell, and Cuter, , 1961).  Relative survival, 𝑆𝑟 captures how survival is 
affected by the disease (net survival rate): 
 
 𝒓𝒆𝒍𝒂𝒕𝒊𝒗𝒆 𝒔𝒖𝒓𝒗𝒊𝒗𝒂𝒍 𝒓𝒂𝒕𝒆 =
𝒐𝒗𝒆𝒓𝒂𝒍𝒍 𝒔𝒖𝒓𝒗𝒊𝒗𝒂𝒍 𝒓𝒂𝒕𝒆
𝒕𝒉𝒆 𝒆𝒙𝒑𝒆𝒄𝒕𝒆𝒅 𝒔𝒖𝒓𝒗𝒊𝒗𝒂𝒍 𝒓𝒂𝒕𝒆 𝒊𝒏 𝒕𝒉𝒆 𝒑𝒐𝒑𝒖𝒍𝒂𝒕𝒊𝒐𝒏
 (1. 8) 
 
When relative survival is less than 1(100 percent), then mortality in the patients in 
the study exceeds that of disease- free persons in the population. When it reaches 
1(100 percent), it indicates that the death rate of patients is equal to that of the 
general population.  
 
In equation 1.8, the expected survival rate in the population is actually the 
survival rate of those who do not have the specific disease under consideration. 
This group of people can be considered as a control group and their survival 
characteristics can be used to adjust the overall survival characteristics of the 
patient group. It is often the case that the mortality from a specific cancer 
constitutes a negligible contribution to total mortality ( Ederer, Axtell, and Cuter, , 
1961).  In this situation, the survival rates of the general population provide 
satisfactory estimates for expected survival rates when the relative survival of 
patients with the cancer under consideration is analyzed. 
 
Relative survival is widely used in prevalence calculation in the literature (see 
Chapter Two). However, as described above, relative survival is easy to define, 
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but is not easy to estimate, especially when parametric models are involved 
(details are explored in Chapters Two). Furthermore, relative survival is a 
reasonable indicator of the survival experience of patients in a population, but is 
less informative if used to predict the prognosis of an individual (Parker, et al., 
1996). 
 
Confounding by age may occur when we predict the prevalence rate in other 
populations (𝑃𝑜𝑝), since disease incidence and survival varies across age groups; 
age usually has a powerful influence on the risk of cancer and on survival. Age 
standardisation (age adjustment), is used to control for differences between the 
age structures of different populations (Leon, 2008). It is accomplished first by 
multiplying the age specific rates (𝑟) of disease in an age group (in area 1) by the 
population size in the corresponding age group in the target area (area 2). Next, 
the sum of those products is divided by the total population size in the target area 
(area 2).  
 
𝒂𝒈𝒆 − 𝒔𝒕𝒂𝒏𝒅𝒂𝒓𝒅𝒊𝒔𝒆𝒅 𝒓𝒂𝒕𝒆 =
∑𝑷𝒐𝒑(𝒊)∗𝒓(𝒊)
∑𝑷𝒐𝒑(𝒊)
   (1. 9) 
 
𝑃𝑜𝑝(𝑖) indicates the population sizes in the relevant age groups (i) in the target 
area (area 2), and 𝑟(𝑖) are the age-specific rates in age groups i in the local area 
(area 1).  
 
1.3.3 Different types of prevalence in this thesis 
 
After the establishment of a cancer registry, new cases are registered every year. If 
the status (dead or alive) of a case on the index date is available, you therefore 
know the number of live cases on that day within the registry. One can even 
calculate the prevalence for a special group of people, such as those diagnosed in 
the most recent years. However, registry data does not include the patients who 
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were diagnosed before the start of the registry and are still alive. Therefore, in the 








                        Observed prevalence 
                        n-year prevalence  
                        Total prevalence 
Figure 1- 4 different types of prevalence 
 
The prevalence calculated for the patients who were diagnosed within the registry 
period is called the observed prevalence (can also be called limited duration 
prevalence). 
 
n- year prevalence includes all persons who were diagnosed with the disease in 
question within n years of the index date. When n equals the length of the registry, 
n-year prevalence is observed prevalence. Therefore, when 
𝑛 ≤ 𝑡𝑕𝑒 𝑙𝑒𝑛𝑔𝑡𝑕 𝑜𝑓 𝑟𝑒𝑔𝑖𝑠𝑟𝑦, n-year prevalence can be obtained directly. It is a 
convenient and commonly used method, calculated based on available data in the 
registry, for example, 5-year prevalence based on 5 years of available registry 
data (Figure 1- 5). 
 
                             Before registry Within registry 









Total prevalence refers to all persons in a given population diagnosed in the past 
with the disease under consideration and who are still alive on a specified index 
date. It is also called unlimited duration prevalence in the literature. Total 
prevalence calculated in this work is an estimate (equation 1.4), and cannot be 
calculated directly by the definition of prevalence. The method used to estimate 
total prevalence is described in Chapter Three. 
 
Total prevalence is estimated from observed data, and in fact, it is a measure of 
the expectation that people being found on the index date, having had present or 
past diagnosis of the disease. The real number of patients who are alive on a 
certain date is unavailable until the length of the registry is long enough to cover 
all living patients. The prevalence that includes all live patients in the real world 
is called true complete prevalence. Total prevalence is an estimate, and it is the 
expected complete prevalence. 
 
Prevalence can be calculated on person basis or on a diagnosis basis. Person 
prevalence only considers the first malignancy diagnosed in each person, and is a 
measure of the number of people actually surviving having received a previous 
diagnosis. On the other hand, diagnosis prevalence refers to diagnosis and 
considers all malignancies in a patient. Although most prevalence studies 
(Capocaccia, et al., 2002; Micheli, et al., 2002a; Verdecchia, et al., 2002; Forman, 
et al., 2003; Lutz, et al., 2003; Möller, et al., 2003) only consider person 
prevalence, diagnosis prevalence is more appropriate for haematological 
 





malignancies due to its characteristic ability to transform. Therefore the 
prevalence estimates of haematological malignancies include all diagnoses, 
regardless of whether they were first or subsequent cancer.   
 
Beyond those main definitions, the definition of prevalence range is introduced, 
which is used to specify a reasonable range of possible total prevalence for 
diseases where survival characteristics have changed dramatically in the past due 
to the introduction of new treatments. It contains an upper limit of total 
prevalence and a lower limit of a certain, n-year prevalence, (details are given in 
Chapter Three Section 3.5).  
 
1.4 Structure and outline of this thesis 
 
To meet the objectives of this study, tasks are carried out in several phases; here 
these are shown in sequential order.  The first phase is a review of the literature. 
The second phase is to introduce and to describe the data from HMRN to be used 
in this study. With data from HMRN, simple calculations are conducted in phase 
three. n-year prevalence is obtained by counting the number of alive patients 
within the registry for n=1 and n=5. In the next, more difficult phase four, a 
method was developed to estimate total prevalence from the limited prevalence 
data that are available. The final phase estimates prevalence ranges for the 
haematological malignancy subtypes where survival characteristics have changed 
significantly due to the introduction in the past of new treatments.  
 
The working phases are summarized in chapters to keep the whole structure clear. 
The structure of the thesis is shown in Figure1- 6.  
 
There are three main sections in Chapter One. Firstly, it discusses background 
information about haematological malignancies and cancer registration. Secondly, 
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it demonstrates the motivation for the study, and identifies the aims for the work. 
Lastly, key definitions used throughout this work concerning prevalence are 
made. 
 
In the second chapter, a literature review is presented of both the methods of 
calculation of cancer prevalence and for reported prevalence figures for 
haematological malignancies in previous studies. The methods are introduced and 
compared to each other in order to find the appropriate methodology to estimate 
the prevalence of haematological malignancies based on the data from HMRN. 
Furthermore, the summary of reported prevalence figures from previous studies 
forms an overview of the prevalence of haematological malignancies, and also 
demonstrates the limitations in these studies. 
 
Chapter Three introduces the methods used in this study. It includes data and 
materials used in calculating and estimating throughout the study, including the 
direct method used to calculate n-year prevalence, how the model for total 
prevalence estimation is built, as well as the statistics involved in the methods. 
There is a further study at the end of this chapter to find a method to show 
prevalence for some diseases that have had great survival improvements in the 
past due to the introduction of new treatments. 
 
Chapter Four describes the results. Firstly, the demographic characteristics of 
hematological malignancies are described. Secondly, n-year prevalence was 
calculated for all diagnostic subtypes. Thirdly, total prevalence is calculated and 
to demonstrate the processes acute myeloid leukaemia and Hodgkin lymphoma 
are used as examples. 
 
In the final chapter, the main findings and contributions of this work are 
described, followed by a discussion of the methodology and the results obtained. 
The advantages and the limitations of this study are explained in this chapter, as 
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well as the comparison with other reports in the world. There are also suggestions 


































Chapter 3: Methods 
Chapter 4: Results 












This chapter has described the different concepts of prevalence and the challenges 
faced in trying to calculate the burden of disease for haematological malignancies. 
This study attempts to surmount the difficulties in calculating prevalence 
estimates for haematological malignancies based on current disease classification. 
General notations have been made for further estimations and the whole thesis 




Chapter 2 Literature review 
 
 
Before estimating the prevalence of haematological malignancies based on data 
from HMRN, it is necessary to consider work that has already been published. 
The first aim of this chapter is to compare the methods used to calculate/estimate 
prevalence in previous studies. It also assesses whether the methods mentioned in 
the literature can be used to estimate the prevalence of haematological 
malignancies using data from HMRN. The second aim is to summarize the 
prevalence of haematological malignancies among countries or areas in the world. 
The temporal and geographic variability of haematological malignancy 
prevalence are described at the end of this chapter.  
 
The terms ―cancer prevalence‖, ―cancer registry‖, ―prevalence of leukemia‖, 
―prevalence of Hodgkin lymphoma‖, ―prevalence of non-Hodgkin lymphoma‖, 
―prevalence of myeloma‖, as well as prevalence of acute myeloid leukemia 
(AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia 
(ALL), and chronic lymphocytic leukemia (CLL) were used to search online 
database (last search, July 2013). The search is not restricted by date. The earliest 
paper used in this section is in 1975, and the most recent one is in 2013. Besides 
Medline, Google scholar was also used to search papers. Web based reports on-
line searches were also conducted, and only articles in English were reviewed. 
Compared with incidence, mortality, and survival, the information on cancer 
prevalence is limited, and the systematic impact of haematological malignancies 
on health systems has not been fully described.  The literature review identifies 
some methods, which will be discussed in the following section. 
 
2.1 The methodology for estimation of cancer prevalence 
 
Broadly speaking, methods for calculating cancer prevalence can be divided into 
two categories: direct calculation and indirect estimation. Direct calculation 
49 
 
computes the prevalence observed from data, whilst indirect estimation provides 
estimates of unobserved prevalence based on the observations in the registry. 
Different methods in the two categories can be found in the literature. These are 
summarized in Figure 2-1.  
 
 
                                    Survey data                                                     Observed 
  Direct calculation                                    Counting method              prevalence 
                                   Cancer registry   
                                                                  PREVAL approach 
 
                                                                                TRM 
                                     Transition rates method     IPM                                                                  
                                                                                DisMod 
 
                                                                                MIAMOD             
  Indirect estimation    Back calculation method                               Unobserved 
                                                                                PIAMOD            prevalence 
                                     Completeness index                      
                                                                                                                         
                                     Other methods 
 
Figure 2- 1 The main methods for calculating prevalence (TRM: transition rates 
method. IPM: incidence-Prevalence-Mortality Model, DisMod: Disease Model. 
MIAMOD: Mortality Incidence Analysis MODel; PIAMOD: Prevalence 
Incidence Analysis MODel) 
 
Direct calculation refers to the methods that involve the number of observed cases 
and population only. Cross sectional research (such as surveys) is the most 
straightforward way to assess prevalence, and prevalence can cover all prevalent 
cases in a defined time. However, longitudinal studies collect data for a period 
and only provide prevalence within the registry. Indirect estimation usually uses 
incidence, mortality and survival probabilities abstracted from cancer registry 
data to estimate prevalence. In the literature, this group of methods is used to 
either predict prevalence in the future or to estimate total prevalence that covers 
all patients diagnosed before and after the start of the registry. 
 
The different methods in the literature pertaining to prevalence calculation and 
estimation are shown one by one in the following sections. The methods are 
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briefly introduced, as well as examples given using certain methods. Each method 
has its advantages and disadvantages. Appropriateness for this study is described 
after making comparisons between the methods.  
 
2.1.1 Cross-sectional population based surveys 
 
To obtain the total prevalence, a conceptually straightforward method is to 
conduct a cross-sectional population based survey. In 1987, the prevalence of 
cancer was estimated based on a sample in the U.S. through the National Health 
Interview Survey (NHIS) (Byrne, Kessler and Devesa, 1992). Weighting 
procedures were developed by the Bureau of the Census and National Center for 
Health Statistics to reflect the civilian population of the U.S. in 1987. In 1991, 
cancer prevalence was calculated using this method in the Netherlands, and the 
results were compared with cancer registry records (Schrijvers, et al., 1994). 
However, this method is conceptually easy but in practice hard to apply to a large 
population. Moreover, when using this method one must consider the problem of 
self-reporting, such as underreporting and misclassification. 
 
2.1.2 The Counting method 
 
Using cancer registry data, prevalent cases observed for a period can be counted 
directly. On the desired index date, the cases still alive are simply counted, whilst 
adjustments are made to estimate the proportion of cases lost to follow-up who 
could have made it to the prevalence date. The survival probability of each lost 
case is estimated from the subset of followed patients belonging to the same sex, 
age, and period of diagnosis.  In 1999, Gail developed the Counting method (Gail, 
et al., 1999). Recalling the definition and notations made in Chapter One, for a 
patient, t is the age at diagnosis, x is the current age, S(t, d) is the probability that 
an individual who developed cancer at age t will survive beyond duration d 
(𝑑 =  − 𝑡) after cancer incidence, and the registry is L years long. Further 




Let  𝑖𝑛𝑑𝑒𝑥 be the calendar time of the index date, 
Let    be the calendar time of cancer incidence for a typical patient, 
Let    be the calendar time of death, 
Let    be the calendar time of loss from follow- up, 
Let 𝑃𝑜𝑝( ) be the total population at age x. 
 
Suppose F is an indicator function equalling one when the argument is true and 
zero otherwise. The number of cases that can be observed to survive to age x is 
the summation over all members in the registry: 
 
       ( ) = ∑ ( ,       −  ≤          ,           ,          ) (2. 1) 
          (1)                               (2)                 (3) 
  
This includes patients at age x t: (1) diagnosed in a certain year within the registry 
period, (2) not deceased before the index date, (3) not lost to follow-up before the 
index date. 
 
For the patient lost to follow-up, the probability of being alive on the index date is 
estimated from the appropriate survival function of the cohort, conditional on the 
time of loss- to- follow-up. Each case lost to follow-up has conditional survival 
(Gail, et al., 1999). It is the probability that a patient will survive at least until the 
index date, given that patient was diagnosed at YI, and lost to follow-up at YU.  
The number of cases of age x alive on the index date among those of the same age 
who were lost from follow- up before age x is: 
 
  ( ) =∑* ( ,  𝑖𝑛𝑑𝑒𝑥 − 𝐿 ≤     𝑖𝑛𝑑𝑒𝑥,      ,     𝑖𝑛𝑑𝑒𝑥)+ 
                            ∗
 (      −  ,𝑡)
 (   −  ,𝑡)




The individual estimate of survival (𝑆(𝑑, 𝑡)) is obtained using the life table (or 
known as the actuarial) method (Cutler and Ederer, 1958; Gail, et al., 1999). 
 
The probability P(x), of a person being alive on the index date at age x is 
calculated by: 
 
 𝑃( ) =
𝑁 (𝑥) 𝑁 (𝑥)
 𝑜𝑝(𝑥)
 (2. 3) 
 
The calculation can be implemented using SEER* Stat software (National Cancer 
Institute, 2010). The prevalence calculated using this method is also called 
―limited duration prevalence‖ (National Cancer Institute, 2010). This method was 
also used to calculate the prevalence of cancer in Quebec, Canada (Louchini, et al. 
2006). An advantage of this method is that it is easy to understand. It calculates 
observed prevalence adjusted for losses in the follow-up. When the cancer 
registries for those papers are long, and most patients diagnosed before the start of 
the registry die before the index date, this method can provide relatively unbiased 
prevalence estimates for the corresponding population.  
 
2.1.3 The PREVAL approach 
 
Observed prevalence based on cancer registry data can also be calculated using 
the PREVAL approach (Krogh and Micheli, 1996). This method uses the same 
idea as the counting method; the number of cases alive on the index date is the 
sum of the number of observed cases and the number of cases lost to follow-up 
and still alive. However, it estimates the prevalence according to the time d since 
diagnosis. Following the general notations of this study, D is the number of deaths; 
N is the number of surviving cases; U is the number of patients lost to follow-up. 
Unlike the counting method, which calculates age-specific prevalence, duration is 
the determinant in the PREVAL approach. Besides the notation of d years from 
diagnosis to index date, it also sets s to be the number of years from diagnosis to 
death, and m to be the number of years from diagnosis to loss to follow-up. In a 
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cohort,  𝑑 is the number of patients who have survived for d years until the index 
date, and  𝑠 is the number of cases surviving for s years until death,  𝑠 is the 
number of cases that died after s years since diagnosis,  𝑚 is the number of 
patients lost to follow- up m years from diagnosis. The formula to calculate the 
expected number of prevalent cases at the index date who have survived for d 
years is: 
 
  𝑑 =  𝑑  ∑  𝑚∏
𝑁 




𝑚   (2. 4) 
 
The formula,  
𝑁 
𝑁    
 is used for making adjustments to account for lost- to- follow- 
up.  𝑑  is calculated using strata of age, gender, and race. It is the expected 
number of patients who survive for a certain number of years until the index date, 
taking into account the survival of those lost to follow-up. 
 
This method was also used to calculate the observed prevalence in 1992 in 
Connecticut, Iowa, and Utah (Micheli, et al. 2002b). The correction in this 
method assumes that the lost-to-follow-up cases have the same survival 
characteristics as those not lost to follow-up. If lost-to-follow-up cases differ from 
other cases by some factor that influences their survival, the assumption of the 
same survival rate will be flawed. 
 
Both the counting method and the PREVAL approach calculate observed 
prevalence based on registry data. Some observed prevalence data pertaining to 
the U.S. and some European countries that have been covered by cancer 
registration for many decades have been published (Hakama, et al., 1975; 
Feldman, et al., 1986; Adami, et al., 1989; Polednak, 1997; Gail, et al., 1999). 
However, the prevalence estimated using these methods is the observed 
prevalence within a limited period of follow-up time. This ignores patients 
diagnosed before the establishment of the registry who are still alive. When the 





2.1.4 The transition rate method 
 
All of the above methods are direct calculations that provide prevalence estimates 
of number of prevalent cases in the population. In this section, it is introduce 
indirect estimate methods. These methods estimate prevalence based on 
probabilities and proportions (recall the definitions in Chapter One, equation 1.4). 
A group of methods that are based on stochastic process modelling are named 
transition rate methods: 
 
2.1.4.1 The Transition Rate Method (TRM)  
 
These methods are based on the assumption that individuals are in different states 
at different times in their life history. They move from one state to another 
according to some state transition probabilities. In the transition rate method 
(TRM), these probabilities are called transition rates. The transition rate method 
( Gras, Daurès and Tretarre, 2006) estimates cancer prevalence using a stochastic 
process with three states as follows: 
 
1. alive and cancer free, state H 
2. alive with cancer, state I 
3. dead, state D 
 
At a point in time on the calendar, the healthy state H may transit to the disease 
state I with transition rate   ( ) which depends on age x. Alternatively, the 
individual may die directly from state H with transition rate   ( ). A subject in 
state I is at risk of death with transition rate   ( ,  ) which depends on the 






   State H: healthy 
𝑟 ( )                                  𝑟 ( ) 
 
       𝑟 ( , 𝑑) 
State D: death                                             State I: disease 
Figure 2- 2 The three states stochastic model 
 
After estimating the transition rates between the states, the model is then allowed 
to run to estimate cancer prevalence under a set of specified conditions (Gail, et 
al., 1999). 
 
It is assumed that no cancer case is ever ―cured‖, which means the patients are 
considered as prevalent cases until they have died once they have been diagnosed 
with cancer. Consider a single birth cohort; the probability of being alive with 
disease in state I at age x is: 
 
 
   ( ,  ) = ∫    .−∫ (     )( )  
 
 
/   ( )    (−∫   ( ,  −  )  
 
 
)   
 
 − 
 (2. 5) 
                                       
                                                 1                       2                    3   
 
1 represents the probability of surviving cancer-free up to age t, 
2 represents the probability of cancer onset at age t, 
3 represents the probability of surviving to age x given that the individual is 





It is assumed that the overall survival of the population at age x is 𝑆𝑜𝑣𝑒𝑟𝑎𝑙( ). 
Next, the L- year prevalence of cancer is: 
 
 𝑃( ) =
  (𝑥, )
        (𝑥)




 𝑃( ) =
∫ 𝑒𝑥𝑝.−∫ (𝑟  𝑟 )(𝑢)𝑑𝑢
 




   
        (𝑥)
 (2. 7) 
 
The probabilities of being in various states of the process are required to estimate 
prevalence. There is an assumption that the transition rates are constant over time 
(Gail, et al., 1999). This method is relatively flexible in prevalence estimates 
since it divided the life history by status. However, as equation 2.7 shows, it is not 
an easy calculation, and includes many probabilities: three transition rates, and 
overall survival. To estimate prevalence using this method, the transition rates 
should be abstracted from data according to age and gender.  
 
2.1.4.2 The Incidence- Prevalence- Mortality Model (IPM) 
 
Using a similar theory to the TRM, the prevalence of cancer in the Netherlands 
was calculated in 2000 (Hoogenveen and Gijsen, 2000), using a model called the 
incidence- prevalence- mortality (IPM) model. Similar to the TRM, it is a two-
state transition model. For a given cancer, in addition to the state ―Death‖, the two 
states are distinguished as ―disease- free‖ and ―with the disease‖ (prevalent). The 
difference to the TRM is that it differentiates between causes of death. There are 
three transition rates: disease incidence rates (disease- free to prevalent), disease- 
related excess mortality rates (prevalent to dead), and mortality rates for all other 
causes (disease- free to dead, and prevalent to dead).  The model structure can be 
expressed as in Figure 2-3. It is also assumed that there is no remission, which 
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means once the individual is diagnosed as a cancer patient, he or she will be a 
prevalent case for the rest of their life. 
 
 
   Disease-free 
                   𝑔𝑒𝑛𝑒𝑟𝑎𝑙 𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦                                 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 
 
     𝑔𝑒𝑛𝑒𝑟𝑎𝑙 𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 
Death                                                       With disease 
𝑑𝑖𝑠𝑒𝑎𝑠𝑒 − 𝑟𝑒𝑙𝑎𝑡𝑒𝑑 𝑒 𝑐𝑒𝑠𝑠 𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 
 
Figure 2- 3 Incidence- prevalence- mortality model structure. (Hoogenveen and 
Gijsen, 2000) 
 
In this model, the mortality rate of the prevalent cases (patients) is considered to 
be the sum of the general mortality rate for people without the disease and the 
disease- related excess mortality. In other words, the mortality rates for all other 
causes are assumed to be the same for persons with and without the disease 
(Hoogenveen and Gijsen, 2000). There is another important assumption: there are 
no trends in the incidence and mortalities in the model, which means that the 
transition rates between states are consistant with calendar years. 
 
2.1.4.3 The Disease Model (DisMod) 
 
Based on the same theory as IPM, in the Disease Model (DisMod) the population 
is described as being in different states, whilst transition rates determine how 
people move from one state to another. The model structure of the DisMod can be 
expressed by Figure 2- 4. Being different to the IPM, it also includes remission as 
a fourth transition rate, however it can be set to zero when cure is not taken into 
account in the registered cancer prevalence (Kruijshaar, Barendregt and  
Hoeymans, 2002). Unlike the epidemiological terminology (disease-related 
excess mortality) in the IPM, the DisMod uses fatality rates to describe ―the 
excess of mortality rate due to the disease, as well as the increased susceptibility 
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The prevalence of cases at an age x should be calculated as: 
 




∗     (−∫  𝑎𝑡𝑎𝑙𝑖𝑡𝑦(𝑡, 𝑢)𝑑𝑢
𝑥
𝑡
)𝑑𝑡               (2. 8) 
 
Where t is the age at diagnosis, and  𝑒 𝑖𝑠𝑠𝑖𝑜𝑛( − 𝑡) is the proportion of cases, 
among the survivors at time ( − 𝑡) since diagnosis that have been cured and 
have consequently been removed from the prevalence. The part in equation 2.8 
    (−∫  𝑎𝑡𝑎𝑙𝑖𝑡𝑦(𝑡, 𝑢)𝑑𝑢
𝑥
𝑡
) can be understood as the net survival function of 
patients in absence of mortality from other causes. 
 
Briefly, the TRM, the IPM, and the DisMod share the same theory in building 
their models, and same assumptions about time-constant cancer incidence, 
mortality and survival probabilities. In this steady-state situation, the prevalence 
estimate for a birth cohort coincides with that of the current population. The 
differences between them are different epidemiological terms used for life status 
and transition rate descriptions for example, the disease-related excess mortality 
in the IPM is called fatality in the DisMod. 
Susceptible Cases Cause-specific 
deaths 




2.1.5 Back calculation methods 
 
Back calculation methods form a broad family of methods. However, they are put 
to special uses in the literature, such as to provide prevalence estimate projections 
for the future. Therefore these methods are considered as a single group. Back 
calculation methods produce statistical solutions to estimate prevalence, using the 
parameter trends estimated from observed data to make estimates for the 
unobserved part. There are two methods in this group: 
 
2.1.5.1 The MIAMOD method 
 
The MIAMOD (Mortality Incidence Analysis Model) (Verdecchia, et al., 1989) 
can be used to estimate cancer prevalence using mortality data. It considers 
prevalent cases as the result of several phenomena acting together on the 
population throughout a period. These include contracting the disease, not dying 
from the disease, or from other causes. An important assumption in the MIAMOD 
is that the disease process is considered irreversible.  
 
Figure 2- 5 shows a compartmental representation of the model with two live 
states (disease-free and with disease) and two death states (from specific disease 
and from all other causes). This model is similar to transition rate methods, where 
the states transition according to different rates. However, there are more kinds of 
death hazard rates. From demographic sources, death hazard rates from the 
specific cause 𝑟𝑎( ), and from all causes together 𝑟𝑏( ) at age x are usually 
known. From registry data, all-cause death hazards at age x 𝑟𝑐( , 𝑡) for people 
who became ill at age t, and the corresponding specific cause death 












         ( )                                                                                             ( ) 




                                                       Dead 




After an estimate of the incidence I(t) in Figure 2-5 (the disease hazard for 
disease- free people of age t) is obtained, the probability of being in the disease 
state for people of age x in the cohort can be expressed as: 
 





 (2. 9) 
 
Therefore, the probability of being in the disease state for people at age x is the 
integral over all younger ages t of the probability of becoming diseased from 
disease-free at each age t, times the probability of surviving the extra death risk 
between age t and x.  𝑟𝑎( ) and  𝑟𝑑( , 𝑡) do not appear in the prevalence equation 
2.9. In fact, they are used to perform other related calculations in the MIAMOD 
(Verdecchia, et al., 1989). 
 
For the MIAMOD, software is freely available using this method to calculate 
prevalence (EUROCARE, 2011). It can be used to estimate current prevalence 
and to calculate future prevalence projections. One of the features of this method 
is that there are many parameters involved in the estimation, which means that the 











2.1.5.2 The PIAMOD method 
 
Unlike the MIAMOD method that focuses on mortality, the PIAMOD 
(Prevalence Incidence Analysis Model) (Verdecchia, et al., 2002) estimates 
prevalence from incidence and survival by fitting a parametric incidence model to 
incidence data. Following the notation in Chapter One, t is patient age at 
diagnosis and x is the current age on the index date. The theory of this method can 
be expressed as the function: 
 
 𝑃( ) = ∑ (1 − 𝑃(𝑡))𝐼(𝑡)𝑆𝑟(𝑡,  ) 
𝑥− 
𝑡   (2. 10) 
 
Where 𝑃( ) is the probability of being a cancer patient, who is still alive at age x, 
𝐼(𝑡) is the probability of being ill between age t and t+1, 𝑆𝑟(𝑡,  ) is the 
probability of surviving the extra death hazard specifically due to the disease 
under consideration, and (1 − 𝑃(𝑡)) represents the proportion of disease-free 
people at age t (Verdecchia, et al., 2002 (a)). The cohort-specific prevalence at 
age x is the summation over all ages up to x of the probabilities. This theory is 
similar to the transition rate method, if it is assumed that incidence, survival and 
population are constant with calendar years.  
 
The PIAMOD can be used to calculate future prevalence projections. It is 
assumed that the projection of modelled incidence to future years is the same as 
during the observation period. Age-specific incidence in every year of observed 
period can be obtained directly. For survival, it is usually assumed that survival 
improvements will no longer be observed in the future. Therefore the hypothesis 
is that cancer patients‘ survival remains stable for future years. Or, in a more 
optimistic scenario, cancer patients‘ survival is assumed as continuing to improve 
at the same rate as observed in recent past years. Lastly, population evolution: 
The numbers of new born and age-specific general mortality in the population are 
assumed to keep constant during the projection period ( Verdecchia, De Angelis, 




Unlike the transition rate methods in the previous sections, the PIAMOD method 
is formulated as a discrete time model. The advantage of this is that it is easy to 
obtain probabilities in discrete time, because practical applications usually deal 
with discrete data (for example, incidence for a single age in every calendar year). 
The disadvantage is that more attention has to be paid to building models. 
Verdecchia, De Angelis, and Capocaccia (2002) assumed that, ―events (that is, 
diagnosis, death) can only occur at the midpoint between two consecutive 
birthdays‖. However, if patients are diagnosed and die within the same calendar 
year, this assumption results in zero survival time. Equation 2.10 shows that the 
prevalence at age x does not include the patients who are diagnosed at age x and 
who are still alive.  
 
 
The MIAMOD and the PIAMOD are widely used to estimate prevalence and to 
make future projections. Prevalence of cancer in Italy was estimated and 
projected to the year 2000 using the MIAMOD method (Mariotto, et al., 1999). In 
2007, it was used to calculate prevalence in Italian regions (Verdecchia, et al., 
2007), and the prevalence of cancer in 2010 was derived with the MIAMOD 
method (De Angelis, et al., 2007). The PIAMOD method was used to make long-
term projections of cancer prevalence up to 2030 in the U.S., based on the data 
from 1973 to 1993 (Verdecchia, De Angelis, and Capocaccia, 2002).  The 
PIAMOD was also used to estimate the number of patients with colorectal 
carcinoma by phases of care in the U.S. from 2000 to 2020 (Mariotto, et al., 2006), 
and cancer survivors in Switzerland in 2020 (Herrmann, et al., 2013).  
 
2.1.6 Completeness index 
 
The completeness index is a statistical model that estimates total prevalence from 
limited duration prevalence data (Capocaccia and De Angelis, 1997; Merrill, et al., 
2000). 
 
Limited duration prevalence (observed prevalence) represents the proportion of 
people alive on an index date that had a diagnosis of cancer within the period of 
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registry. It can be obtained using the counting method. Parametric incidence and 
survival models are used to estimate the proportion of modelled prevalence that is 
observed; the proportion is called the completeness index. This in turn is used to 
inflate the limited duration prevalence (Gigli, et al., 2006). Therefore, together 
with incidence and follow-up data from the registry, the total (unlimited) 
prevalence may be estimated using the completeness index method (Capocaccia 
and De Angelis 1997). 
 
Total prevalence can be estimated by modeling a mathematical relationship 
between prevalence, incidence and survival. This is done in a single cohort, 
observed for a time period of L years. If the disease is not reversible, the 
relationship between prevalence, incidence and relative survival can be expressed 
as: 
 
    ( ) = ∫ 𝐼(𝑡)𝑆𝑟( − 𝑡, 𝑡)𝑑𝑡
𝑥
 
    (2. 11) 
 
Where ( ) is the proportion in the population of individuals with cancer at age x,  
𝐼(𝑡) is the incidence rate at age t and 𝑆𝑟( − 𝑡, 𝑡) indicates the probability that a 
single patient diagnosed with a certain cancer at age t is still alive at age x (t: 
diagnosed age, x: current age). 
 
Both incidence and relative survival in equation 2.11 are estimated using 
parametric functions. Usually the model assumes that there is an exponential 
relationship between incidence and age, adjusting for birth cohort. 
 
 𝐼(𝑡) = 𝑎𝑡𝑏  (2. 12) 
 
Where a is a scale parameter which is dependent on the birth cohort, b is the age 
slope parameter, and t is the incidence age. If we take the logarithm of both sides 
of this equation we find a linear relationship between log (incidence) and log 
(age): 
 




Because age and cohort parameters are additive on the logarithmic scale, this 
model has the advantage of mathematical simplicity. However, there is 
disadvantage in this incidence model, which is the underlying assumption of lack 
of interaction between age and cohort. Nevertheless, this model does provide a 
good fit for the incidence data of some cancers (details are in Chapter Four). 
 
For the survival model, it considered that a proportion of the patients are cured. It 
is assumed that they are exposed to the same mortality rates as the general 
population. Under the assumption that only a proportion of the patients have an 
excess mortality, whilst the remainder, share the same death rate as the general 
population, a mixture model is used for relative survival. If A is the proportion of 
individuals with cancer who will die of the cancer with a relative survival 
function following the Weibull distribution, whilst the remaining proportion (1-A) 
have the same mortality rate as the general population, then: 
 
 𝑆𝑟( − 𝑡, 𝑡) = [(1 −  )   𝑒 𝑝(− ( − 𝑡)
 )]
𝑒𝑥𝑝 ( (𝑡−𝑡 ))
  (2. 14) 
 
Where t is the age at diagnosis and x is the current age,    and   are the scale and 
shape parameters of Weibull distribution. In this model, (1 −  ) represents the 
proportion of patients who are not exposed to excess risk of death. The 
parameters 𝚼 are the log relative risk of being diagnosed one year older; the 
constant 𝑡  is reference age. Usually the median age of diagnosis is used as the 
reference age in the calculation. 
 
The computation of prevalence is particularly simple if incidence and relative 
survival are known parametric functions. However, the estimates depend on the 
goodness of fit of the chosen models. Therefore, Capocaccia and De Angelis 
(1997) continue to produce the completeness index method. It uses the incidence 
and relative survival parametric models to estimate the proportion of modelled 





The total prevalence could be divided into two parts:  𝑜( , 𝐿) which is the 
observed prevalent cases, and unobserved prevalent cases  𝑢( , 𝐿), which were 
diagnosed before the start of the registry and who are still alive: 
 
  ( ) =  𝑜( , 𝐿)   𝑢( , 𝐿)  (2. 15) 
 
It can be expressed as: 
 





 (2. 16) 
 
The proportion of observed prevalence of the total prevalence is given by the ratio 








  (2. 17) 
 
The completeness index R, is in turn used to inflate the observed prevalence to 
total prevalence: 
 
  ( ) =
𝑁 (𝑥, )
 
  (2. 18) 
 
This method has been widely used in European countries and in the U.S. In the 
U.S., cancer prevalence was estimated using this method based on tumour registry 
data from the Surveillance Epidemiology and End Results (SEER) program 
(Merrill, et al., 2000). The completeness index method was also used to estimate 
cancer prevalence in Europe in the EUROPREVAL program (Micheli, et al. 
2002a; Capocaccia, et al. 2002). Cancer prevalence in France, Italy and Spain, 
Northern Europe and Central Europe, and in the UK was calculated using this 
method separately (Verdecchia, et al., 2002; Forman, et al., 2003; Lutz, et al., 
2003; Möller et al., 2003). The total prevalence of leukaemia in Australia based 
on this method in1997 was reported in 2002 (Brameld, et al., 2002); cancer 
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prevalence was estimated in Queensland in 2002 using this method (Youlden, 
Health, and Baade, 2005). In 2010, the completeness index method was applied to 
calculate total prevalence based on the North Carolina Central Cancer Registry 
(NCCCR) data (Wobker, Yeh and Carpenter, 2010). This method was also used to 
estimate the complete childhood prevalence of acute lymphocytic leukaemia and 
all cancer combined based on SEER cancer registry data (Simonetti, et al., 2008). 
 
The completeness index method has an obvious advantage. It estimates the 
proportion of observed prevalence and uses it to calculate the total prevalence. 
Therefore, compared with the methods outlined in previous sections, the 
completeness index method comes closer to the observed data (Capocaccia and 
De Angelis, 1997; Merrill, et al., 2000; Gigli, et al., 2006). 
 
However, in this study, some subtypes of haematological malignancies show 
different incidence curves (see Appendix A5) and cannot be modelled using 
equation 2.12. Furthermore, there is no evidence to show that there is a linear 
relationship between ―the log relative risk‖ and diagnosed age for some subtypes. 
Indeed, for some haematological malignancies, the mortality goes down with age 
in the young groups and increases in the elderly (details are shown in Chapter 
Three and Four). 
 
2.1.7 Additional Methods 
 
Other methods used to calculate cancer prevalence appear in the literature, and 
these are discussed in this section. Since they are used less in literature, they are 
discussed together and only briefly outlined. 
 
2.1.7.1 The relationship between incidence, mortality and prevalence 
 
This method uses the relationship that exists between the risk of getting cancer, 
the net risk of dying of a given cancer, and the age-specific prevalence of cancer 








  (𝑥)−  (𝑥)
 −  (𝑥)
  (2. 19) 
 
Where 𝑝( ) is the prevalence within people of age x,  𝑖( ) is the risk of getting 
cancer, and  𝑑( ) is the net risk of dying of a certain cancer for the same 
individuals. A birth cohort is used to calculate the total prevalence. It is used to 
calculate prevalence, assuming the population size and structure are stationary 
( Estève, Benhamou and Raymond, 1994). In 2000, the total prevalence of cancer 
in France was estimated using this method (Colonna, et al., 2000). The advantage 
of this method is its simple formula (equation 2.19), whilst the disadvantage is 
that the net risk of dying of the specific cancer is not usually directly available 
from registry data. 
 
2.1.7.2 Age specific n-year prevalent cases 
 
This method can provide age-specific prevalence. The International Agency for 
Research on Cancer (IARC) reported the world-wide prevalence of cancer by 
estimating 1-, 2-3, and 4-5 year prevalence in 1990 (Pisani, Bray and Parkin, 
2002). Prevalent cases of a given age were estimated from incidence rates and 
year-specific survival probabilities according to the following formula: 
 
   𝑃(𝑛 − 𝑦𝑒𝑎𝑟 𝑐𝑎𝑠𝑒𝑠) = ∑ ∗ 𝑆(𝑖 − 0.5)   (2. 20) 
 
Where   is the annual number of new cases in age x, 𝑆(𝑑) represents the 
proportion of cancers diagnosed at age x and alive at time d after diagnosis, and n 
is the number of years as cases. Age-specific n-year prevalence includes all 
patients at a certain age that were diagnosed within n years before the index date, 
and who are still alive. For example, 5-year prevalent cases of age 45 in year 1990 
are those diagnosed at age 41 in 1986 and who survive 4.5 years (from mid time 
of a year), plus those diagnosed at age 42 in 1987 and who survive 3.5 years, and 





                       1986          1987           1988         1989          1990 
 
                  𝐼   ∗ 𝑆  (4.5)    𝐼   ∗ 𝑆  (3.5)  𝐼   ∗ 𝑆  (2.5) 𝐼   ∗ 𝑆  (1.5)  𝐼  5 ∗ 𝑆  (0.5)   5-year  
                                                                                                             prevalent 
                                                                                                             cases of age 45 
 
 
Figure 2- 6 Explanation of the method using the example of 5-year prevalent 
cancers at the age of 45 (Pisani, Bray and Parkin, 2002). 
 
In the example, ―5-year prevalent cases of age 45‖ are the patients at age 45 in 
1990 who were diagnosed between 1986 and 1990 and who were still alive in 
1990. This can be expressed as: 
 
𝑃 5(5 − 𝑦𝑒𝑎𝑟) =    ∗ 𝑆  (4.5)     ∗ 𝑆  (3.5)     ∗ 𝑆  (2.5) 
     ∗ 𝑆  (1.5)    5 ∗ 𝑆 5(0.5) (2. 21) 
 
At IARC, information on incidence and survival rates was directly obtained from 
the different countries and areas (Pisani, Bray and Parkin, 2002). In 2008, in 
Japan this method was used to estimate future prevalence for the year 2020 
(Tabata, et al., 2008). Colorectal cancer and gastric cancer prevalence was 
calculated using this method in 2009 and in 2010, according to incidence and 
survival data in Iran (Mehrabian, et al., 2010; Esna-Ashari, et al., 2012). 5-year 
prevalence in Germany in 2004, based on this method, was published in 2010 
(Haberland, et al., 2010). Recently, the n-year prevalence has been updated to 
2008 world-wide using this method, in the GLOBOCAN project (GLOBOCAN is 
a project to provide contemporary estimates of the incidence of, mortality and 
prevalence from major types of cancer, at national level, for 184 countries of the 






2.1.7.3 Future prevalence based on trends 
 
Fiorentino, et al. (2011) showed a method to estimate future trends in prevalence, 
taking data concerning the current prevalence and externally generated trends in 
cancer incidence and survival as input. In addition to the general notation given in 
Chapter One, the following are also to be noted: 
 
Let Yindex denote the most recent year for which data concerning cancer 
prevalence is available. 
Let Yfuture denote the year for which we want to forecast cancer prevalence. 
Let YI denote the year of incidence, with YI= Y0 the earliest year of diagnosis. 
Let C(t, YI) denote the number of cancer diagnoses confirmed during year 
    𝑖𝑛𝑑𝑒𝑥for patients at age t. 
Let A denote the contribution to cancer prevalence at Yfuture from those diagnosed 
at a time ≤  𝑖𝑛𝑑𝑒𝑥. 
Let B denote the contribution to cancer prevalence at Yfuture, from those diagnosed 
at a time  𝑖𝑛𝑑𝑒𝑥. 
Let Tot denote the total cancer prevalence at Yfuture. 
 
The conditional probability of an individual, diagnosed at   ≤   ≤  𝑖𝑛𝑑𝑒𝑥, of 
age t, surviving at least a time of  𝑓𝑢𝑡𝑢𝑟𝑒 −    after diagnosis, given that they have 
survived a period of  𝑖𝑛𝑑𝑒𝑥 −   , is  
 
                                                 
 (𝑡,       −  ,  )
 (𝑡,      −  ,  )




The number of patients expected to be alive at Yfuture , given that they  have 
survived to Yindex is: 
 
                               = ∑ ∑  (𝑡,   ) ∗
 (𝑡,       −  ,  )
 (𝑡,      −  ,  )
  
𝑡  
      
     
                  (2. 23) 
 
Next, the prevalence attributable to those cancer diagnoses occurring after Yindex 
needs to be added: 
 
                         = ∑ ∑  (𝑡,   ) ∗ 𝑆(𝑡,  𝑓𝑢𝑡𝑢𝑟𝑒 −   ,   )
  
𝑡  
       
           
         (2. 24) 
 
The total prevalence in some year Yfuture in the future is: 
 
                                                      𝑜𝑡 =                                                (2. 25) 
 
This method is used to estimate the prevalence up to 20 years after index an date 
in the UK (Fiorentino, et al., 2011). It uses data from 1985 to 2004, which means 
that in the calculation,  𝑖𝑛𝑑𝑒𝑥 = 2004 and   = 1985.  It was also applied to data 
from the NCIN (NCIN is the National Cancer Intelligence Network that works to 
drive improvement in standards of cancer care and clinical outcomes using 
information collected about cancer patients for research and analysis in the UK. 
[NCIN, 2012]) to estimate the prevalence in 2040 in the UK, with  𝑖𝑛𝑑𝑒𝑥 = 2008 
and   = 1971 (Maddams, Utley, and Møller, 2012). The significant advantage 
of this method is that the future prevalence can be estimated using a simple 
analytical model. Incidence and survival in the future are assumed to follow the 
observed trend in data. However, this method requires a relatively long registry 
period to avoid the bias from surviving patients who were diagnosed before the 




2.1.8 Summary of the methods 
 
References describing the major methodologies used to estimate prevalence are 
summarised in Table 2-1. These methods calculate or estimate various different 
types of prevalence. In the earlier methods, prevalence was calculated directly 
without estimation or adjustment. This means that there were frequent 
underestimates of prevalence at that time (Hakama, et al., 1975; Feldman, et al., 
1986; Adami, et al., 1989). After the 1990s, most estimates were made from 
cancer registries based on mathematical models. Such estimation-based methods 
were used to calculate total prevalence in Europe (Capocaccia, et al., 2002; 
Micheli, et al., 2002a), and provided country- specific estimations of total 
prevalence in the UK, France, Italy, Sweden, Norway, Denmark, and so on 
(Verdecchia, et al., 2002; Forman, et al., 2003; Lutz, et al., 2003; Möller, et al., 
2003). Total prevalence in the U.S. was also estimated using SEER (SEER is the 
Surveillance, Epidemiology, and End Results Program in the National Cancer 
Institute. It works to provide information on cancer statistics with the aim to 
reduce the burden of cancer among the U.S. population. [SEER, 2012]) data from 
the mathematical model (Merrill et al. 2000). There are also some studies that 
have focussed on examining the trends and projecting forward prevalence 
estimates in the U.S. (Mariotto, et al., 2006), UK (Fiorentino, et al., 2011; 
Maddams, Utley, and Møller., 2012), and Switzerland (Herrmann, et al., 2013). 
 
Most of the prevalence estimates were based on patients, however some estimated 
tumour prevalence based on diagnoses. For example, patients with multiple 
malignant primaries were included in the computation of total prevalence in Italy 
in 2006 (Guzzinati, et al., 2012). The reports in Canada focused on tumour-based 
prevalence instead of person- based prevalence (Ellison and Wilkins, 2009).    
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Table 2- 1 Summary of methods used to calculate prevalence 
Author Published date Region Prevalence Method 
Hakama, et al. 1975 Finland Observed prevalence Direct method (count numbers) 
Feldman, et al. 1986 US Observed prevalence Direct method (count numbers) 
Adami, et al. 1989 Sweden Observed prevalence Direct method (count numbers) 
Byrne, Kessler and  1992 US Observed prevalence Cross-sectional population-based surveys 
Devesa 
Schrijvers, et al. 
1994 Netherland Observed prevalence Cross-sectional population-based surveys 
De Angelis, et al. 1994 Italy Future prevalence MIAMOD 
Polednak 1997 US Observed prevalence Direct method (count numbers) 
Capocaccia and De Angelis 1997 NA. Total prevalence Completeness index 
Gail, et al. 1999 US 
Observed prevalence Counting method 
Total prevalence Transition rate 
Mariotto, et al. 1999 Italy Future prevalence MIAMOD 
Zanetti, et al. 1999 
Nordic countries, EU, Observed prevalence Counting method 
Connecticut, Italy Total prevalence Completeness index 
Hoogenveen, et al. 2000 Netherland Total prevalence IPM 
Colonna, et al 2000 France Total prevalence Other 
Merrill, et al. 2000 US Total prevalence Completeness index 
Merrill 2001 US Observed prevalence Counting method 





Table 2-1 continued 
Author Published date Region Prevalence Method 
Kruijshaar, Barendregt 2002 Netherland Total prevalence DisMod 
and Hoeymans 
Verdecchia, et al. 
2002 Europe and US Future prevalence PIAMOD 
Pisani, Bray and Parkin 2002 Worldwide  n-year prevalence Other 
Micheli, et al.  2002b US Observed prevalence PREVAL 
Micheli,, et al. 2002a Europe Total prevalence Completeness index 
Capocaccia, et al 2002 Europe Total prevalence Completeness index 
Verdecchia, et al.  2002 France, Italy, Spain Total prevalence Completeness index 
Brameld, et al. 2002 Western Australia Total prevalence Completeness index 
Forman, et al. 2003 UK Total prevalence Completeness index 
Möller, et al.  2003 Northern Europe Total prevalence Completeness index 
Lutz, et al. 2003 Central Europe Total prevalence Completeness index 
Youlden, Health, and Baade  2005 Queensland Total prevalence Completeness index 
Louchini, et al. 2006 Quebec (Canada) Observed prevalence Counting method 
Gigli, et al. 2006 US Total prevalence Completeness index 
Mariotto, et al. 2006 US Future prevalence PIAMOD 
De Angelis, et al. 2007 Italy Future prevalence MIAMOD 
Verdecchia, et al. 2007 Italy Total prevalence MIAMOD 
Tabata, et al. 2008 Japan n-year prevalence Other 




Table 2-1 continued 
Author Published date Region Prevalence Method 
Ellison and Wilkins 2009 Canada n-year prevalence Counting method 
Mehrabian, et al. 2010 Iran n-year prevalence Other 
Haberland, et al.  2010 Germany n-year prevalence Other 
Wobker, Yeh and  2010 US Total prevalence Completeness index 
Carpenter 
Fiorentino, et al.  
2011 UK Future prevalence Other 
Esna-Ashari, et al. 2012 Iran n-year prevalence Completeness index 
Guzzinati, et al. 2012 Italy Total prevalence Completeness index 
Maddams, Utley and 2012 UK Future prevalence Other 
Møller 
Visser, et al. 
2012 Europe Total prevalence Completeness index 
Bray, et al. 2013 Worldwide  n-year prevalence Other 
Herrmann, et al. 2013 Switzerland Future prevalence PIAMOD 
 
MIAMOD: Mortality Incidence Analysis Model; PIAMOD: Prevalence Incidence Analysis Model; IPM: incidence, prevalence, and mortality; 
DisMod: disease model; SEER: Surveillance Epidemiology and End Results; IARC: International Agency for Research on Cancer; EU: 
European Union. NA: Not Available.
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2.2 Comparison of the methods  
  
2.2.1 The differences between the methods 
 
Amongst the main methods mentioned in the previous section, direct calculations 
(the counting method and the PREVAL approach) and the transition rate methods 
are non-parametric methods to calculate prevalence, whilst back calculation and 
completeness index methods estimate prevalence using parametric models. Direct 
calculations provide prevalence for patients diagnosed within the registry period, 
and transition rate methods are more flexible and can provide n-year prevalence 
or total prevalence. Back calculation methods project future prevalence, as well as 
estimate total prevalence, whilst the completeness index is a method purely 
designed to estimate total prevalence.   
 
The relationships between incidence, survival, mortality, and prevalence are used 
in models to make estimates, and the models are built based on assumptions that 
make the estimation process feasible. The assumptions used in prevalence 
estimation are not in order to adopt the best hypothesis, but to keep the model 
easy to be understood and calculate, as well as to provide plausible results 
( Verdecchia, De Angelis, and Capocaccia,  2002). The most convenient 
assumption is to keep probabilities (such as incidence and transition rates) 
constant over time in the calculation. However for the projection of prevalence in 
the future, the incidence is modelled to follow the observed trend into future years. 
Usually cancer is considered as an irreversible disease, and all incident cases are 
counted as prevalent cases up to death, even if treatment is effective (Estève, 
Benhamou and Raymond, 1994).  However, there are some methods in the 
literature that involve remission rates and calculate prevalence for curable disease 
(Capocaccia and De Angelis, 1997; Hoogenveen and Gijsen 2000).  Sometimes 
the advantages and disadvantages are not so obvious, and it is difficult to say 
which one is the best method. Table 2-2 summarizes the characteristics of the 
different methods of prevalence estimation. 
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Observed and lost in follow-up patients 









Lost cases have the same mortality as not 
lost to follow-up 
- 
Prevalence for n 
years 
within the registry period 
Transition  TRM 
Incidence 
&Mortality Constant over time No     
rate  IPM 
Incidence 
&Mortality Constant over time No Non-parametric, Requires many probabilities 
method DisMod 
Incidence 
&Mortality Constant over time Yes 
Easy to use and 
robust 




Change follow the observed trends No 
Project prevalence 
in future 
Strongly depends on parametric 
assumptions on incidence and 
calculation 
PIAMOD 






Change follow the observed trends OR 







Cohort parameter in incidence can be 
omitted in calculation Yes 
More closed to 
observed data 
Parametric models do not suitable  
Index Survival Constant over time for the data in this study 
Other 
Other (Estève, 
et al., 1994) 
Incidence & 
Mortality 
Constant over time No 
Use easily available 
information 
Net risk of dying  is not usually available 
from registry data 







Restriction of limited duration 






Constant over time No 
Project prevalence 
in future 






In this study, the aim was to estimate the number of past cases that were not 
registered. Since it was not concerned with the extrapolation of prevalence 
estimates for the future, back calculation methods were not appropriate for this 
work. Apart from this, transition rate methods and completeness index methods 
can be used to estimate total prevalence based on the observed data. Usually the 
completeness index method uses parametric functions to estimate incidence and 
relative survival. The transition rates are obtained from actuarial estimates.  
 
At first sight, those methods have different models for estimation. However, there 
is a relationship between them. This is because there are theoretical relationships 
which link incidence, mortality, and survival (Estève, Benhamou and Raymond, 
1994). The feasibility of estimating prevalence can be assessed from this. 
 
  
2.2.2 The relationship between the transition rate method and the 
completeness index method 
 
This section gives an insight into the relationship between two prevalence models. 
In this calculation, the relationships between the transition rate method and 
completeness index method can be found. Although the models appear totally 
different to each other, a certain amount of algebraic manipulation will show them 
to be similar. These manipulations can be found in the literature (Verdecchia, et 
al., 1989; Gras, Daurès andTretarre,, 2006); the relationship between transition 
rate models and the completeness index model is shown as follows:   
 
Following the definitions given for transition rate methods, let 𝑟 
∗( ) indicate the 
general mortality rates at age x. 𝑟 ( ) is the incidence rate at age x. 𝑟 ( ,  − 𝑡) is 
the death rate at age x for patients who had a cancer diagnosed at age t. If 
𝑆𝑟( ,  − 𝑡) is the relative survival, then it can be shown that: 
 










It is assumed that: 
Firstly, the disease is rare and the incidence is low: 𝑟  1. So,  
 
 𝑒 𝑝 (−∫ 𝑟 (𝑡)𝑑𝑡
𝑢
 
)  1  (2. 27) 
 
Furthermore, since the model is used to estimate prevalence in a population, u 
represents age and will not be very large (usually less than 100). In addition, the 
mortality rate of non-cases 𝑟  is approximated using the mortality rate of the 
general population 𝑟 
∗( ). Therefore, 
 
 𝑟 ( )  𝑟 
∗( )   (2. 28) 
 
The age-specific L- year partial prevalence using the method of transition rates is: 
 
 𝑃 =
  (𝑥, )
 (𝑥)
=
∫ 𝑒𝑥𝑝.−∫ (𝑟  𝑟 )(𝑢)𝑑𝑢
 




   
        (𝑥)
(2. 29) 
 
Because of the first assumption of 𝑟  1 and equation (2.26), equation (2.28) 
can be reformulated as follows: 
 
 𝑃 =
∫ 𝑒𝑥𝑝.−∫ 𝑟 (𝑢)𝑑𝑢
 




   
        (𝑥)
  (2. 30) 
 
Because of the second assumption 𝑟 ( )  𝑟 
∗( ), equation (2.29) can be 
continued to be reformulated as follow: 
 
 𝑃 =
∫ 𝑒𝑥𝑝.−∫ 𝑟 
∗(𝑢)𝑑𝑢
 




   
        (𝑥)
  (2. 31) 




























𝑒 𝑝(−∫ 𝑟 (𝑢, 𝑢 − 𝑡)𝑑𝑢
𝑥
𝑡
)𝑑𝑡  (2. 32) 
 
Because of the equation (2.26), this can be expressed as follows: 
 
 𝑃 = ∫ 𝐼(𝑡)𝑆𝑟( ,  − 𝑡)𝑑𝑡
𝑥
𝑥− 
  (2. 33) 
 
Where I(t) is incidence at age t, Sr(x, x-t) is the relative survival at age x surviving 
for x-t years. This is the basic model of the completeness index method. In other 
words, under certain conditions, the completeness index method is approximately 
equal to the transition rates method in calculating the L- year prevalence. 
 
 
2.3 Reported prevalence figures of haematological malignancies in the 
literature 
 
2.3.1 Prevalence reports from main cancer registries in the world 
 
Some well-established cancer registries that provide prevalence figures are 
summarized in Table 2-3.  These cancer registries can provide total prevalence or 
n-year prevalence for the UK, Italy, Canada, Australia, the U.Ss, and the Nordic 
European countries, with latest reports from 2006 to 2011. N-year cancer 
prevalence in the UK in 2006 is obtained from the NCIN (National Cancer 
Intelligence Network (NCIN), 2010). For Italy, data is derived from the network 
of cancer registries, AIRTUM (Guzzinati, et al., 2012) to estimate total 
prevalence. For Canada, the latest n-year prevalence in 2009 was derived from the 
Canadian Cancer Registry (CCR) maintained by Statistics Canada (Ellison and  
Wilkins, 2009; CCR, 2012). For the U.S., total prevalence can be obtained from 
the Surveillance, Epidemiology and End Results (SEER) Program (SEER, 2012), 
in which information is from specific geographic areas representing 28 percent of 
the U.S. population. Longer period cancer prevalence can be obtained directly 
from registries that operated for longer times. For Australia, data is from the 
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Australian Institute of Health and Welfare (AIHW) (AIHW, 2012), which 
provides 26- year prevalence, and for the Nordic European countries, data is from 
NORDCAN, which provides up to 48- year prevalence in Denmark (Engholm, et 
al., 2013).  
 
Apart from the reports from these main cancer registries, international n-year 
prevalence was estimated using GLOBOCAN (GLOBOCAN, 2008) which covers 
184 countries. Some prevalence figures in this chapter are derived from a specific 
publication (Pisani, Bray and Parkin, 2002), whilst for countries in the world, the 
prevalence has been updated to 2008 on its web site however are not shown here 
(GLOBOCAN, 2008; Bray, et al., 2013). The estimated prevalence in 
GLOBOCAN relies on incidence and survival at country level, therefore it is 
greatly limited in terms of some of its data sources. For example, compared to 
developed countries, many low-income countries rarely have survival estimates 
and proxies of their survival are created under assumptions. The European Cancer 
Registry-based study on survival and Care (EUROCARE) is a large cooperative 
registry based study which covers 23 countries and 89 cancer registries in Europe 
(Sant, et al., 2009). The EUROPREVAL and HAEMACARE are projects that 
were set up to estimate total prevalence of cancer, and to improve the 
standardization of data on haematological malignancies respectively, archived by 
EUROCARE. The EUROPREVAL project presented total prevalence in 
European countries in 1992. However, in some countries, such as France, the 
cancer registries providing the data only covered small fractions of the 
populations (Verdecchia, et al., 2002; Crocetti, et al., 2013). The HAEMACARE 
project provided incidence and survival for haematological malignancies under 
WHO classification in 48 cancer registries, however the reports concerning 
prevalence were not available (Sant, et al., 2010; Marcos-Gragera, et al., 2011; 
Maynadié, et al., 2013). Apart from these projects, total prevalence of myeloid 
malignancies and other rare cancers were provided by RARECARE, which 
extracted data from 64 cancer registries (excluding cancer registries which did not 





Table 2- 3 Main cancer registries in this section, projects for prevalence, percentage of the population of the country, and latest year for 
prevalence reports 
Country Cancer registry Project 
Population covered 
by cancer registry 
Year of 
prevalence Web-site 
United Kingdom Cancer Networks NCIN 100% 2006 http://www.ncin.org.uk/ 
Italy AIRTUM ITACAN 40% 2006 http://www.registri-tumori.it/cms/en 
Canada CCR - 100% 2009 http://www.statcan.gc.ca/start-debut-eng.html 
Australia AACR AIHW 100% 2007 http://www.aihw.gov.au/ 
United States SEER SEER 28% 2010 http://seer.cancer.gov/ 
Nordic European 
Countries* ANCR NORDCAN 100% 2010(2011) http://www.ancr.nu/nordcan.asp 
 
*Norway, Sweden, Denmark, Finland, Iceland (Norway and Sweden provided prevalence in 2010; Denmark, Finland, Iceland provided 
prevalence in 2011). 
 
Abbreviations:  
NCIN: National Cancer Intelligence Network. AIRTUM: The Italian Association of Cancer Registries. CCR: Canadian Cancer Registry. AACR: 
Australasian Association of Cancer Registries. AIHW: Australian Institute of Health and Welfare. SEER: Surveillance, Epidemiology and End 




2.3.2 Lack of systematic reports about haematological malignancies 
 
Although there are many methods in the literature that are used to calculate the 
prevalence of cancer, few publications have focused on prevalence studies for 
haematological malignancies, therefore their prevalence is not routinely available. 
For example, Gail (1999) used breast and brain cancers only as the example to 
show the Transition Rates Method and Counting method (Gail, et al., 1999).  In 
2006, Gigli (2006) calculated the prevalence of colon cancer from an Italian 
registry. The PIAMOD was used to calculate and project cancer prevalence in the 
future, but only the prevalence of breast cancer was reported in that study 
(Verdecchia, De Angelis, and Capocaccia 2002). Breast cancer, prostate cancer, 
lung cancer, and colon cancer were routinely reported in the studies, however not 
all the papers about prevalence demonstrated the prevalence of haematological 
malignancies.  
 
Furthermore, haematological malignancies were considered as a whole group for 
prevalence estimates in France (Colonna, et al., 2000) and Norway (Skjelbakken, 
et al., 2002) in 2000 and 1996 respectively.  In the EUROPREVAL project, only 
the prevalence of leukemia and Hodgkin lymphoma were reported (Verdecchia, et 
al., 2002; Micheli, et al., 2002a; Capocaccia, et al., 2002; Forman, et al., 2003; 
Lutz, et al., 2003). The SEER project only reported the number of prevalent cases 
without the prevalence rates (Merrill, et al., 2000). The reported prevalence of 
haematological malignancies is summarized in the Table 2-4 and Table 2-5. The 
prevalence of haematological malignancies is abstracted from the results in the 
literature, shown in order of increasing index date. Not all of them are total 
prevalence, and the types of prevalence they calculated are indicated in the 
column ―Note‖. Among those reports, GLOBOCAN estimated prevalence for 
adults only (over 15 years old) (GLOBOCAN, 2008), whilst others included all 
age groups. 
 
Although there are some reports of prevalence in the literature, most of the studies 
were published before the new classification of haematological malignancies by 
the WHO (WHO, 2008). Therefore prevalence is only reported by the four broad 
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categories—leukaemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and 
myeloma. It is very interesting that some of the studies exclude non-Hodgkin 
lymphoma, as this is the biggest group, yet the reasons for this are not given 
(Verdecchia, et al., 2002; Micheli, et al., 2002a; Capocaccia, et al., 2002; Forman, 
et al., 2003; Lutz, et al., 2003). It is worth noting that the prevalence indicated of 
Hodgkin lymphoma in some countries (for example the UK [Forman, et al., 2003]) 
is not total prevalence but 15-year prevalence due to the marked changes in 
treatment (Capocaccia, et al., 2002). For some recent web based measures, the 
prevalence of some subtypes were provided: NORDCAN presented prevalence of 
acute leukaemia and other leukaemia separately (Engholm, et al., 2013); SEER 
provided prevalence of acute myeloid leukaemia, chronic myelogenous leukaemia, 
acute lymphocytic leukaemia, and chronic lymphocytic leukaemia in the broad 
leukaemia group, as well as of myelodysplastic syndromes and chronic 
myelomonocytic leukaemia (SEER, 2012); RARECARE showed the prevalence 




Table 2- 4 Prevalence of haematological malignancies per 100, 000 for males 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
Canada     1.4             1990 5-year prevalence 
SSA 
GLOBOCAN 





































































































































Table 2-4 continued 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
SSA 
GLOBOCAN 
  1.7   2.7   6.4   0.7 1990 2-3 years prevalence 
MENA   2.7   2.1   4.2   0.3 1990   
LAC   3.5   2.6   5.1   0.7 1990   
North America   14.4   6.0   26.2   6.2 1990   
China and OEA   2.3   0.5   1.3   0.1 1990   
Japan   8.6   0.9   12.5   2.4 1990   
South- Eastern Asia   2.5   1.0   3.8   0.4 1990   
South- Central Asia   2.4   1.9   3.3   0.4 1990   
Eastern Europe   8.7   6.3   7.0   2.2 1990   
EU and EEA   12.3   6.5   18.7   5.2 1990   
Oceania   12.0   3.8   19.4   4.8 1990   
Developed   11.5   5.6   16.9   4.3 1990   
Developing   2.4   1.5   3.1   0.4 1990   





































Table 2-4 continued 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
China and OEA 
GLOBOCAN 
  1.7   0.4   1.0   0.1 1990 4-5 years prevalence 
Japan   6.9   0.8   10.6   1.5 1990   
South- Eastern Asia   1.8   0.8   2.9   0.3 1990   
South- Central Asia   1.4   1.6   2.2   0.3 1990   
Eastern Europe   6.0   5.3   5.3   1.3 1990   
EU and EEA   8.7   5.8   14.7   3.2 1990   
Oceania   8.5   3.3   15.2   3.0 1990   
Developed   8.5   5.0   13.7   2.7 1990   
Developing   1.7   1.2   2.4   0.2 1990   
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Table 2-4 continued 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
Netherland 
EUROPREVAL 
  31.6   20.2         1992 Total prevalence 
Germany   46.2   35.0         1992   
Austria   49.9   30.1         1992   
Switzerland   64.6   25.6         1992   
Slovenia   30.4   22.2         1992   
Slovakia   42.3   19.7         1992   
Poland   15.2   18.7         1992   
All European countries   39.5   26.3         1992   
Worldwide GLOBOCAN 233,100   113,500   381,400   74,300   2000 5-year prevalence 
Canada 
  3,426 21.5 883 5.5 4,930 31 1,362 8.6 2005 2-year prevalence 
  6,720 42.2 2,079 13.1 10,015 92.9 2,428 15.2 2005 5-year prevalence 
  10,170 63.9 3,806 23.9 15,316 96.2 3,126 19.6 2005 10-year prevalence 
England 
NCIN 
2,192 7.9 673 2.6 3,440 12.1 1,294 4.4 2006 1-year prevalence 
Scotland 244 8.9 65 2.6 322 11.1 148 4.9 2006 
 
Wales 172 9.8 34 2.2 228 12.9 97 5.1 2006 
 
Northern Ireland 60 6.8 20 2.3 104 12.1 56 6.3 2006 
 





Table 2-4 continued 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
England 
NCIN 
8,225 29.8 2,939 11.5 12,898 45.6 4,277 14.5 2006 5-year prevalence 
Scotland 1,008 36.2 313 12.5 1,284 44.8 472 15.8 2006   
Wales 891 33.5 161 10.9 794 45.4 325 17.3 2006   
Northern Ireland 229 26.1 84 9.6 402 46.2 173 19.7 2006   
United Kingdom 10,053 30.5 3,497 11.5 15,378 45.6 5,247 14.9 2006   
England 
NCIN 
12,876 46.7 5,521 21.6 24,204 71.5 5,659 19.2 2006 10-year prevalence 
Scotland 1,619 57.9 550 21.8 2,020 70.3 606 20.2 2006 
 
Wales 897 51.2 303 20.6 1,146 65.7 427 22.7 2006 
 
Northern Ireland 346 39.3 162 18.9 634 72.9 229 26.0 2006 
 




17,392 63.2 9,498 38.1 27,144 108.9 6,327 21.4 2006 20-year prevalence 
Scotland 2,145 77.3 990 38.6 2,734 95.8 660 22.0 2006   
Italy ITACAN 7,608 97.0 6,418 82.0 14,102 180.0 3,194 40.0 2006 Total prevalence 
Texas TCR 5,740   2,406   9,389   1,854   2006 10-year prevalence 
Australia AIHW - - 3,877 36.7 16,547 156.7 3,030 28.7 2007 1982-2007 






Table 2-4 continued 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
Canada 










2009 5-year prevalence 
  13,044   3,890   19,140   4,103   2009 10-year prevalence 
United States SEER 162,651   93,890   266,487   42,185   2010  Total prevalence 
Nordic countries 
NORDCAN 
12,920 101.7 6,438 50.7 19,355 152.4 3,896 30.7 2010 1980-2010 
Norway 2,400 97.5 1,297 52.7 3,662 148.8 859 34.9 2010 1973-2010 
Sweden 5,099 108.7 2,080 44.4 6,734 143.6 1,549 33.0 2010 1980-2010 
Denmark 2,988 108.0 1,489 53.8 4,463 161.4 807 29.2 2011 1963-2011 
Finland 2,355 88.8 1,523 57.4 4,757 179.3 692 26.1 2011 1973-2011 
Iceland 166 103.5 102 63.6 225 140.2 52 32.4 2011 1975-2011 
 
*per 100, 000 
 
Abbreviations in the table: 
HL: Hodgkin lymphoma, NHL: non-Hodgkin lymphoma, SEER:  the Surveillance, Epidemiology, and Ends Results, IARC: International Agency for Research on Cancer, 
SSA: sub-Saharan Africa, MENA: Middle East and Northern Africa, EU: European Union, EEA: European Economic Area, LAC: Latin America and Caribbean, OEA: 
Korea, Mongolia, and Hong Kong, NCIN: National Cancer Intelligence Network, TCR: Texas Cancer Registry, AIHW: Australian Institute of Health and Welfare, ASP: age 
standardized proportion, NA: not available
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Table 2- 5 Prevalence of haematological malignancies per 100, 000 for females 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
Canada     1.4             1990 5-year prevalence 
SSA 
IARC 


































































































































Table 2-5 continued 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
SSA 
IARC 
  1.4   1.3   4.4   0.5 1990 2-3 years prevalence 
MENA   1.6   1.3   3.4   0.5 1990   
LAC   2.9   1.6   3.5   0.7 1990   
North America   10.4   4.7   20.1   5.4 1990   
China and OEA   1.8   0.5   1.0   0.1 1990   
Japan   5.9   0.4   8.2   2.6 1990   
South- Eastern Asia   2.1   0.5   2.9   0.3 1990   
South- Central Asia   1.7   0.7   1.8   0.4 1990   
Eastern Europe   6.9   4.1   4.9   2.6 1990   
EU and EEA   9.7   3.9   14.7   4.8 1990   
Oceania   8.3   3.0   15.3   4.2 1990   
Developed   8.7   3.8   12.7   4.1 1990   
Developing   1.9   0.8   2.2   0.3 1990   













































Table 2-5 continued 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
China and OEA 
IARC 
  1.4   0.4   0.8   0.1 1990 4-5 years prevalence 
Japan   4.8   0.4   6.9   1.6 1990   
South- Eastern Asia   1.5   0.4   2.2   0.2 1990   
South- Central Asia   1.0   0.6   1.3   0.2 1990   
Eastern Europe   4.9   3.7   3.7   1.6 1990   
EU and EEA   7.2   3.6   11.6   2.9 1990   
Oceania   6.1   2.7   12.1   2.5 1990   
Developed   6.5   3.4   10.2   2.5 1990   
Developing   1.3   0.7   1.7   0.2 1990   







    




































































Table 2-5 continued 
 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
Netherland 
EUROPREVAL 
  26.6   17.0         1992 Total prevalence 
Germany   26.1   19.2         1992   
Austria   31.8   23.4         1992   
Switzerland   38.3   17.4         1992   
Slovenia   31.5   15.1         1992   
Slovakia   32.9   18.3         1992   
Poland   13.7   15.9         1992   
All European countries   31.9   19.3         1992   
Worldwide GLOBOCAN 187,500   83,300   291,200   69,300   2000 5-year prevalence 
Canada 
  2,368 14.6 735 4.5 4,323 26.6 1,175 7.2 2005 2-year prevalence 
  4,791 29.5 1,672 10.3 8,976 55.3 2,136 13.2 2005 5-year prevalence 
  7,514 46.3 3,100 19.1 14,303 88.1 2,776 17.1 2005 10-year prevalence 
England 
NCIN 
1,533 4.8 541 2.0 2,890 8.8 1,050 2.9 2006 1-year prevalence 
Scotland 138 4.4 60 2.3 317 9.0 108 2.6 2006 
 
Wales 123 5.8 27 1.9 203 9.4 78 3.3 2006 
 
Northern Ireland 53 5.4 17 1.9 87 8.5 58 4.8 2006 
 







Table 2-5 continued 
 
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
England 
NCIN 
5,792 18.7 2,236 8.5 11,309 34.4 3,404 9.6 2006 5-year prevalence 
Scotland 659 20.2 265 9.9 1,248 35.5 383 9.4 2006   
Wales 432 21.0 114 9.2 722 34.9 242 10.0 2006   
Northern Ireland 175 17.6 78 8.6 395 37.6 146 13.0 2006   
United Kingdom 7,058 18.9 2,693 8.6 13,674 34.6 4,175 9.7 2006   
England 
NCIN 
9,353 30.2 4,133 15.7 18,023 54.7 4,521 12.8 2006 10-year prevalence 
Scotland 1,143 34.3 479 17.9 2,006 56.4 506 12.5 2006 
 
Wales 670 33.3 218 14.4 1,078 52.0 324 13.4 2006 
 
Northern Ireland 264 26.4 129 14.5 661 63.1 193 17.3 2006 
 




13,072 42.6 7,127 26.8 24,010 92.9 5,065 14.2 2006 20-year prevalence 
Scotland 1,566 47.7 786 28.8 2,668 74.7 564 13.9 2006   
Italy ITACAN 6,479 78.0 5,305 64.0 14,360 173.0 3,162 38.0 2006 Total prevalence 
Texas TCR 4,235   2,147   8,623   1,546   2006 10-year prevalence 
Australia AIHW - - 3,291 30.8 14,099 132.0 2,415 22.6 2007 1982-2007 








Table 2-5 continued  
Country/ Area Project 
Leukaemia HL NHL Myeloma 
Index date Note 
Counts Rates* Counts Rates* Counts Rates* Counts Rates* 
Canada 










2009 5-year prevalence 
  9,470   3,271   17,082   3,358   2009 10-year prevalence 
United States SEER 125,312   88,038   242,587   35,432   2010  Total prevalence 
Nordic countries 
NORDCAN 
10,568 82.0 5,050 39.2 17,323 134.5 3,258 25.3 2010 1980-2010 
Norway 1,894 77.0 916 37.2 3,358 136.5 697 28.3 2010 1973-2010 
Sweden 4,193 88.7 1,670 35.3 5,714 120.9 1,288 27.3 2010 1980-2010 
Denmark 2,419 86.0 1,149 40.9 3,874 137.8 647 23.0 2011 1963-2011 
Finland 2,093 76.1 1,299 47.3 4,571 166.3 606 22.0 2011 1973-2011 
Iceland 109 68.5 67 42.1 174 109.3 40 25.1 2011 1975-2011 
 
 
 *per 100, 0000 
 
Abbreviations in the table: 
HL: Hodgkin lymphoma, NHL: non-Hodgkin lymphoma, SEER:  the Surveillance, Epidemiology, and Ends Results, IARC: International Agency for Research on Cancer, 
SSA: sub-Saharan Africa, MENA: Middle East and Northern Africa, EU: European Union, EEA: European Economic Area, LAC: Latin America and Caribbean, OEA: 
Korea, Mongolia, and Hong Kong, NCIN: National Cancer Intelligence Network, TCR: Texas Cancer Registry, AIHW: Australian Institute of Health and Welfare, ASP: age 




2.3.3The reported prevalence figures in the literature vary according to 
geography, time, and method of calculation 
 
2.3.3.1 Geographic variability 
 
Developed countries show higher prevalence (Table 2-4 and Table 2-5) than 
developing countries (Pisani, Bray and Parkin, 2002). For example, for males, 
according to GLOBOCAN reports in 1990, the 1 year prevalence of leukemia in 
developed countries was more than four times that of developing countries; the 
highest prevalence figure which appeared in America was 6.2 times greater than 
that in sub- Saharan Africa (SSA), with a prevalence of leukemia of 9.4 per 100, 
000 and 1.4 per 100, 000 respectively. This may be because people in developed 
countries generally enjoy a higher standard of living and the life expectancy is 
higher when compared with developing countries (Lutz, et al., 2003). The reason 
may also lie in the relatively poor registration in developing countries (Parkin, 
2006). Figure 2-8 indicates the percentage of population covered by cancer 
registries; 83% in North America and 32% in Europe, compared with only 6% in 
Central and South America, 4% in Asia and 1% in Africa (IARC, 2013a). 
Furthermore, not all of these cancer registries can produce data of a sufficiently 
high quality to provide accurate and unbiased estimates. Although there are large 
cancer problems in low and middle-income countries, Asia, the Middle East, 
North and Sub-Saharan Africa, and Central and South America, there still remains 
a lack of high-quality population-based cancer registries (Curado, et al., 2007; 
IARC, 2013a).  
 
In addition, geographic heterogeneity of cancer prevalence may be influenced by 
different age structures in populations. Age standardized 5-year prevalence in 
some developed countries are calculated to make comparisons (Crocetti, et al., 
2013). After age adjustment, Italy showed the highest 5-year prevalence of 
Hodgkin lymphoma and myeloma out of the countries of U.S., Italy, Australia, 
France, and the Nordic European countries, whilst the U.S. showed the highest 5-
year prevalence of non-Hodgkin lymphoma and leukaemia. The population was 
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younger in the U.S. compared with the Nordic European countries, whilst Italy 
had an older population (Crocetti, et al., 2013). This may explain why higher total 
prevalence of myeloma (which is primarily a disease of later adulthood; see 
Appendix A5) emerged in Italy in comparison with the Nordic European 




Figure 2- 8 Cancer registry coverage; the geographic coverage (per cent of total 
population) of cancer registries by region. (IARC, 2013a). 
 
2.3.3.2 Increasing prevalence with calendar years 
 
In general, the prevalence of haematological malignancies increases with 
increasing calendar year. For example, the prevalence of male leukemia in 
Denmark calculated in the EUROPREVAL project in 1992 was 47.2 per 100, 000, 
whilst by 2011, it had increased to 108.0 per 100, 000 as reported by the 
NORDCAN project (Möller, et al., 2003; Engholm, et al., 2013). Similarly, the 
total prevalence of male leukaemia in Italy increased from 42.6 per 100,000 in 
1992 to 97.0 per 100,000 in 2006 (Verdecchia, et al., 2002; Guzzinati, et al., 
2012). Several explanations exist for the marked increase in prevalence estimates 
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between the previous and more recent studies.  Firstly, the survival prognosis 
tends to become better with increasing calendar year of diagnosis (Capocaccia 
and De Angelis, 1997). This could be linked to early diagnosis and the 
improvement of therapies. Secondly, improvements in data collection and 
reporting may result in more cases being recorded in cancer registries. Increasing 
prevalence may also be the result of other multiple factors: Population aging can 
augment the number of prevalent cases even with stable or decreasing incidence 
trends (Guzzinati, et al., 2012). Furthermore, increasing life expectancy or other 




After reviewing the literature, two problems appear: although some of the 
available methods in the literature can be used to calculate cancer prevalence, it is 
necessary to make more suitable method for haematological malignancies; in 
addition compared with other common cancers, there are fewer reports about 
prevalence of haematological malignancies because of its complexity in 
classification and difficulty in getting high quality data, as discussed in Chapter 
One. This study calculates prevalence of haematological malignancies based on 




Chapter 3 Methodology 
 
 
3.1 Database and materials 
        
3.1.1 The Haematological Malignancy Research Network (HMRN)  
 
The data for this study comes from the Haematological Malignancy Research 
Network (HMRN) (HMRN, 2011; Smith, et al., 2010). This section describes the 
area of study, data collection, and study period as follow: 
 
3.1.1.1 Area of study 
 
At the time of the inception of the study, cancer care in the UK was co-ordinated 
through a series of 34 area-based cancer networks: 28 cancer networks in England, 
three cancer networks in Wales, and three cancer networks in Scotland (see 
Appendix A1)  (NHS, 2011). HMRN covers two adjacent UK Cancer Networks: 
Yorkshire, and Humber and Yorkshire Coast (Smith, et al., 2010), and a 




Figure 3- 1 Map of Cancer Networks in England and the HMRM region (shaded 
dark red) (HMRN, 2011) 
 
 
In these two cancer networks, 14 hospitals provide clinical care to patients 
diagnosed with a haematological malignancy (Figure 3-2); each year around 
2,000 patients are newly diagnosed (Smith, et al., 2010).  
 
 
Figure 3- 2 14 hospitals in the Haematological Malignancy Research Network 




3.1.1.2 Data collection 
 
HMRN is a population-based registry (HMRN, 2011), and a collaboration 
between the Clinical Network, the specialist integrated diagnostic laboratory 
(Haematological Malignancy Diagnostic Service [HMDS] [HMDS, 2011]), and 
the Epidemiology and Cancer Statistics Group (ECSG), based at the University of 
York (HMRN, 2011; Smith, et al., 2010).  The processes of case ascertainment 
and data collection are summarised in Figure 3-3, and are discussed in more detail 
in the next sections. 
 
                              Diagnostic 
                                Sample 
 
 
Figure 3- 3 Case ascertainment and data collection in the Haematological 
Malignancy Research Network (HMDS: Haematological Malignancy Diagnostic 
Service; ECSG: Epidemiology & Cancer Statistics Group; HILIS:  HMDS 
Integrated Laboratory Information System) 
 
The network provides the clinical care for patients diagnosed with a 
haematological malignancy. Patients‘ samples are sent to the centralized 
diagnostic laboratory HMDS and information is logged onto a bespoke web-based 
laboratory information system- HMDS Integrated Laboratory Information System 
(HILIS), which provides a tracking system for each patient (HMDS, 2011). In 
HMDS, diagnoses are made in a single department that contains all relevant 
expertise and technologies to provide an integrated diagnostic service including 
histology, cytology, immunophenotyping and molecular cytogenetics. All 










The ECSG are responsible for collecting the detailed information of patients 
newly diagnosed with a haematological malignancy in the Network. In the ECSG, 
a list of newly diagnosed patients is downloaded on a weekly basis, and a group 
of trained nurses abstract clinical data from patients‘ medical records. They 
collect relevant information that includes demographic details, prognostic factors, 
and treatment and response to treatment for all patients. These data extracted by 
the ECSG are input into HILIS linking patients‘ diagnostic information with their 
clinical data (HMRN, 2011; Smith et al., 2010).  
 
 All HMRN patients are registered at the NHS Central Register and the date of 
death and the cause of death are updated monthly. This data along with gender, 
diagnosis, age at diagnosis, and date of diagnosis were downloaded from HILIS 
in order to estimate the prevalence of all haematological malignancies. 
 
3.1.1.3 Study period 
 
HMRN was established and began to collect information on newly diagnosed 
haematological malignancies patients on 1
st
, September 2004 (Smith, et al., 2010). 
Subjects diagnosed up to the 31
st
 August 2011 had been flagged for death 
certification, so it is chosen as the index date. Therefore, all patients newly 
diagnosed between 1
st
, September 2004 and 31
st,
 August 2011 were included in 
the estimation of prevalence. 
 
3.1.2 Diagnostic subtypes 
 
In HMRN, all diagnoses are coded to International Classification of Diseases for 
Oncology, 3rd Edition (ICD-O-3) (WHO, 2008). There are more than 60 ICD-O-
3 codes in HMRN data from 2004 to 2011. Table 3-1 summarizes the diagnoses 
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with ICD-O-3, ICD-10, and lineage of diseases. It is shown on the basis of 
HMRN bridge-coded data. It is worth noting that not all ICD-O-3 codes have 
clear ICD -10 counterparts.  To interpret the findings in this study, the bridge 
coding here may provide a reasonable approximation for conditions such as 
Hodgkin lymphoma, whilst for others, it may not (for example, T- cell leukaemia, 
hairy cell leukaemia, and chronic myelomonocytic leukaemia could be coded as 
leukaemia or other). Furthermore, conditions such as myeloproliferative 
neoplasms and myelodysplastic syndromes that are classified as in situ neoplasms 
in  the ICD-10 are recognized as malignancies in the ICD-O-3 (Fritz, 2000). 
 
It is not possible to analyse separately each subtype defined by the ICD- O- 3 
separately, since there are too many entities and many of them are too rare to 
enable a robust estimation of prevalence. Therefore for estimation purposes, 21 
main subtypes were used to estimate total prevalence: chronic myelogenous 
leukaemia, chronic myelomonocytic leukaemia, acute myeloid leukaemia, acute 
lymphoblastic leukaemia, chronic lymphocytic leukaemia, hairy cell leukaemia, 
T-cell leukaemia, marginal zone lymphoma, follicular lymphoma, mantle cell 
lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, T-cell lymphoma, 
Hodgkin lymphoma, plasma cell myeloma, plasmacytoma, myelodysplastic 
syndromes, myeloproliferative neoplasms, monoclonal B-cell Lymphocytosis, 
monoclonal gammopathy of undetermined significance, and lymphoproliferative 
disorder not otherwise specified. The third column in Table 3-1 lists the subtypes 
used in this study. Although there may be diversities within one main subtype, it 




Table 3- 1 HMRN diagnoses with ICD-O-3, ICD-10, and lineage from 2004 to 2011 
Broad 
Category ICD-10 group Main WHO groups  Diagnosis ICD-O-3 Lineage 
Leukaemia Myeloid leukaemia Chronic myelogenous leukaemia Chronic myelogenous leukaemia 9875/3 Myeloid 
   (C92-C94)   Atypical chronic myeloid leukaemia 9876/3 Myeloid 
    Chronic myelomonocytic leukaemia Chronic myelomonocytic leukaemia 9945/3 Myeloid 
      Juvenile chronic myelomonocytic leukaemia 9946/3 Myeloid 
    Acute myeloid leukaemia AML with inv(16)(p13;q22) or t(16;16) 9871/3 Myeloid 
    
 
AML NOS 9861/3 Myeloid 
    
 
AML - probable therapy related 9861/3 Myeloid 
    
 
AML NOS 9895/3 Myeloid 
    
 
APML t(15;17)(q22;q11-12) 9866/3 Myeloid 
    
 
AML t(8;21)(q22;q22) 9896/3 Myeloid 
    
 
AML with NPM mutation as sole abnormality 9861/3 Myeloid 
    
 
AML - probable therapy related 9920/3 Myeloid 
    
 
AML with MLL (11q23) rearrangement 9897/3 Myeloid 
      Blastic plasmacytoid dendritic cell neoplasm 9727/3 Myeloid 
  Lymphoid leukaemia  Acute lymphoblastic leukaemia B-lymphoblastic leukaemia NOS 9811/3 Lymphoid 
  (C91) 
 
B-lymphoblastic leukaemia with hyperdiploidy 9815/3 Lymphoid 
    
 
B-lymphoblastic leukaemia with t(12;21) 9814/3 Lymphoid 
    
 
B-lymphoblastic leukaemia with t(9;22) 9812/3 Lymphoid 
    
 
B-lymphoblastic leukaemia with MLL rearrangement 9813/3 Lymphoid 
      B-lymphoblastic leukaemia with hypodiploidy 9816/3 Lymphoid 
      Precursor T-lymphoblastic leukaemia 9837/3 Lymphoid 
    Chronic lymphocytic leukaemia B-cell chronic lymphocytic leukaemia 9823/3 Lymphoid 
    Hairy cell leukaemia Hairy cell leukaemia 9940/3 Lymphoid 
    T-cell leukaemia T-cell or NK cell large granular lymphocytosis 9831/3 Lymphoid 





Table 3-1 Continued 
Broad 
Category ICD-10 group Main WHO groups  Diagnosis ICD-O-3 Lineage 
Non-Hodgkin Non-Hodgkin lymphoma Marginal zone lymphoma Systemic marginal zone lymphoma 9689/3 Lymphoid 
lymphoma  (C82–C85)   Extranodal marginal zone lymphoma 9699/3 Lymphoid 
    Follicular lymphoma Follicular lymphoma 9690/3 Lymphoid 
      Follicular lymphoma with large cell transformation 9698/3 Lymphoid 
    Mantle cell lymphoma Mantle cell lymphoma 9673/3 Lymphoid 
    Diffuse large B-cell lymphoma Diffuse large B-cell lymphoma 9680/3 Lymphoid 
      Plasmablastic large B-cell lymphoma 9735/3 Lymphoid 
      T-cell/histiocyte-rich large B-cell lymphoma 9688/3 Lymphoid 
      Mediastinal large B-cell lymphoma 9679/3 Lymphoid 
      Diffuse large B-cell lymphoma 9596/3 Lymphoid 
      Intravascular large B-cell lymphoma 9712/3 Lymphoid 
    Burkitt lymphoma Burkitt lymphoma 9687/3 Lymphoid 
    T-cell lymphoma Anaplastic large cell lymphoma of T/null type ALK+ 9714/3 Lymphoid 
      Mycosis fungoides 9700/3 Lymphoid 
      Extranodal NK/T-cell lymphoma, nasal type 9719/3 Lymphoid 
      Anaplastic large cell lymphoma of T/null type ALK- 9702/3 Lymphoid 
      Peripheral T-cell lymphoma - common; unspecified 9702/3 Lymphoid 
      Enteropathy-type T-cell lymphoma 9717/3 Lymphoid 
      Angioimmunoblastic T-cell lymphoma 9705/3 Lymphoid 
      Primary cutaneous CD30 positive T-cell lymphoproliferative disorder 9718/3 Lymphoid 
      Sezary syndrome 9701/3 Lymphoid 
      Anaplastic large cell lymphoma of T/null type 9714/3 Lymphoid 
      Adult T-cell lymphoma/leukaemia (HTLV-1 positive) 9827/3 Lymphoid 
Hodgkin Hodgkin's disease Hodgkin Lymphoma Mixed cellularity classical Hodgkin lymphoma 9652/3 Lymphoid 
 lymphoma  (C81) 
 
Nodular sclerosis classical Hodgkin lymphoma 9663/3 Lymphoid 
      Lymphocyte-rich classical Hodgkin lymphoma 9651/3 Lymphoid 




Table 3-1 Continued 
Broad Category ICD-10 group Main WHO group  Diagnosis ICD-O-3 Lineage 
Myeloma Myeloma  Plasma cell myeloma Plasma cell myeloma 9732/3 Lymphoid 
  (C90) Plasmacytoma Extraosseous plasmacytoma 9734/3 Lymphoid 
      Solitary plasmacytoma of bone 9731/3 Lymphoid 
Myelodysplastic Myelodysplastic syndromes  Myelodysplastic syndromes Refractory cytopenia with multilineage dysplasia 9985/3 Myeloid 
syndromes (D46) 
 
Refractory anaemia with ring sideroblasts 9982/3 Myeloid 
    
 
Refractory anaemia with excess blasts 9983/3 Myeloid 
      Myelodysplastic syndrome (5q-) 9986/3 Myeloid 
Other Other neoplams of uncertain  Myeloproliferative neoplasms Myeloproliferative neoplasm, unclassifiable 9960/3 Myeloid 
  or unknown behaviour    Chronic eosinophilic leukaemia 9964/3 Myeloid 
  (D47)   Systemic mastocytosis 9741/3 Myeloid 
    
  
Chronic myeloproliferative neoplasm with myelofibrosis 9961/3 Myeloid 
    Myelodysplastic / Myeloproliferative neoplasms unclassifiable 9975/3 Myeloid 
    Monoclonal B-cell Lymphocytosis Monoclonal B-cell lymphocytosis (CLL phenotype) 9823/3 Lymphoid 
    Monoclonal gammopathy  Monoclonal gammopathy of undetermined significance 9765/1 Lymphoid 
    of undetermined significance Monoclonal gammopathy of undetermined significance 9769/1 Lymphoid 
    Lymphoproliferative disorder NOS Lymphoproliferative disorder NOS 9591/3 Lymphoid 
      Lymphoproliferative disorder NOS 9823/3 Lymphoid 




3.1.3 Population in the study area 
 
For the purpose of calculating prevalence, the population in the defined area is 
needed.  
 
3.1.3.1 Population in the UK and HMRN 
 
Population data were obtained from the 2001 UK census (Office for National 
Statistics, 2001), which was the most recent available when the study began.  
Census Area Statistics on the Web (CASWEB) (Office for National Statistics, 
2001) provides online access to UK census aggregate data. It was developed by 
the Census Dissemination Unit (CDU), based within Mimas at the University of 
Manchester (Census Dissemination Unit, 2001).  
 
Figure 3-4 is a diagram depicting the geographical structure of England; there are 
similar structures for Wales, Scotland and Northern Ireland. From this figure, it 
can be seen that the statistics are available from country level to Output Areas 
(OA). OAs are the base unit for census data releases, and allow for a finer 
resolution of data analysis due to their small size. OAs are based on postcodes, 
and were designed to have similar population sizes and be as socially 
homogenous as possible (Office for National Statistics, 2008). Therefore if we 
know the output area codes of HMRN area, the defined population can be 




Figure 3- 4 The hierarchy of administrative areas in England for the 2001 Census. 
(There are 56 unitary authorities in England, and 27 shire counties split into 201 
districts. Counties, districts and unitary authorities are subdivided into electoral 
wards) (Census Dissemination Unit, 2001) 
 
HMRN covers two cancer networks, and the NHS postcode directory was used to 
identify which output area codes were in the two cancer networks (see Figure 3- 
5). 
 
Population data were downloaded for England and then restricted to the two 
cancer networks. The detailed steps were: 
(1) Downloaded cancer network codes (CANNET) and the corresponding Output 
area codes (OACODE) from the NHS postcode directory;  
(2) Merged that information with the data of the 2001 census matching with 
Census Output Area Codes (population in every age group by cancer networks is 
then obtained);  
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(3) Only kept the population data with the cancer network codes N06 (Yorkshire 
Cancer Network) and N07 (Humber and Yorkshire Coast Cancer Network). 
 
                       2001               Population in every age group         
                     Census             Output area codes (OACODE) 
                                                           Matching on 
           NHS Postcode          Output area codes (OACODE) 
               Directory             Cancer network codes (CANNET) 
 
Figure 3- 5 Process identifying HMRN population 
 
3.1.3.2 Comparing the population in HMRN area and in the UK 
 
Populations that were obtained from the census are shown in Table 3-2. The peak 
of the population is in the age group 35- 39; males and females have broadly a 
similar age distribution. A slightly higher population of males are in the 0-4 










Table 3- 2  Population in the UK and HMRN (from the 2001 census) 
Age 
group 
UK   HMRN 
  
(Years) Male % Female % Total % Male % Female % Total % 
0-4 1784418 6.2 1703181 5.6 3487599 5.9 107160 6.2 104373 5.7 211533 5.9 
5-9 1915964 6.7 1823598 6.0 3739562 6.4 119103 6.9 113668 6.2 232771 6.5 
10-14 1987442 7.0 1891124 6.3 3878566 6.6 124558 7.2 120175 6.5 244733 6.9 
15-19 1870485 6.5 1794571 5.9 3665056 6.2 117089 6.8 114423 6.2 231512 6.5 
20-24 1766041 6.2 1780229 5.9 3546270 6.0 107301 6.2 110671 6.0 217972 6.1 
25-29 1895216 6.6 1971412 6.5 3866628 6.6 108539 6.3 114524 6.2 223063 6.2 
30-34 2199746 7.7 2293926 7.6 4493672 7.6 128167 7.4 134554 7.3 262721 7.4 
35-39 2277756 8.0 2348442 7.8 4626198 7.9 133384 7.7 138410 7.5 271794 7.6 
40-44 2056382 7.2 2095058 6.9 4151440 7.1 123962 7.2 125696 6.8 249658 7.0 
45-49 1851535 6.5 1884582 6.2 3736117 6.4 113034 6.5 113814 6.2 226848 6.4 
50-54 2003276 7.0 2037455 6.7 4040731 6.9 124644 7.2 125792 6.8 250436 7.0 
55-59 1651372 5.8 1687710 5.6 3339082 5.7 99325 5.7 99606 5.4 198931 5.6 
60-64 1409740 4.9 1470273 4.9 2880013 4.9 86445 5.0 90097 4.9 176542 4.9 
65-69 1241343 4.3 1355789 4.5 2597132 4.4 75680 4.4 83945 4.6 159625 4.5 
70-74 1058882 3.7 1280770 4.2 2339652 4.0 63721 3.7 79433 4.3 143154 4.0 
75-79 817783 2.9 1149010 3.8 1966793 3.3 50210 2.9 70475 3.8 120685 3.4 
over 80 793015 2.8 1644341 5.4 2437356 4.1 47593 2.8 101461 5.5 149054 4.2 




According to the 2001 UK census, the population of the UK was 59 million, with 
3.6 million in HMRN area. Both share a similar age and sex distribution (see 
Figure 3-6); the bars on the population pyramid show the age and sex distribution 
for the UK, and the lines show the distribution of HMRN region. This means that 
the prevalence rate calculated using HMRN data could be generalised to the 
whole of the UK without age standardization. Indeed, it could be applied to any 
well-characterised population to estimate the number of prevalent cases with age 
adjustment, with assumptions (details are shown in Chapter Five).  
 
 
Figure 3- 6 Population age and sex structure of Haematological Malignancy 
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3.2 Descriptive statistics 
 
Following the purpose of this study and the information available in the database, 
characteristics of the patients in HMRN are described first, including: diagnosis, 
gender, age at diagnosis, incidence and survival.  
 
3.3 n-year prevalence 
 
Although the main purpose of this work is to estimate total prevalence, it is 
necessary to first show the prevalence in the observed period. Furthermore, the 
observed prevalence calculated in this section is one of the steps in total 
prevalence estimation (details are shown in Section 3.4 and Chapter Five). 
Therefore n-year prevalence and observed prevalence calculation plays a 
transition role, and serves as a connecting link between the calculation from 
observed data and the estimation for the real disease burden. 
 
HMRN includes newly diagnosed cases from 2004 to 2011. Figure 3-7 shows n-
year prevalence and the corresponding calendar years.  
 
2004                              2006                                                         2010            2011 
 
Figure 3- 7 n-year (1-year and 5-year) prevalence, observed prevalence (7-year 







3.3.1 1-year and 5-year prevalence 
 
According to the definition of prevalence n-year prevalence can be calculated 
simply by counting the incidence cases that were still alive on a certain given date 
(31
st
, August, 2011) in the registry region, and then dividing by the population 
covered by HMRN.  
 
 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑠𝑡𝑖𝑙𝑙 𝑎𝑙𝑖𝑣𝑒 𝑜𝑛 𝑡𝑕𝑒 𝑖𝑛𝑑𝑒𝑥 𝑑𝑎𝑡𝑒
𝑡𝑜𝑡𝑎𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
 (3. 1) 
 
1-year prevalence counts the patients diagnosed within the most recent year 
before the index date (diagnosed between 1
st
, September 2010 and 31
st
, August 
2011), and 5-year prevalence counts the patients diagnosed within recent five 
years before the index date (diagnosed between 1
st
, September 2006 and 31st, 
August 2011).   
 
As described above, HMRN region population structure mirrors that of the UK as 
a whole in terms of age and sex. The number of prevalent cases of haematological 
malignancies for the UK could be estimated by applying HMRN prevalent rates 
to the UK population for both genders. The number of prevalent cases in the UK 
(   ) can be calculated by: 
 
    = 𝑃𝐻𝑀 𝑁 ∗ 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑡𝑕𝑒 𝐾 (3. 2) 
 





3.3.2 Observed prevalence 
 
Observed prevalence covers all patients diagnosed within the registry, and in fact 
is special n-year prevalence (n equals the length of registry). In this study, 
observed prevalence is 7-year prevalence. It is also extrapolated to estimate the 
number of prevalent cases in the UK. 
 
3.3.3 Years of follow up 
 
The maximum number of years of follow-up available is seven years, which may 
be long enough to show the burden for some subtypes with relatively short 
survival. For some subtypes with good prognosis, however, total prevalence is a 
more appropriate method to estimate prevalence. This section provides a visual 
representation of whether the length of the registry is sufficient or not to cover 
complete prevalent cases, and shows the necessity of estimating total prevalence.  
 
The years of follow- up in HMRN may be sufficient for some diagnostic subtypes 
to show the disease burden. When the registry is long enough compared to the 
duration of the disease, the patients who are diagnosed before the start of registry 
and who died before the index date, do not contribute to prevalence. In this 
situation, the length of the registry will stop its effect on the observed prevalence, 
and observed prevalence will be stable if there is no change in incidence and 
survival. 
 
The prevalence rate of each subtype can be calculated according to n (n=1-7) 
cumulative years before index date. Percentage changes in prevalence rate 
between successive years of cumulative prevalence (that is, n and n+1) within 
each subtype were calculated to indicate the number of years of follow- up 
required for complete prevalence. If we define prevalence as being sufficiently 
complete when the percentage change falls below 5%, this means that n+1-year 
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prevalence approaches to n-year prevalence, and the prevalence becomes stable 
after n years accumulated, therefore the length of the registry seems to be enough 
to show the burden of disease. 
 
3.3.4 Move to “total prevalence” 
 
Observed prevalence cannot show the real burden for some subtypes. Rather than 
showing separate haematological malignancies subtypes by survival, it is more 
convenient to develop a method to estimate the real burden for all subtypes either 
with short or long survival rates. Recalling the definitions in Chapter One, total 
prevalence (the expected complete prevalence) includes all those cases alive on a 
given date regardless of when they were diagnosed (those directly observed by a 
registry plus those that were diagnosed before the registry started). The 
characteristics of estimations of total prevalence should reflect the relationship 
between disease duration and registry length by itself. It goes without saying that 
diseases with shorter survival have a total prevalence approaching to observed 
prevalence, whilst diseases with longer survival have a total prevalence that is 
much higher than what can be observed in the data. Estimates of total prevalence, 
were calculated based on the mathematical relationships between prevalence, 
incidence, survival, and general mortality in the population. The method of 
calculation is presented in the next section. 
 
3.4 Methods to estimate total prevalence 
 
3.4.1 Definitions in the model 
 
Cancer prevalence at a given time is the proportion of people in a population at a 
certain time diagnosed with cancer in the past and who are still alive. It may vary 
with calendar years, however in this study, it was assumed that it was constant 




Consider the life history of an individual with cancer, whose life can be split into 
two parts according to the incidence of cancer: disease-free and survival with the 
disease (Figure 3-8). 
 
                                                              Incidence                                  mortality 
 
                                                                               ……. 
Age u=0        1              2            3            4         5           x- 1         x       x+1      
                   life disease-free            include this point         occurrence of disease 
                   survival with cancer     exclude this point         occurrence of death 
Figure 3- 8 the life of a patient (split into two parts according to the incidence of 
cancer: alive and disease- free, and survival with disease) 
 
Ages are considered as discrete integer values in the calculation, however they are 
in fact continuous quantities. Therefore patients who die between their 𝑖𝑡𝑕 and 
(𝑖  1)𝑡𝑕 birthday are survival cases up to the end of their age interval,𝑖, 𝑖  1). 
Patients diagnosed between their 𝑖𝑡𝑕 and (𝑖  1)𝑡𝑕 birthdays (in the interval,𝑖, 𝑖  
1)) were incident cases on the 𝑖𝑡𝑕 birthday. For example, suppose a patient 









 birthdays. In this calculation, the patient is considered as living disease- 
free up to the end of age interval ,3, 4), and becomes an incidence case on his 4th 
birthday. After that, the patient was alive as a cancer patient up until the end of 
his age interval ,35, 36). This will be described as ―incidence was at age 4‖ and 





3.4.5 Mathematical modelling of total prevalence 
 
I. For the general population: 
 
Let  (𝑢) be the general mortality in a reference year. Let u be an integer (𝑢  0), 
which is the age of death. This means that  (𝑢) is the conditional probability of 
an arbitrary person in the population dying between his 𝑢𝑡𝑕 and (𝑢  1)𝑠𝑡 
birthdays, conditioned on surviving to his 𝑢𝑡𝑕 birthday.   (𝑢) may vary with 
reference years, however in order to simplify the calculation, it is assumed that 
 (𝑢) is constant with the reference year chosen. 
 
The probability of a person being alive at the end of their age interval ,0, 1) is 1 −
 (0). The probability of a person being alive at the end of their age interval ,1, 2) 
using the definition of conditional probability is (1 −  (0))(1 −  (1)). Similarly 
the probability of a person surviving to the end of his age interval , ,   1) is 
 
 ∏ (1 −  (𝑢))𝑥  (3. 3) 
 
II. For patients: 
 
Suppose a patient was diagnosed at age t (t is an integer (𝑡  0)). Let 𝐼(𝑡) be the 
incidence at age t, which is the probability of a person being diagnosed with 
cancer in the age interval ,𝑡, 𝑡  1). It was assumed that all cases between their 
𝑡𝑡𝑕 and (𝑡  1)𝑡𝑕 birthdays were diagnosed on their 𝑡𝑡𝑕 birthday.  This means that 
the proportion of people diagnosed with disease in the age interval ,𝑡, 𝑡  1) is 
considered as the estimated probability of people diagnosed on their 𝑡𝑡𝑕 





In the first part, the case is disease free, which means there is no probability of 
transiting to death or disease. Let  ∗(𝑢) be the non-disease mortality at age u, 
which means the conditional probability of death directly from disease free. (see 
Figure 3- 9). With the definition that incidence is considered as the beginning of 
an age interval, the probability of being considered disease free at the start of age 
interval ,0, 1) is 1 − 𝐼(0). With the definition that survival is considered up to the 
end of an age interval, the probability of being disease free at the end of age 
interval ,0, 1) is (1 − 𝐼(0)) ∗ (1 −  ∗(0)).  
 
 
                                I(u) 
                               1-I(u)                                    G*(u) 
                                                                          1-G*(u) 
 
 
Figure 3- 9 The probability of being healthy at the end of an age interval. 
 
Therefore, before the t
th  
birthday, (𝑡  1), the probability at birth that an arbitrary 
person in the population will live disease free until age t is: 
 
 ∏ ((1 −  ∗(𝑢)) ∗ (1 − 𝐼(𝑢))𝑡−  )  (3. 4) 
 
In the second part of the patient‘s life, the person survives with cancer (Figure 3-
10). Let 𝑆(𝑡, 𝑑) be the probability of a patient surviving d years after being 
diagnosed at age t. If the patient survives until age x (  𝑡), then 𝑑 =   1 − 𝑡. 
When 𝑡 = 0, the probability that a person diagnosed with cancer at age 0 will 












  𝐼(0) ∗ 𝑆(0,   1) (3. 5) 
 
When 𝑡  1 the probability that a person diagnosed with cancer at some age t will 
survive with cancer until age x is: 
 
 ∑ ((∏ ((1 −  ∗(𝑢)) ∗ (1 − 𝐼(𝑢))𝑡− 𝑢  ) ∗ 𝐼(𝑡) ∗ 𝑆(𝑡,   1 − 𝑡))
𝑥
𝑡   (3. 6)                                                                             
                                                    1                              2                    3 
 
Equation 3. 6 is comprised of two parts. The inner part of the equation is the 
probability that an arbitrary person in the population will be diagnosed at age t 
and will survive until x. This part describes the life of a person from being disease 
free (1) to the occurence of disease (2), then survives with the disease (3). The 
outer part sums this all up for the values of t to give the probability of some x. For 
a prevalent case at age x, the diagnosed age t can exist at any time between birth 
and age x, but can only appear once. Therefore all the possibilities of the value of 
t are mutually exclusive. The summation of the probabilities in the inner part of 
the equation makes the probability that a person diagnosed with cancer at some 
age t (1 ≤  𝑡 ≤  ) will survive with cancer until age x.  
 
                                                                                                       S(t,d) 
                                                                I(t) 
                                                                           
Figure 3- 10 The probability of a person diagnosed with cancer at age t surviving 












If the mortality rate of people who do not suffer from the disease  ∗(𝑢) is 
approximated by the mortality rate of the general population  (𝑢) (see definitions 
of relative survival in Chapter One), the probability that a person diagnosed with 
cancer at some age t (𝑡  1) will survive with cancer until age x is: 
 
 ∑ .∏ (1 −  (𝑢)) ∗ ∏ (1 − 𝐼(𝑢))𝑡− 𝑢  ∗ 𝐼(𝑡)
𝑡− 
𝑢  ∗ 𝑆(𝑡,   1 − 𝑡)/
𝑥
𝑡   (3. 7) 
 
Furthermore, in this study, the part ∏ (1 − 𝐼(𝑢))𝑡−   contributes little to the results. 
This is because the diseases have an incidence rate of less than 10−  (see 
incidence rates in Appendix 5). Considering the life span of a person is usually no 
more than 100 years, this makes: 
 




 ∑ .∏ (1 −  (𝑢)) ∗ 𝐼(𝑡)𝑡− 𝑢  ∗ 𝑆(𝑡,   1 − 𝑡)/
𝑥
𝑡   (3. 9) 
 
Therefore, the probability at birth that an arbitrary person diagnosed with cancer 
at age t and survives until age x, 𝑃( ), can be divided into two parts: 𝑡 = 0 and 
𝑡  1. Both of them are calculated as a ratio with equation (3. 4) as the 
denominator 
 




 𝑃( |𝑡 = 0) =
 ( )∗ ( ,𝑥  )
∏ ( − (𝑢))  
 (3. 10) 
 
When 𝑡  1, 
 
 𝑃( |𝑡  1) =
∑ .∏ ( − (𝑢))∗       (𝑡)∗ (𝑡,𝑥  −𝑡)/
 
   
∏ ( − (𝑢))    
 (3. 11) 
 
This can be simplified to:  
 
 𝑃( |𝑡  1) = ∑ (
 (𝑡)∗ (𝑡,𝑥  −𝑡)
∏ ( − (𝑢))    
𝑥
𝑡  ) (3. 12) 
 
Therefore the probability that an arbitrary person diagnosed with cancer at some 
age t will survive until age  , can be expressed as: 
 
 𝑃( ) = ∑ (
 (𝑡)∗ (𝑡,𝑥  −𝑡)
∏ ( − (𝑢))    
)𝑥𝑡   (3. 13) 
 
Since 𝑃( ) is the prevalence rate at age x, it is highly dependent on the model of 
incidence and survival. To make the results more closely to observed data, a 
method of estimating prevalence, from previous studies, is introduced in the next 
section. (Capocaccia and De Angelis 1997; Merrill, et al., 2000; Forman, et al., 





3.4.6 Completeness index of the observed prevalence 
 
3.4.6.1 Model and definition of the completeness index 
 
Suppose that a case is at age x on the index date, and the definition of age x is 
constant with that of survival. Patients alive at ages between their  𝑡𝑕 and 
(  1)𝑡𝑕 birthday on the index date are prevalent cases at age x, and are 
considered to live until the end of age interval [x, x+1). For example, suppose a 





on the index date. In the calculation, it is considered that he has been a survivor 
for 11 years (20 − 10  1) up until the index date. Suppose that incidence is 
recorded on a registry for a time period of only L years, this means that a 
prevalent patient was at the age of ( − 𝐿  1) when the registry started.  
 
Here, the probability of a person being alive with cancer is used as the expected 
proportion of people being alive with cancer in the population. For ease of 
explanation, however, proportion was used for prevalence instead of probability 
in the following description.  
 
Total prevalence in a population who are at age x on the index date can be 
separated into an observed part 𝑃𝑜( , 𝐿) and an unobserved part 𝑃𝑢( , 𝐿). The 
observed part derives from the incident cases observed between the age interval 
, − 𝐿  1,  -, while the unobserved part refers to those cases diagnosed at 
previous a age and still living at x (see Figure 3- 11). That is: 
 





                                           Start of registry                                               Index date 
        …… 
                       Unobserved                                                 Observed 
            age                            x-L         x-L+1                                                                x           
Figure 3- 11 Total prevalence can be separated into observed part and unobserved 
part 
 
L is the time period of a registry; here it is seven years. The proportion of 
observed prevalence to the total prevalence is given by the ratio R: 
 
  ( ) =
  (𝑥, )
 (𝑥)
= 1 −
  (𝑥, )
 (𝑥)
 (3. 15) 
 
R is called the completeness index and varies between 0 and 1. When all the 
prevalent cases have been diagnosed after the start of a registry, completeness 
index has the maximum value of 1. At the other extreme, the minimum value is 0 
when all the prevalent cases were diagnosed before the beginning of the registry. 
 
The completeness index R, is in turn used to inflate the observed prevalence to 
estimate the total prevalence: 
 
  ( ) =
𝑁 (𝑥, )
 
 (3. 16) 
 
 ( ) is the number of prevalent cases at age x.  𝑜( , 𝐿) in function (3. 16)  is the 
actual number of prevalent cases within the registry period based on the data, 
obtained using the direct method (counting the number of incident cases still alive 
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on the index date). The details have been described in Section 3.3.2. The total 
prevalence calculated in this way is closer to observed data, since it is estimated 
using a proportion of observed prevalence and total prevalence.  
 
The completeness index R varies with age, and age-specific prevalence can be 
used to estimate the number of total prevalent cases for every age. For the 
prevalence of all ages on the index date, the algorithm is: 
 
 𝑡𝑜𝑡𝑎𝑙 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 =
∑𝑡𝑜𝑡𝑎𝑙 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑡 𝑐𝑎𝑠𝑒𝑠 𝑓𝑜𝑟 𝑎𝑛 𝑎𝑔𝑒 
𝑡𝑜𝑡𝑎𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
 (3. 17) 
 
Similarly, R can be used to estimate the partial prevalence of a period longer than 
the observation period in the registry, for example, the 10-year and 20-year 
prevalence in the population observed only for 7 years (Capocaccia, et al., 2002). 
 
3.4.6.2 How to calculate completeness index R 
 
To get the completeness index, the probabilities 𝑃( ) are involved in the equation 
3.15.  According to the equations in 3.4.5, 𝑃( ) (observed part and unobserved 
part) can be expressed as: 
 
   ( ,  ) = ∑
 (𝑡)∗ (𝑡,𝑥  −𝑡)
∏ ( − (𝑢))    
𝑥− 
𝑡    (3. 18) 
 
   ( ,  ) = ∑
 (𝑡)∗ (𝑡,𝑥  −𝑡)
∏ ( − (𝑢))    
𝑥




The age-specific completeness index can be directly computed by means of the 
equation 3.20, when the incidence, survival, and general mortality functions are 
known: 
 
  ( ) = 1 −




 ( )∗ ( ,     )
∏ (   ( ))    
   
   
∑
 ( )∗ ( ,     )
∏ (   ( ))    
 
   
  (3. 20) 
 
 Incidence may change over the years, and general mortality decreases with 
calendar year. The balance between these effects is difficult to predict in the 
calculation. For the purpose of simplicity of the model, for convenience it was 
assumed that those rates are constant with years. The details are described in the 
next section. 
 
3.4.7 General mortality, incidence, and survival 
 
General mortality and estimations of incidence and survival required for the total 
prevalence model are introduced in this section. These probabilities can be 
obtained either directly or by predictions. They are introduced one by one in the 
following sections. As the method is in discrete version, the effect factors (such as 
age and year) are truncated to integers (see Table 3- 3).  
 
Table 3- 3 Probabilities used in estimating completeness index 
  Mortality Incidence Survival 
Data Source Life table* HMRN  HMRN 
Effect factors 





Age and Survival time 
Continue age and duration 
Use in the method Direct use Modelling Modelling 
Model - Non-parametric Parametric 




An important assumption in the whole calculation is that general mortality, 
incidence, and survival probabilities are constant with calendar years. This means 
that the proportions and probabilities observed and estimated from the current 
information and data can be extrapolated to the years before the start of the 
registry. This assumption makes the estimates easier, and seems the most 
convenient way to calculate prevalence. This means that the calendar year 
component is omitted in the following models: 
 
3.4.7.1 General mortality 
  
General mortality is the fraction of the population of those living at the beginning 
of the age interval that died during the interval. It can be derived from certain data 
(number of deaths (𝑢) in a year and population  (𝑢) at the beginning of a year, 
at age u by sex):  
 
  (𝑢) =
 (𝑢)
 (𝑢)
 (3. 21) 
 
General mortality figures are obtained from life tables. They provide a summary 
of mortality for age and sex in a general population in an area.  Life tables can be 
categorised further as either static or fluent life tables (Ederer, Axtell, and Cuter, 
1961). A static life table shows the age-specific mortality rates at a given point 
time; this is also called a time-specific life table. However, if the observation time 
were longer, the mortality would change over calendar time. The fluent life table 
takes this factor into account and is referred to as a cohort life table. As stated 
earlier, to simplify the calculation for total prevalence, calendar year component 
is not considered in this model. In this case, general mortality should be consistent 
with the assumptions of incidence and survival. Thus, the static life table was 




General mortality rates in this study were obtained from the London School of 
Hygiene & Tropical Medicine life tables (LSHTM, 2012). They provide general 
mortality from 1971-2009 for England and Wales for both genders, by one-year 
age stratum.  
 
However, the index date (31
st
, August 2011) in this study is later than 2009, 
which is when this life table ended. In this situation, it is the standard practice to 
assume that the probabilities are the same as those most recently available 
(LSHTM, 2012).  
 
The general mortality is obtained as a discrete version for every single age, 





I. Model for incidence 
 
For incidence, newly diagnosed cases at every age can be directly obtained from 
HMRN data. Theoretically, the incidence for every single age can be calculated 
and introduced into the model without estimations. However, for some subtypes, 
the number of cases is small. Incidence for every single age abstracted from data 
may be not identifiable. Therefore ages are grouped into every five years, and the 
corresponding incidence is:  
 
 𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 =
 𝑛𝑐𝑖𝑑𝑒𝑛𝑡 𝑐𝑎𝑠𝑒𝑠 𝑖𝑛 𝑎𝑛 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝 𝑝𝑒𝑟  𝑒𝑎𝑟 
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝




The exact rate values are taken to be the midpoint of the age group of possible 
values. For example, the incidence for age group 0-4 is considered as the certain 
incidence at age 2. Based on those scatters of age and incidence, the incidence 
model is built to calculate the estimated incidence of every single age. (Prevalent 
cases were aggregated into the corresponding age groups as used for incidence.) 
 
Parametric incidence functions in the literature (Capocaccia and De Angelis 1997; 
Merrill, et al., 2000; Gigli, et al., 2006) could not provide a good fit for the data 
for some cancers. Haematological malignancies can occur at any age, and may 
have a different age distribution compared to other common cancers. To 
accommodate variation over age of a predictor‘s effect on incidence, a new model 
using regression splines was developed to model the incidence rate as a flexible 
function of age.  
 
A spline is a function that is constructed piece-wise from polynomial functions. 
Cubic spline is a commonly used spline, which has linear, quadratic, and cubic 
terms. It makes a smooth curve composed of a linear combination of those terms:  
 
 𝐼(𝑡) =      𝑡    𝑡
    𝑡
  ∑  𝑖(𝑡 −  𝑖) 
 𝑚
𝑖   (3. 23) 
 
In this cubic regression spline, t is age, whilst b1, b2, b3, and βi are coefficients; b0 
is a constant. In the function, (𝑡 −  𝑖)  are hinge functions    (0, (𝑡 −  𝑖)), 
which equals 0 if 0  (𝑡 −  𝑖), else (𝑡 −  𝑖). In those hinge functions,  𝑖 are 
called knots ( 𝑖 is the 𝑖
𝑡𝑕 knot). Usually, knots are equidistant, and we chose 
quartile knot sequence which disjoint the variable—age into equal intervals 
(Racine, 2011). Thus, there are five knots in total: three internal knots (m is the 
number of internal knots) and two end point knots.  
 
   𝐼(𝑡) =      𝑡    𝑡
    𝑡
    (𝑡 −   ) 
    (𝑡 −   ) 
    (𝑡 −   ) 




This non-parametric method makes a smoothing curve, which is not sensitive to 
the assumptions made for a parametric incidence function. In this work, this 
flexible incidence function of age was used to calculate the total prevalence. The 
estimates of incidence by parametric and non-parametric methods are described in 
the next chapter. 
 
II. Steps to predict incidence for every single age 
 
As the method is in a discrete version, the algorithm requires estimation of the 
distribution of incidence by single year of age. However, as stated earlier, this 
could not be done directly. To predict incidence for every single age from data, 
we need to interpolate the rates specified per 5-year interval to 1-year age groups, 
using the spline method. There are five steps (see Figure 3- 12): 
 
(1) Group the continuous diagnosis age into five years strata 
(2) Calculate average incidence (7 years) for every 5- year age groups in 
HMRN (Figure 3-12-1) 
(3) Plot the incidence with the midpoint age of every corresponding age group 
(Figure 3-12-2) 
(4) Regression spline: 17 incidence value and 17 midpoint ages (Figure 3-12-
3) 























I. Model for survival  
 
Unlike incidence, data on survival may not be adequate due to the limited length 
of the registry. The proportion of cases surviving decreases with time, but is 
unobserved when time since diagnosis becomes longer than the length of the 
registry (Capocaccia and De Angelis, 1997). With the data from HMRN, only 
seven years of observation can directly provide estimates of survival, and after 
that, model-based assumptions and estimations are required in predicting long-
term survival proportions (Bray, et al., 2013). Unlike non-parametric approaches 
(such as the Kaplan-Meier survival analysis) to survival analysis, a certain 
distribution of survival time is assumed for parametric survival analysis. This 
makes the estimates for survival which are unobserved from data, follow a 
distribution. From this point of view, the parametric approach for survival 
analysis is more powerful in making estimates.  Therefore a parametric model 
was used to estimate survival using the general Weibull distribution. Weibull 
function has previously been successfully applied to prevalence estimates 
(Capocaccia and De Angelis, 1997; Merrill, et al., 2000; Gigli, et al., 2006; 
Simonetti, et al., 2008). Unlike another common form used — exponential 
distribution that assumes constant hazard function with time, Weibull distribution 
assumes the hazard function will change monotonically over time. Exponential 
distribution can be considered as a special case of Weibull when the parameter 
that determines hazard rate trend equals 1. Due to this characteristic, Weibull 
distribution has broader application in research, and seems more suitable for 
survival analysis in this study (Golestan, et al., 2009).   
 
Data from HMRN was used to fit the Weibull function and to estimate the 
survival pattern after seven years (the length of HMRN registry). According to 
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previous studies (Capocaccia and De Angelis, 1997; Merrill, et al., 2000; Gigli, et 
al., 2006; Simonetti, et al. 2008), survival is influenced by the age at diagnosis:  
 
 𝑆( − 𝑡, 𝑡) = [𝑒 𝑝(− ( − 𝑡) )]
𝑒𝑥𝑝 (𝑞∗𝑡)
 (3. 25) 
 
Where t is the age at diagnosis and x is the current age, then ( − 𝑡) is the 
duration d.    and   are scale and shape parameters of Weibull distribution. 
𝑒 𝑝 (𝑞 ∗ 𝑡) represents the effect of age at diagnosis, which means the relative risk 
of being diagnosed every one year older (Gigli, et al., 2006). 
 
However, the log risk and age at diagnosis do not really have a linear relation. 
Some common cancers that the previous studies interested rarely occur at early 
age groups (such as lung cancer, stomach cancer, and colorectal cancer). It is 
reasonable to assume that survival deceases with age at diagnosis, and only 
calculate prevalence for adults (Merrill, et al., 2000). If a disease can occur at any 
age, the mortality may show different trends in childhood and adulthood. Indeed, 
for some subtypes of haematological malignancy, mortality decreases in younger 
age groups and increases in the old, for example with AML.  
 
The effect of age on survival is difficult to be modeled for some subtypes of 
haematological malignancy, therefore a spline to model diagnosis age has been 
used.  
 
 𝑆( − 𝑡, 𝑡) = [𝑒 𝑝(− ( − 𝑡) )]
𝑓(𝑡)
 (3. 26) 
 
Equation (3.26) estimates survival probability under Weibull distribution. 𝑓(𝑡) 
represents a spline model of age at diagnosis. It allows for a smooth diagnosis age 
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effect. In this method, survival time is extrapolated using a parametric method, 
whilst the effect of age is a described using a spline method, which is flexible to 
capture the functional shape (Becher, et al., 2009).  
 
The parametric method for survival is used for prevalence estimates in this study. 
It determined by both disease duration and age at diagnosis. The goodness of fit 
of survival models is checked, by comparing the Weibull estimated curves to 
Kaplan-Meier survival graphs. Survival was analyzed for males and females 
separately, since there are different survival figures for the two genders. However, 
for subtypes with a small number of cases, the survival analysis is not done 
separately for males and females in order to minimize the problems introduced by 
small numbers. 
 
II. Steps to predict survival 
 
Equation (3.26) provides survival for any continuous age and disease duration. To 
make predictions of survival in terms of integral age with integral years of 
duration that are involved in the discrete method, the survival probabilities at 
single ages and integral years are abstracted. The calculation process can be 
summarized into five steps (Figure 3-13): 
 
(1) Obtain and format survival data from HMRN 
(2) Fit a curve to data (7 years data) under Weibull distribution (Figure 3-13-1) 
(3) Extrapolate the curve to estimate survival for longer disease duration 
(Figure 3-13-2) 
(4) Introduce equation 3.26 to the method for prevalence estimation, and 
predict survival for every integral age with integral years of duration 




















Figure 3- 13 Steps to predict survival for every integral age with integral years of 
duration 
 
3.4.8.2 The process of calculation 
 
In brief, total prevalence calculation has three main steps: (1) Calculate observed 
prevalent cases by age group. (2) Estimate completeness index, and apply it to 
observed prevalent cases by age group. (3) Estimate total prevalent cases by age 
group, and then calculate total prevalence rate for all ages together (see Figure 3-
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Figure 3-15 shows the total prevalence calculation process using the method 
developed in this study. The basic data for the whole calculation are: HMRN data 
for all observed cases (HMRN, 2011), population from census ( Office for 
National Statistics, 2001) , and general mortality from the London School of 
Hygiene and Tropical Medicine life table (LSHTM, 2012). Within the registry 
data, one can simply count the number of observed prevalent cases of every age 
group. We can also fit the data to a Weibull function and get parameters for 
survival. HMRN data combined with population in the area can provide the 
incidence for specific age groups.  Thus, with parameters, it is possible to predict 
survival by given age and duration under Weibull function. A regression spline 
predicts incidence of every single age by smoothing the observed prevalence of 
every age group. Next, combined with data concerning general mortality, one can 
continue to get an age-specific completeness index. In order to keep the work 
coherent, the R-values of midpoint age in every age group are considered as the 
values for the specific whole age group, and then back- transformed to the 
calculation for the 5-year age groups. The number of observed prevalent cases 
from HMRN is divided by the R-value of the corresponding age group, and total 
prevalent cases for every age group are available until here. To get total 
prevalence, simply add up the total prevalent cases of every age group, then 
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3.4.9 Validation and sensitivity analysis 
 
The aim of this section is to validate the total prevalence estimated from HMRN.  
It should be noted that it is difficult to validate the method and results in this 
study, until the registry is long enough to cover all prevalent cases on the index 
date. The validation analysis was done from two aspects: (1) Check the goodness 
of fit, and (2) Predict the power of the method. These analyses identify whether 
the model is consistent with data, and whether the model has good predictive 
powers.  
 
3.4.9.1 Goodness of fit 
 
 n-year prevalence (n=1, 2, 3, 4, 5, 6, 7) is estimated using the method in this 
study. It is then compared them to the actual n-year prevalence to check the 
goodness of fit. 
 
Hodgkin lymphoma was chosen as an example for validation analysis, because it 
has uncommon age distribution on incidence and survival. In other words, it 
requires a more flexible method to fit the data than other common cancers. If the 
model in this work can provide suitable descriptions for Hodgkin lymphoma, it 
will be fine to make estimations for other subtypes with common distribution 
(such as monotone increasing incidence trend with age).  There are also another 
two advantages to choose Hodgkin lymphoma. On the one hand, there is a 
relatively good sample size to support the estimations. On another, the prognosis 
of Hodgkin lymphoma is good (see Appendix A5) and so compared with subtypes 





 3.4.9.2 Power to predict 
 
According to the validation method used by Gigli et al. (2004), part of the data to 
estimate L –year prevalence is used, and then the estimated L-year prevalent cases 
are compared to the actual L -year prevalent cases. 
 
The goodness of the total prevalence estimation for HMRN data is evaluated by 
comparing the observed 7-year prevalence with the estimated 7-year prevalence. 
The latter one is obtained by estimating total prevalence from recent five-year 
data (2006-2011), and then truncating the total prevalence to seven year 
prevalence (Gigli, et al., 2004): 
 
   




  (3. 27) 
 
A plot of the estimated   
𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑( ) and   
𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑( ) versus age highlights the 
difference between observed and estimated prevalence. This can help to identify 
whether the model fits the data well.  
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3.5 Subtypes where survival has changed greatly in the past 
 
3.5.1 Method to estimate total prevalence range 
 
For some diseases, the method in Section 3.4 may not accurately estimate total 
prevalence. This is because it assumes that the survival rate of a disease changes 
following the pattern observed over time in the data. However, the survival of 
some subtypes of haematological malignancy changed drastically in the past due 
to the introduction of new treatments. Therefore the survival pattern abstracted 
from a limited period of time cannot stand for the whole history of survival of the 
disease. In this study, the survival model was estimated using HMRN data from 
2004 to 2011. If a new treatment were applied in clinical practice earlier than 
2004, extrapolation of the survival trend to before 2004 would not reflect the poor 
survival before the new treatment was introduced.  
 
Total prevalence range is a practical method to avoid the need for introducing 
another dataset to address the problems associated with changes in survival in the 
past. This method may be applied to some of the subtypes of haematological 
malignancies to complement the results estimated using the method in Section 3.4. 
 
―Total prevalence‖ 
                         T-year prevalence     
                     
    …… 
 
 










Figure 3-16 shows the total prevalence range for a disease. Under the general 
method, ―total prevalence‖ can be estimated based on observed data (from the 
start of the registry to the index date). However, as described above, it may be 
overestimated, since the survival rate may be much poorer before the application 
of new treatment. Observed data can only be extrapolated to the year when the 
new treatment applied. Prevalence for that period is called the T-year prevalence. 
Obviously, it is underestimated if T-year prevalence is considered as complete 
prevalence, because although the survival has previously been poorer, there still 
may be some cases alive on the index date. Therefore, a range is demonstrated 
with the ―total prevalence‖ as an upper limit and T-year prevalence as a lower 
limit. The exact total prevalence cannot be estimated without bias, however the 
real complete prevalence must exist in this range (recall definitions about total 
prevalence and complete prevalence in Chapter One). 
 
T-year prevalence is special n-year prevalence, when n equals the length of time 
(years) for which a new treatment (which improved survival greatly) is used on 
patients. It can be calculated by general method. The completeness index here is:  
 
   =
  (𝑥, )
  (𝑥)
 (3. 29) 
 
Where 𝑃𝑜( , 𝐿) is observed prevalence in L years, and 𝑃 ( ) is T-year prevalence 
(𝐿   ). 
 
3.5.2 The choosing of “T” 
 
In this method, data from HMRN is the only material used to make the estimates, 
except for the information used to choose ―T‖, which is taken from the literature. 
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The choice of ―T‖ is related to the calendar years of the application of the new 
treatments. 10-year prevalence for chronic myelogenous leukaemia (CML), 12-
year prevalence for myeloma, 40-year prevalence for Hodgkin lymphoma, and 
50-year prevalence for acute lymphocytic leukaemia (ALL) were calculated to 
show their total prevalence ranges with the ―total prevalence‖ calculated using the 
method in section 3.4. The details of the chosen values of ―T‖ for these conditions 
are described in Chapter Four. 
 
3.5.3 The process of calculation for total prevalence range 
 
Prevalence range is an easy way to show total prevalence and make suggestions 
for health resource allocation and survivorship planning. In this study, it is used to 
make estimations instead of trying to calculate an exact number for some 
subtypes. Thus in brief, there are two main steps in estimation: calculate ―total 
prevalence‖, and calculate T-year prevalence (see Figure 3-17).  
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Data were obtained and formatted using Stata 11.0 software. The calculation for 
total prevalence was conduct using R 3.0.1 software. This included predicting 
incidence using regression splines, fitting data to Weibull function to find 
parameters, calculating observed prevalence, and calculating completeness index. 
Other mathematical calculations related to this work were implemented using 
Excel 2010.  
 
R program for total prevalence calculation is an entire program (R codes are 
shown in Appendix A7). Observed prevalence, total prevalence and their ratios 
can be obtained directly by running this program for subtypes. However, it is 
necessary to show the full calculation progress to explain the method. Therefore 
calculations in this thesis have been done manually for some subtypes by way of 
example, whilst for other subtypes, automatic calculation using R software was 







Chapter 4 Results 
 
 
4.1 Demographic characteristics  
 
4.1.1 Diagnosis and gender 
 
There were 15,810 diagnoses of haematological malignancies from 2004 to 2011 
in HMRN, of which 8,799 were males (55.7%) and 7,011 were females (44.3%), 
(see Table 4- 1). The numbers of cases are shown in Figure 4-1, ordered by 
frequency. The most common subtype of haematological malignancies was 
diffuse large B-cell lymphoma (2,066 diagnosis), and the next most common one 
was chronic lymphocytic leukaemia (1,721 diagnosis).  
 
Figure 4- 1 Malignancy Research Network (HMRN), 2004-2011. 
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The proportions for both genders are shown in Figure 4-2 (in the order of the ratio 
of males and females). Males predominated for most subtypes, except T-cell 
leukaemia (46.0%), myeloproliferative neoplasms (45.8%), and follicular 
lymphoma (45.3%). This was most significant in the comparatively rare hairy cell 
leukaemia with 80.2% being male cases and 19.8% female cases. Some related 
conditions had similar proportions, for example, monoclonal gammopathy of 
undetermined significance and plasma cell myeloma were almost identical (males 
accounted for 54.9% and 57.7% respectively). However, others such as chronic 
lymphocytic leukaemia and monoclonal B-cell lymphocytosis showed different 
proportions (males accounted for 62.2% and 54.5% respectively). (Percentages 
for all subtypes were shown in Table 4-1). In fact, variations were also evident 
within some of these main subtypes. For example, for Hodgkin lymphoma, males 
accounted for 56.4% generally, but this ranged from 51.9% for nodular sclerosis 




Figure 4- 2 Distribution by sex: The Haematological Malignancy Research 
Network (HMRN), 2004-2011 
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4.1.2 Age at diagnosis 
 
Table 4-1 showed the number of cases, median age and age ranges for subtypes. 
Unlike many other common cancers, haematological malignancy can be 
diagnosed at any age and the range within the data was from one day to 100 years. 
Different subtypes dominated at different ages. The median age at diagnosis 
ranged from 15.3 years for acute lymphoblastic leukaemia to 77.3 years for 
chronic myelomonocytic leukaemia. Age similarities could be found within 
related conditions. Figure 4-3 showed similarities between precursor conditions 
and their more aggressive counterparts. For example, monoclonal B-cell 
lymphocytosis and chronic lymphocytic leukaemia had the same median ages at 
diagnosis of 71.6 year. Likewise, there were similar median ages at diagnosis for 
monoclonal gammopathy of undetermined significance and myeloma (72.6 and 
73.1 years respectively).  
 
Some subtypes, such as diffuse large B-cell lymphoma spanned the entire age 
range. It principally occurs at older ages, but sporadic cases arise at younger ages. 
Such wide age spans were not seen for all haematological malignancies. For 
example, monoclonal B-cell lymphocytosis, chronic lymphocytic leukaemia, 
mantle cell lymphoma, and myeloma seldom occurred below the age of 35. 
Variation could be found within some of the main subtypes. For example, acute 
myeloid leukaemia occurred at any age, but the median age of patients with MLL 
(11q23) rearrangement was 19.2 years, whilst the therapy– related acute myeloid 
leukaemia patients showed a median age at 73.0. 
 
Although most subtypes had a median diagnostic age in old age (70.6 years for all 
haematological malignancies combined), some tended to be diagnosed at younger 
age, for example acute myeloid leukaemia, acute lymphoblastic leukaemia, 
Burkitt lymphoma, and Hodgkin lymphoma (see Figure 4-3). Paediatric cases 
may have significant effects on total prevalence estimates together with the 
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bimodal age distributions for Burkitt lymphoma and Hodgkin lymphoma. It was 
reasonable to suspect that they comprise several sub-subtypes with different 
features.  However, for the purpose of estimation, the heterogeneities within the 
main subtypes were not considered, and the prevalence was only estimated for the 
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Table 4- 1 Demographic characteristics: The Haematological Malignancy Research Network (HMRN), 2004-2011  
  
Total Male Female 
N Median age (range) N % Median age (range) N % Median age (range) 
Total 15,810 70.6 (0.003-99.7) 8,799 55.7  69.4 (0.003-99.7) 7,011 44.3  71.9 (0.05-99.0) 
Leukaemia 3,683 69.3 (0.1-97.8) 2,193 59.5  67.8 (0.003-96.1) 1,490 40.5  71.5 (0.05-97.8) 
   Chronic myelogenous leukaemia 242 59.0 (15.1-94.7) 146 60.3  57.6 (15.7-94.7) 96 39.7  61.6 (15.1-92.6) 
   Chronic myelomonocytic leukaemia 173 77.2 (0.1-96.4) 108 62.4  76.4 (1.4-95.7) 65 37.6  78.5 (0.1-96.4) 
   Acute myeloid leukaemia 1,061 70.2 (0.2-97.8) 576 54.3  69.4 (0.2-94.3) 485 45.7  70.9 (0.2-97.8) 
   Acute lymphoblastic leukaemia 305 15.3 (0.003-90.5) 175 57.4  16.4 (0.003-84.6) 130 42.6  14.1 (0.05-90.5) 
   Chronic lymphocytic leukaemia 1,721 71.6 (25.0-97.2) 1,077 62.2  69.6 (25.0-96.1) 644 37.8  74.7 (26.1-97.2) 
   Hairy cell leukaemia 81 65.4 (28.9-90.9) 65 80.2  63.5 (28.9-88.5) 16 19.8  73.5 (46.9-90.9) 
   T-cell leukaemia 100 74.2 (3.4-95.2) 46 46.0  74.8 (3.4-94.0) 54 54.0  73.8 (30.7-95.2) 
Non-Hodgkin lymphoma 4,271 69.0 (1.6-98.3) 2,254 52.8  67.9 (1.6-97.7) 2,017 47.2  70.5 (3.3-98.3) 
   Marginal zone lymphoma 839 72.4 (20.4-97.7) 456 54.4  71.3 (20.4-97.7) 383 45.6  73.6 (20.9-96.2) 
   Follicular lymphoma 804 64.6 (19.6-98.3) 364 45.3  62.9 (19.5-95.2) 440 54.7  65.9 (27.0-98.3) 
   Mantle cell lymphoma 219 73.9 (39.4-96.3) 141 64.4  71.2 (39.4-96.3) 78 35.6  75.6 (51.4-93.0) 
   Diffuse large B-cell lymphoma 2,066 69.8 (1.6-97.8) 1,080 52.3  68.2 (1.6-97.0) 986 47.7  71.4 (12.1-97.8) 
   Burkitt lymphoma 87 52.2 (3.1-95.6) 65 74.7  37.9 (3.1-88.2) 22 25.3  58.4 (3.3-93.4) 
   T-cell lymphoma 256 64.9 (2.9-95.6) 148 57.8  64.0 (2.9-91.1) 108 42.2  68.4 (3.7-95.6) 
Hodgkin lymphoma 754 41.1 (3.6-90.9) 425 56.4  41.3 (3.6-88.0) 329 43.6  39.6 (9.4-90.9) 
Myeloma 1,794 72.7 (30.6-95.5) 1,051 58.6  71.8 (30.6-94.4) 743 41.4  73.6 (36.0-95.5) 
   Plasma cell myeloma 1,646 73.1 (30.6-95.5) 949 57.7  72.2 (30.6-94.4) 697 42.3  73.8 (36.0-95.5) 
   Plasmacytoma 148 68.5 (36.6-94.5) 102 68.9  67.4 (36.6-87.3) 46 31.1  70.2 (38.7-94.5) 
Myelodysplastic syndromes 944 75.6 (3.8-96.4) 627 66.4  75.6 (10.1-96.4) 317 33.6  75.6 (3.8-93.6) 
Other Neoplasms of Uncertain or Unknown Behaviour 4,364 72.4 (1.8-99.7) 2,249 51.5  71.3 (1.8-99.7) 2,115 48.5  73.3 (4.0-99.0) 
   Myeloproliferative neoplasms 1,553 71.3 (1.8-99.7) 712 45.8  69.5 (1.8-99.7) 841 54.2  72.7 (17.0-99.0) 
   Monoclonal B-cell Lymphocytosis 690 71.6 (39.1-98.4) 376 54.5  70.9 (40.4-96.5) 314 45.5  72.9 (39.1-98.4) 
   Monoclonal gammopathy of undetermined significance 1,644 72.6 (27.7-95.7) 903 54.9  72.4 (27.7-94.3) 741 45.1  72.9 (29.9-95.7) 





4.1.3 Incidence and survival 
 
The incidence for all haematological malignancies combined was 63.2 per 
100,000 per year. Subtypes showed different incidence: the incidence was as low 
as 0.3 per 100,000 for hairy cell leukaemia, and as high as 8.3 per 100,000 for 
diffuse large B-cell lymphoma. Fatal subtypes such as acute myeloid leukaemia 
showed a 5-year survival of 19.7%; in contrast, rare forms like hairy cell 
leukaemia and comparatively common subtypes like monoclonal B-cell 
lymphocytosis had 5-year survival estimates of 88.4% and 82.3% respectively.  
Table 4-2 shows grouped subtypes according to their incidence and 5-year 
survival rate combinations. Marginal zone lymphoma has a modest incidence (3.4 
per 100, 000) and 5-year survival (62.5%). Mantle cell lymphoma may have 
lower prevalence estimates, due to its high mortality and low incidence. In 
contrast, myeloproliferative neoplasms with a relatively high incidence and 
survival, provides strong evidence for higher total prevalence estimates. The 
details of incidence and survival for every subtype were shown in Appendix A5. 
However, determination for total prevalence value cannot be made only based on 
Table 4-2, since incidence and survival varies with age. For example, although 
Hodgkin lymphoma and monoclonal B-cell lymphocytosis were grouped together 
with medium incidence and good survival, the higher incidence of Hodgkin 
lymphoma in childhood and young adulthood (see Figure 4-3) with good survival 
may result in much higher total prevalence estimates than monoclonal B-cell 






Table 4- 2 Subtypes considered in this study, according to their incidence and survival categories
* 
Incidence** Survival** 
(per 100,000) Poor (5-year prevalence<30%) Medium (5-year survival 30-70%) Good (5-year survival >70%) 
Low (<2) Chronic myelomonocytic leukaemia Acute lymphoblastic leukaemia Chronic myelogenous leukaemia 




   
 
T-cell lymphoma 
   
 
Plasmacytoma 
   
 
Lymphoproliferative disorder not otherwise specified 
 Medium (2-5) Acute myeloid leukaemia Marginal zone lymphoma Follicular lymphoma 
  Myelodysplastic syndromes 
 
Hodgkin lymphoma 
      Monoclonal B-cell lymphocytosis 
High (>5) 
 
Chronic lymphocytic leukaemia Myeloproliferative neoplasms 
  
 
Diffuse large B-cell lymphoma 








   
*Incidence and 5-year survival rates in HMRN from 2004 to 2011. Categories were made for this analysis only, and cannot be generalized to 
other diseases or other data 




4.2 n-year prevalence 
 
4.2.1 1-year, 5-year, and observed prevalence 
 
The basic data of n-year prevalence are shown in Table 4-3 and Table 4-4, along 
with the calculation of the proportion of n-year prevalence over observed 
prevalence. For all haematological malignancies combined, there were 10,069 
prevalent cases on the index date; 5,503 males and 4,566 females. Observed 
prevalence rate within the registry was 318.1 per 100,000 for males, and 248.0 per 
100,000 for females.  
 
Approximately 20% of observed prevalent cases were diagnosed in the last year, 
whilst about 80% were diagnosed in the last five years. These proportions varied 
with diagnostic subtypes. High proportions reflects that the diseases are 
frequently fatal; for example, 1- year prevalence of mantle cell lymphoma 
accounted for the largest proportion for both genders (31.3% and 36.7% 
respectively), whilst 5- year prevalence accounted for 94.0% in males, and for 
96.7% in females. This implies that nearly all the alive patients were diagnosed in 
the last five years. On the other hand, those diseases with better survival, such as 
acute lymphoblastic leukaemia, accounted for a smaller proportion (19.7% for 1-
year prevalence and 73.5% for 5-year prevalence). 
 
Due to the similar age structure between the area covered by HMRN and the UK 
(see Chapter Three, section 3.1.3.3), prevalence in HMRN can be used to estimate 
the number of prevalent cases in the UK using equation 3.2.  The number of n-
year prevalent cases in the UK was shown in Table 4-5. For most subtypes, there 
were more prevalent cases in males than in females. For the two genders 
combined, it was estimated that about 35,679 of prevalent cases were diagnosed 
in the last year and still alive on the index date in the UK.  The number of 5-year 
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prevalent cases was estimated to be 133, 565. Thus there were about 134 thousand 
persons living with haematological malignancies in 2011 who had been diagnosed 
within the last five years.   
 
Figure 4-4 depicts the observed (7-year) prevalence counts (the two genders 
combined) in the UK by subtypes, and the proportion of cases surviving for one 
year and 5-year respectively. Within 165,841cases, chronic lymphocytic 
leukaemia was the most prevalent subtype, with 21,127 survivors on the index 
date diagnosed from 2004. The number of observed prevalence cases of 
myeloproliferative neoplasms ranked second, with similar 5-year prevalent cases 
to chronic lymphocytic leukaemia (about 17,000 cases each).  Monoclonal 
gammopathy of undetermined significance, diffuse large B-cell lymphoma, and 
plasma cell myeloma ranked third to fifth. The five subtypes in combination were 
responsible for over half (56.5%) of the observed prevalence burden in the UK.
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Table 4- 3 n-year prevalence rate per 100,000 population for males on 31
st
, August 2011 in HMRN 
  Observed 1 year 5 years 
 
N Prevalence % N Prevalence % N Prevalence % 
Total 5,503 318.1 100.0 1,222 70.6 22.2 4,483 259.1 81.5 
Leukaemia 1,326 76.7 100.0 314 18.2 23.7 1,063 61.4 80.2 
   Chronic myelogenous leukaemia 125 7.2 100.0 26 1.5 20.8 102 5.9 81.6 
   Chronic myelomonocytic leukaemia 36 2.1 100.0 10 0.6 27.8 34 2.0 94.4 
   Acute myeloid leukaemia 155 9.0 100.0 43 2.5 27.7 129 7.5 83.2 
   Acute lymphoblastic leukaemia 117 6.8 100.0 23 1.3 19.7 86 5.0 73.5 
   Chronic lymphocytic leukaemia 805 46.5 100.0 192 11.1 23.9 644 37.2 80.0 
   Hairy cell leukaemia 58 3.4 100.0 15 0.9 25.9 44 2.5 75.9 
   T-cell leukaemia 30 1.7 100.0 5 0.3 16.7 24 1.4 80.0 
Non-Hodgkin lymphoma 1,408 81.4 100.0 309 17.9 21.9 1,145 66.2 81.3 
   Marginal zone lymphoma 328 19.0 100.0 70 4.0 21.3 275 15.9 83.8 
   Follicular lymphoma 304 17.6 100.0 58 3.4 19.1 244 14.1 80.3 
   Mantle cell lymphoma 67 3.9 100.0 21 1.2 31.3 63 3.6 94.0 
   Diffuse large B-cell lymphoma 596 34.5 100.0 135 7.8 22.7 481 27.8 80.7 
   Burkitt lymphoma 38 2.2 100.0 6 0.3 15.8 28 1.6 73.7 
   T-cell lymphoma 75 4.3 100.0 19 1.1 25.3 54 3.1 72.0 
Hodgkin lymphoma 342 19.8 100.0 65 3.8 19.0 276 16.0 80.7 
Myeloma 509 29.4 100.0 143 8.3 28.1 438 25.3 86.1 
   Plasma cell myeloma 445 25.7 100.0 124 7.2 27.9 382 22.1 85.8 
   Plasmacytoma 64 3.7 100.0 19 1.1 29.7 56 3.2 87.5 
Myelodysplastic syndromes 214 12.4 100.0 55 3.2 25.7 192 11.1 89.7 
Other Neoplasms of Uncertain or Unknown Behaviour 1,704 98.5 100.0 336 19.4 19.7 1,369 79.1 80.3 
   Myeloproliferative neoplasms 561 32.4 100.0 116 6.7 20.7 482 27.9 85.9 
   Monoclonal B-cell Lymphocytosis 315 18.2 100.0 54 3.1 17.1 243 14.0 77.1 
   Monoclonal gammopathy of undetermined significance 652 37.7 100.0 117 6.8 17.9 507 29.3 77.8 





Table 4- 4 n-year prevalence rate per 100,000 population for females on 31
st
, August 2011 in HMRN 
  Observed 1 year 5 years 
 
N Prevalence % N Prevalence % N Prevalence % 
Total 4,566 248.0 100.0 944 51.3 20.7 3,626 196.9 79.4 
Leukaemia 849 46.1 100.0 186 10.1 21.9 685 37.2 80.7 
   Chronic myelogenous leukaemia 81 4.4 100.0 19 1.0 23.5 67 3.6 82.7 
   Chronic myelomonocytic leukaemia 28 1.5 100.0 7 0.4 25.0 25 1.4 89.3 
   Acute myeloid leukaemia 127 6.9 100.0 37 2.0 29.1 100 5.4 78.7 
   Acute lymphoblastic leukaemia 82 4.5 100.0 8 0.4 9.8 61 3.3 74.4 
   Chronic lymphocytic leukaemia 477 25.9 100.0 105 5.7 22.0 391 21.2 82.0 
   Hairy cell leukaemia 15 0.8 100.0 1 0.1 6.7 12 0.7 80.0 
   T-cell leukaemia 39 2.1 100.0 9 0.5 23.1 29 1.6 74.4 
Non-Hodgkin lymphoma 1,259 68.4 100.0 283 15.4 22.5 1,004 54.5 79.7 
   Marginal zone lymphoma 282 15.3 100.0 70 3.8 24.8 238 12.9 84.4 
   Follicular lymphoma 355 19.3 100.0 63 3.4 17.7 264 14.3 74.4 
   Mantle cell lymphoma 30 1.6 100.0 11 0.6 36.7 29 1.6 96.7 
   Diffuse large B-cell lymphoma 528 28.7 100.0 121 6.6 22.9 425 23.1 80.5 
   Burkitt lymphoma 11 0.6 100.0 2 0.1 18.2 9 0.5 81.8 
   T-cell lymphoma 53 2.9 100.0 16 0.9 30.2 39 2.1 73.6 
Hodgkin lymphoma 277 15.0 100.0 37 2.0 13.4 196 10.6 70.8 
Myeloma 342 18.6 100.0 88 4.8 25.7 298 16.2 87.1 
   Plasma cell myeloma 316 17.2 100.0 82 4.5 25.9 278 15.1 88.0 
   Plasmacytoma 26 1.4 100.0 6 0.3 23.1 20 1.1 76.9 
Myelodysplastic syndromes 126 6.8 100.0 33 1.8 26.2 116 6.3 92.1 
Other Neoplasms of Uncertain or Unknown Behaviour 1,713 93.0 100.0 317 17.2 18.5 1,327 72.1 77.5 
   Myeloproliferative neoplasms 703 38.2 100.0 130 7.1 18.5 567 30.8 80.7 
   Monoclonal B-cell Lymphocytosis 275 14.9 100.0 39 2.1 14.2 207 11.2 75.3 
   Monoclonal gammopathy of undetermined significance 602 32.7 100.0 118 6.4 19.6 456 24.8 75.7 






Table 4- 5 The number of n-year prevalent diagnoses of males and females in the UK on 31
st
, August,2011 
  Total Male Female 
 
Observed 1-year 5-year Observed 1-year 5-year Observed 1-year 5-year 
Total 165,841 35,679 133,565 90,917 20,189 74,065 74,925 15,490 59,500 
Leukaemia 35,839 8,240 28,802 21,907 5,188 17,562 13,932 3,052 11,240 
   Chronic myelogenous leukaemia 3,394 741 2,785 2,065 430 1,685 1,329 312 1,099 
   Chronic myelomonocytic leukaemia 1,054 280 972 595 165 562 459 115 410 
   Acute myeloid leukaemia 4,645 1,318 3,772 2,561 710 2,131 2,084 607 1,641 
   Acute lymphoblastic leukaemia 3,279 511 2,422 1,933 380 1,421 1,346 131 1,001 
   Chronic lymphocytic leukaemia 21,127 4,895 17,056 13,300 3,172 10,640 7,827 1,723 6,416 
   Hairy cell leukaemia 1,204 264 924 958 248 727 246 16 197 
   T-cell leukaemia 1,136 230 872 496 83 397 640 148 476 
Non-Hodgkin lymphoma 43,921 9,749 35,392 23,262 5,105 18,917 20,659 4,644 16,475 
   Marginal zone lymphoma 10,046 2,305 8,449 5,419 1,156 4,543 4,627 1,149 3,905 
   Follicular lymphoma 10,848 1,992 8,363 5,022 958 4,031 5,825 1,034 4,332 
   Mantle cell lymphoma 1,599 527 1,517 1,107 347 1,041 492 181 476 
   Diffuse large B-cell lymphoma 18,511 4,216 14,921 9,847 2,230 7,947 8,664 1,986 6,974 
   Burkitt lymphoma 808 132 610 628 99 463 181 33 148 
   T-cell lymphoma 2,109 576 1,532 1,239 314 892 870 263 640 
Hodgkin lymphoma 10,196 1,681 7,776 5,650 1,074 4,560 4,545 607 3,216 
Myeloma 14,021 3,807 12,126 8,409 2,363 7,236 5,612 1,444 4,890 
   Plasma cell myeloma 12,537 3,394 10,873 7,352 2,049 6,311 5,185 1,346 4,562 
   Plasmacytoma 1,484 412 1,253 1,057 314 925 427 98 328 
Myelodysplastic syndromes 5,603 1,450 5,076 3,536 909 3,172 2,068 542 1,903 
Other Neoplasms of Uncertain or Unknown Behaviour 56,261 10,753 44,393 28,152 5,551 22,618 28,109 5,202 21,775 
   Myeloproliferative neoplasms 20,804 4,050 17,267 9,268 1,916 7,963 11,536 2,133 9,304 
   Monoclonal B-cell Lymphocytosis 9,717 1,532 7,411 5,204 892 4,015 4,513 640 3,397 
   Monoclonal gammopathy of undetermined significance 20,650 3,869 15,859 10,772 1,933 8,376 9,878 1,936 7,483 






Figure 4- 4 Bar chart of observed prevalence counts in the UK by subtypes; 





 Sep. 2006, and 1
st
 Sep. 2004, respectively (two 
genders combined, and order sorted by observed prevalence counts) 
 
 
For some diseases with a relatively high incidence rate and a good prognosis, n-
year prevalence and observed prevalence within the registry may not provide 
accurate estimates, since there will be cases diagnosed before the start of the 
registry and still alive on the index date. Since HMRN is relatively young with 
only seven years of data, observed prevalence was only sufficient to show the 
burden of the subtypes with short survival, however for those with relatively 
longer survival, the bias due to the limited length of the registry cannot be ignored. 
 
0 5,000 10,000 15,000 20,000
Prevalence counts
   Burkitt lymphoma
   Chronic myelomonocytic leukemia
   T-cell leukemia
   Hairy cell leukemia
   Plasmacytoma
   Mantle cell lymphoma
   T-cell lymphoma
   Acute lymphoblastic leukemia
   Chronic myelogenous leukemia
   Acute myeloid leukemia
   Lymphoproliferative disorder not otherwise specified
Myelodysplastic syndroms
   Monoclonal B-cell Lymphocytosis
   Marginal zone lymphoma
Hodgkin lymphoma
   Follicular lymphoma
   Plasma cell myeloma
   Diffuse large B-cell lymphoma
   Monoclonal gammopathy of undetermined significance
   Myeloproliferative neoplasms





4.2.2 Sufficient years for complete prevalence 
 
Table 4-6 showed n-year prevalence (per 100, 000) of haematological 
malignancies in HMRN on 31
st
, August 2011, according to number of years from 
diagnosis for both sexes. 1-year, 2-year, 3-year, 4-year, 5-year, 6-year, and 7-year 
prevalence were calculated separately. Percentage changes in prevalence between 
successive years (n and n+1) for every subtype, are shown by columns (change 
[%]). This information may be helpful to determine whether the years of follow 
up are sufficient to show complete prevalence. If the changes decrease and 
become very low, the prevalence tends to be stable with the accumulated years. It 
can therefore be said that observed prevalence was fine to show the burden of the 






























Chronic myelogenous leukaemia 1 1.5   1.0   
  2 2.8 84.6 1.4 36.8 
  3 3.5 27.1 2.2 53.8 
  4 4.6 31.1 2.9 32.5 
  5 5.9 27.5 3.6 26.4 
  6 6.5 10.8 4.1 13.4 
  7 7.2 10.6 4.4 6.6 
Chronic myelomonocytic  1 0.6 
 
0.4 
 leukaemia 2 1.1 90.0 1.0 157.1 
  3 1.6 42.1 1.1 11.1 
  4 1.8 14.8 1.3 20.0 
  5 2.0 9.7 1.4 4.2 
  6 2.0 0.0 1.4 4.0 
  7 2.1 5.9 1.5 7.7 
Acute myeloid leukaemia 1 2.5 
 
2.0 
   2 4.1 65.1 3.0 51.4 
  3 5.7 39.4 3.8 25.0 
  4 6.6 16.2 4.5 17.1 
  5 7.5 12.2 5.4 22.0 
  6 8.3 10.9 6.1 12.0 
  7 9.0 8.4 6.9 13.4 
Acute lymphoblastic leukaemia 1 1.3 
 
0.4 
   2 2.5 87.0 1.1 162.5 
  3 2.9 16.3 1.9 66.7 
  4 3.8 30.0 2.7 42.9 
  5 5.0 32.3 3.3 22.0 
  6 5.8 16.3 3.7 13.1 
  7 6.8 17.0 4.5 18.8 
Chronic lymphocytic leukaemia 1 11.1 
 
5.7 
   2 19.5 75.5 10.0 76.2 
  3 26.8 37.7 14.6 44.9 
  4 32.6 21.6 17.9 23.1 
  5 37.2 14.2 21.2 18.5 
  6 41.7 12.1 23.7 11.5 
  7 46.5 11.5 25.9 9.4 
Hairy cell leukaemia 1 0.9 
 
0.1 
   2 1.2 40.0 0.1 100.0 
  3 1.5 23.8 0.2 100.0 
  4 1.8 23.1 0.5 150.0 
  5 2.5 37.5 0.7 20.0 
  6 2.8 11.4 0.7 8.3 
















T-cell leukaemia 1 0.3 
 
0.5 
   2 0.6 120.0 1.0 100.0 
  3 1.0 54.5 1.2 27.8 
  4 1.0 0.0 1.4 8.7 
  5 1.4 41.2 1.6 16.0 
  6 1.5 8.3 2.0 27.6 
  7 1.7 15.4 2.1 5.4 
Marginal zone lymphoma 1 4.0 
 
3.8 
   2 8.0 98.6 6.7 75.7 
  3 11.8 46.8 9.0 34.1 
  4 14.2 20.1 11.6 29.1 
  5 15.9 12.2 12.9 11.7 
  6 17.9 12.7 14.0 8.4 
  7 19.0 5.8 15.3 9.3 
Follicular lymphoma 1 3.4 
 
3.4 
   2 6.2 84.5 7.1 106.3 
  3 8.5 37.4 9.7 37.7 
  4 11.6 36.1 12.6 29.6 
  5 14.1 22.0 14.3 13.8 
  6 16.0 13.5 16.8 17.4 
  7 17.6 9.7 19.3 14.5 
Mantle cell lymphoma 1 1.2 
 
0.6 
   2 2.1 76.2 1.0 72.7 
  3 2.8 32.4 1.2 15.8 
  4 3.5 22.4 1.5 27.3 
  5 3.6 5.0 1.6 3.6 
  6 3.8 3.2 1.6 3.4 
  7 3.9 3.1 1.6 0.0 
Diffuse large B-cell lymphoma 1 7.8 
 
6.6 
   2 14.0 80.0 11.0 66.9 
  3 18.4 31.3 15.4 40.6 
  4 23.6 27.9 19.5 26.4 
  5 27.8 17.9 23.1 18.4 
  6 31.4 12.9 26.0 12.7 
  7 34.5 9.8 28.7 10.2 
Burkitt lymphoma 1 0.3 
 
0.1 
   2 0.7 100.0 0.2 100.0 
  3 0.9 33.3 0.4 75.0 
  4 1.3 37.5 0.5 28.6 
  5 1.6 27.3 0.5 0.0 
  6 1.9 17.9 0.5 11.1 
















T-cell lymphoma 1 1.1 
 
0.9 
   2 1.6 47.4 1.1 25.0 
  3 2.3 39.3 1.4 25.0 
  4 2.7 20.5 1.7 24.0 
  5 3.1 14.9 2.1 25.8 
  6 3.7 18.5 2.6 23.1 
  7 4.3 17.2 2.9 10.4 
 Hodgkin lymphoma 1 3.8 
 
2.0 
   2 7.7 104.6 4.8 140.5 
  3 11.0 43.6 7.1 46.1 
  4 13.5 22.0 8.6 21.5 
  5 16.0 18.5 10.6 24.1 
  6 17.7 10.9 12.5 17.9 
  7 19.8 11.8 15.0 19.9 
Plasma cell myeloma 1 7.2 
 
4.5 
   2 12.5 74.2 8.0 80.5 
  3 16.8 34.3 10.6 32.4 
  4 19.9 19.0 13.3 25.0 
  5 22.1 10.7 15.1 13.5 
  6 24.0 8.6 16.5 9.0 
  7 25.7 7.2 17.2 4.3 
Plasmacytoma 1 1.1 
 
0.3 
   2 1.7 52.6 0.4 16.7 
  3 2.5 51.7 0.7 85.7 
  4 3.1 22.7 0.9 23.1 
  5 3.2 3.7 1.1 25.0 
  6 3.5 8.9 1.2 10.0 
  7 3.7 4.9 1.4 18.2 
 Myelodysplastic syndromes 1 3.2 
 
1.8 
   2 7.1 123.6 3.3 84.8 
  3 8.7 22.0 4.8 44.3 
  4 10.2 18.0 5.6 18.2 
  5 11.1 8.5 6.3 11.5 
  6 11.8 6.2 6.6 5.2 
  7 12.4 4.9 6.8 3.3 
Myeloproliferative neoplasms 1 6.7 
 
7.1 
   2 12.7 89.7 12.8 80.8 
  3 19.0 49.5 18.1 41.7 
  4 23.4 23.1 24.6 35.7 
  5 27.9 19.0 30.8 25.4 
  6 30.8 10.4 35.7 15.9 

















Monoclonal B-cell lymphocytosis 1 3.1 
 
2.1 
   2 6.6 113.0 4.6 117.9 
  3 9.4 40.9 6.6 42.4 
  4 11.5 22.8 9.3 41.3 
  5 14.0 22.1 11.2 21.1 
  6 16.5 17.7 13.3 18.4 
  7 18.2 10.1 14.9 12.2 
Monoclonal gammopathy  1 6.8 
 
6.4 
 of undetermined significance 2 13.3 96.6 12.2 90.7 
  3 19.4 46.1 17.4 42.2 
  4 25.3 30.4 21.3 22.8 
  5 29.3 15.8 24.8 16.0 
  6 33.6 14.6 28.8 16.4 
  7 37.7 12.2 32.7 13.4 
Lymphoproliferative disorder  1 2.8 
 
1.6 
 not otherwise specified 2 4.1 44.9 2.4 50.0 
  3 5.0 22.5 3.2 28.9 
  4 6.4 27.6 4.2 32.8 
  5 7.9 23.4 5.3 26.0 
  6 8.8 11.7 6.6 25.8 
  7 10.2 15.0 7.2 9.0 
 
From Table 4-6, it is easy to see that the percentage changes fall to under 5% for 
mantle cell lymphoma and myelodysplastic syndromes. This indicated that the 
seven year follow up in HMRN registry seemed sufficient for those subtypes with 
poor survival such as mantle cell lymphoma and myelodysplastic syndromes. 
Observed data for these cases was sufficient to estimate the true prevalence. 
However, subtypes such as Hodgkin lymphoma and acute lymphoblastic 
leukaemia still had percentage changes up to 19% between 6-year and 7-year 
prevalence. Therefore the length of HMRN registry was not enough to cover all 
patients who were alive with those diseases on the index date. Prevalence 
estimates of haematological malignancies in these ways (n-year prevalence or 
observed prevalence) may be of little value for those subtypes with better survival, 
and therefore for these subtypes it was necessary to estimate the total prevalence 
on the index date. It should be mentioned here that this presentation may not be 
appropriate for subtypes with small numbers of cases. For example, hairy cell 
leukaemia showed up to a 150% change for females (only 16 diagnoses in 
HMRN), which seems unreasonable compared with males. For similar reasons, 
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for some subtypes, the percentage change falls down to 0 in two certain n-year 
prevalence but increases again. Usually the 0% in the middle length of follow-up 
appears in the subtypes with a small number of cases. For example, the 
percentage change was 0% between 4-year and 3-year prevalence for T-cell 
leukaemia, but went up to 41.2% between 5-year and 4-year prevalence. This is 
because there were no newly diagnosed cases of T-cell leukaemia in the 4
th
 year 
after the start of the registry (see Figure 4-5).  
 
                                                   If no diagnosis in 4th year  
     1
st
              2
nd
              3
rd
              4
th
             5
th
              6
th
            7
th




          1-year                       2-year                          3-year                  4-year 
          5-year                       6-year                          7-year 
Figure 4- 5 The i
th





Using HMRN data, the figures shown in section 4.2 were all within the registry 
(information from 2004 to 2011). These statistics may provide limited insight 
regarding the longer survivor population and its needs. Seven years follow-up 
may not be sufficient to show the real burden of most of the subtypes. Therefore it 
is necessary to estimate total prevalence for all the patients in the population alive 




4.3 Total prevalence 
 
The results for all subtypes of haematological malignancies calculated using the 
method for total prevalence are explored in this section. However, results for 
acute myeloid leukaemia and Hodgkin lymphoma have been used as examples to 
illustrate the method, as they represented two typical diseases with different 
incidence and survival characteristics. 
  
4.3.1 Acute myeloid leukaemia (AML) 
 
Generally, the incidence rate of AML increases with age, however it can occur at 
any age, in these data ranging from 0.2 to 97.8 years old with a median age of 
70.2 years.  There was a male predominance, and males had a higher incidence 
rate of AML than females in all age groups. The divergence between the two 
genders‘ rates became more marked as age increases (see Figure 4- 6). Crude 
incidence of AML by age and gender (per 100,000 population) was shown in 






Figure 4- 6 Incidence of AML per 100,000 for males, females, and total 
 
Table 4- 7 Crude incidence of AML rate per 100,000 by age and gender  
Age group Total Male Female 
(Years) N Incidence N Incidence N Incidence 
0-4 18 1.2 10 1.3 8 1.1 
05-Sep 5 0.3 3 0.4 2 0.3 
Oct-14 9 0.5 5 0.6 4 0.5 
15-19 15 0.9 11 1.3 4 0.5 
20-24 21 1.4 9 1.2 12 1.5 
25-29 18 1.2 8 1.1 10 1.2 
30-34 24 1.3 13 1.4 11 1.2 
35-39 27 1.4 13 1.4 14 1.4 
40-44 33 1.9 22 2.5 11 1.3 
45-49 32 2 18 2.3 14 1.8 
50-54 48 2.7 25 2.9 23 2.6 
55-59 69 5 39 5.6 30 4.3 
60-64 96 7.8 59 9.8 37 5.9 
65-69 103 9.2 56 10.6 47 8 
70-74 151 15.1 86 19.3 65 11.7 
75-79 163 19.3 89 25.3 74 15 
over 80 229 21.9 110 33 119 16.8 





















































































The survival for AML was shown in the Figure 4- 7. AML had a poor survival 
(regardless of age), and there were 779 deaths in HMRN from 2004 to 2011. Men 
and women had a similar survival (log rank test: p=0.845). 
 
 
Figure 4- 7 Kaplan-Meier survival estimates for AML patients by gender 
 
4.3.1.1 The modelling of incidence 
 
As an example of the calculation process, the predictions of incidence were 
shown in this section. The incidence for males has been taken as the example to 
show the benefit of my method (the comparison with the method to estimate 
incidence in the literature are shown in Chapter Five): 
 
In the literature, the parametric incidence model, 𝐼 = 𝑎 𝑏 (I is incidence and x is 
age), has been widely used (Capocaccia and De Angelis, 1997; Merrill, et al., 
2000; Gigli, et al., 2006). For a general class of cancers that rarely occur at an 






















485 147 99 69 49 28 16 0Sex = females
576 182 114 69 47 28 13 0Sex = males
Number at risk





the incidence cases at an early age (age before 35 years) could be ignored, this 
parametric model could be useful and fit the incidence data (see Figure 4- 8). 
However, according to the incidence calculations (see Appendix A5), 
haematological malignancies were a group of diseases that usually include earlier 
ages.  The parametric incidence model did not fit the incidence data well, 
especially for the older age groups, if all ages were considered (see Figure 4- 9). 




Figure 4- 8  The modelling of incidence using a log linear model for age after 35 





Figure 4- 9 The modelling of incidence using a log linear model for all ages for 
AML 
 
The regression spline demonstrates good fit of incidence (Figure 4- 10), and this 
method of modelling incidence was used in the whole work to calculate the total 
prevalence of hematological malignancies. 
 
 




4.3.1.2 The modelling of survival 
 
The estimates of survival in the calculation involved parametric functions (see 
Chapter Three, Section 3.4.6.3). They depended on both the duration of the 
disease (years since diagnosis) and age. Survival probability decreased with 
disease duration, however the hazard may vary according to age at diagnosis.  
 
Figure 4- 11 shows AML survival of the model in this study as a 3D version of 
age (years) and duration (survival years) for males in HMRN, to achieve a better 
visual impression of the probability of survival. The observed data was limited to 
7 years (the green lines on the curve show the survival with the disease duration at 
7 years). Graph A was the one seen from a 30-degree angle, and graph B was 
from a 120-degree angle. Both indicate that survival of AML is determined by 
both age and duration from diagnosis.  
 
There was an arch around age 20 years in Figure 4- 11. However, the curve at 
early ages may lack precision due to the small number of cases in the younger age 
groups. The confidential interval for younger age groups may be wider than for 
the older age groups (details were shown in Section 4.3.4), and there may be no 





























Figure 4- 11  3D Version for survival curve of AML by age and duration (A: 30 






4.3.1.3 Total prevalence 
 
The completeness indices for AML based on 7 years of follow up for both 
genders in HMRN was reported by age (see Figure 4- 12). The values of R 
(completeness index) vary according to age and gender. For AML, it ranged from 
0.53 to 1. Such high values demonstrated the poor survival for AML. The values 
of completeness index of males were a little higher than those of females in most 
age groups. This may be because males have a higher incidence of AML than 
females. 
 
The values of R shown in Table 4- 8 were the completeness index values of the 
middle age in every age group. Because the length of the registry was 7 years 
(from 2004 to 2011), in the age group 0-7years, there was no case diagnosed 
before the start of the registry and the completeness index values in those age 
groups were 1. Generally, for both genders, the values of R had a decreasing trend 
in younger age, and increased after 40 years old. Details are shown in Table 4- 9. 
 
 













































































Total prevalence was 10.2 per 100,000 for males and 9.0 per 100, 000 for females. 
Figure 4- 13 shows age specific observed and total prevalence (dark blue bars are 
observed prevalence and light blue bars are total prevalence). The total prevalence 
was slightly higher than observed prevalence in the middle age groups, but similar 
to observed prevalence in the young (due to the length of the registry) and older 
age groups (due to the high mortality in older patients). 
 





No R Nt No R Nt 
0-4 4 1 4 1 1 1 
5-9 3 1 3 3 1 3 
10-14 1 0.80708 1 5 0.650215 8 
15-19 2 0.835425 2 1 0.765125 1 
20-24 9 0.845672 11 6 0.793124 8 
25-29 8 0.801608 10 9 0.711563 13 
30-34 6 0.74334 8 8 0.608586 13 
35-39 9 0.712666 13 5 0.539299 9 
40-44 8 0.732622 11 7 0.533163 13 
45-49 9 0.797788 11 9 0.602103 15 
50-54 9 0.865273 10 8 0.714961 11 
55-59 12 0.905976 13 7 0.816199 9 
60-64 17 0.929141 18 14 0.885529 16 
65-69 18 0.951631 19 10 0.926413 11 
70-74 16 0.975479 16 13 0.943646 14 
75-79 13 0.990472 13 11 0.961207 11 
over 80 11 0.994419 11 10 0.975478 10 
Total 155 0.88 176 127 0.77 166 
Prevalence 9.0   10.2 6.9   9.0 
No: number of observed prevalent cases      Nt: number of total prevalent cases  
R: completeness index 





Figure 4- 13  Age-specific observed and total prevalence (per 100 000) for males 
and females with AML in HMRN on the index date of 31
st
, August 2011.  
 
 
4.3.2 Hodgkin lymphoma 
 
 
Unlike some other cancers, whose incidence increases with age, Hodgkin 
lymphoma has a bimodal incidence curve. Patients diagnosed with Hodgkin 
lymphoma had a median age of 41.3 years (ranging from 3.6 to 90.9 years).  It 
occurred most frequently in HMRN in two separate age groups, the first being 
young adulthood (age 15–35 years) and the second being in those over 60 years 
old (see Figure 4- 14). The annual incidence was 3.5 per 100,000 and 2.6 per 
100,000 for men and women respectively. Overall, it was more common in males 
in adult years, and females had a deeper trough (differences in age and sex 
patterns had been described in Section 4.1). Crude incidence of Hodgkin 




































Figure 4- 14 Incidence of Hodgkin lymphoma per 100,000 for males, females, 
and total 
Table 4- 9 Crude incidence of Hodgkin lymphoma rate per 100,000 by age and 
gender  
Age group Total Male Female 
(Years) N Incidence N Incidence N Incidence 
0-4 2 0.1 2 0.3 0 0 
05-Sep 4 0.2 3 0.4 1 0.1 
Oct-14 23 1.3 11 1.3 12 1.4 
15-19 59 3.6 32 3.9 27 3.4 
20-24 71 4.7 42 5.6 29 3.7 
25-29 76 4.9 35 4.6 41 5.1 
30-34 68 3.7 37 4.1 31 3.3 
35-39 64 3.4 38 4.1 26 2.7 
40-44 45 2.6 32 3.7 13 1.5 
45-49 40 2.5 29 3.7 11 1.4 
50-54 42 2.4 30 3.4 12 1.4 
55-59 43 3.1 23 3.3 20 2.9 
60-64 42 3.4 27 4.5 15 2.4 
65-69 51 4.6 22 4.2 29 4.9 
70-74 53 5.3 27 6.1 26 4.7 
75-79 39 4.6 22 6.3 17 3.4 
Over 80 32 3.1 13 3.9 19 2.7 
















































































The survival of Hodgkin lymphoma is shown in Figure 4-15. Hodgkin lymphoma 
had a good survival; there were only 135 deaths in HMRN from 2004 to 2011. 
The median age of death in HMRN was 72.2 years (ranging from 5.8 to 89.5 
years). The difference in survival between males and females was not significant 
(log rank test: p=0.087). Both incidence and survival determine the total 








4.3.2.1 The modelling of incidence 
 
For Hodgkin lymphoma, the disadvantage of a log linear incidence model and the 






















329 258 199 154 123 83 46 0Sex = females
425 309 227 160 112 67 36 0Sex = males
Number at risk





Obviously, the exponential shape for age of incidence failed to describe the 
bimodal incidence data of Hodgkin lymphoma (Figure 4-16).  
 
 
Figure 4- 16 The modelling of incidence using a log linear model for Hodgkin 
lymphoma 
 
The regression spline model aptly described the bimodal incidence data of 
Hodgkin lymphoma. Figure 4- 17 shows Hodgkin lymphoma incidence for men 









4.3.2.2 The modelling of survival 
 
Compared with AML, Hodgkin lymphoma had good survival (see Figure 4- 7 and 
Figure 4- 15). However, the age at diagnosis had a non- linear effect on the 
survival of Hodgkin lymphoma. Figure 4- 18 shows a 3D version of the estimated 
survival curve by age and duration of Hodgkin lymphoma for males in HMRN. It 
is more complicated than the survival curves for AML. However, again, the 
precision may be low in some age groups due to the small number of cases. The 
observed data was limited to 7 years (the green lines on the curve showed the 
duration of survival with the disease at 7 years). Graph A was the one seen from a 





































Figure 4- 18  3D-version for survival curve of Hodgkin lymphoma by age and 






4.3.2.3 Total prevalence 
 
The completeness indices for Hodgkin lymphoma based on 7 years of follow up 
for both genders in HMRN was reported by age (see Figure 4- 19). The values of 
R (completeness index) varied according to age and gender. For Hodgkin 
lymphoma, it had a range from 0.1 to 1; such low values demonstrated the good 
prognosis for Hodgkin lymphoma.  
 
The balance of incidence and survival determined the pattern of completeness 
index. The higher incidence of males made the completeness index lower, but the 
better survival of females resulted in more cumulative survivors on the index date. 
Generally, for both genders, the values of R had a significant decreasing trend 




















































































Total prevalence was estimated to be 73.3 per 100,000 for males and 71.4 per 100, 
000 for females. There were no prevalent cases in the first age group for females, 
however there were more cumulative prevalent cases in the last age group for 
females (see Table 4-10). This may be because women generally have a longer 
life span, and female Hodgkin lymphoma patients had a slightly better survival 
rate than male patients. Figure 4- 20 showed age-specific total prevalence of 
Hodgkin lymphoma for both genders. Unlike incidence, the total prevalence curve 
of Hodgkin lymphoma did not show a bimodal distribution. This is because the 
high incidence and good prognosis in young adulthood (age 15–35 years) resulted 
in a large amount of cumulative prevalent cases in middle age. On the other hand, 
although there was a second incidence peak over the age of 60, the survival 
















Table 4- 10 Total prevalence calculation process of Hodgkin lymphoma by age 




No R Nt No R Nt 
0-4 1 1 1 0 1 0 
5-9 2 1 2 1 1 1 
10-14 4 0.942242 4 1 0.954945 1 
15-19 19 0.85558 22 19 0.896376 21 
20-24 43 0.719678 60 25 0.719359 35 
25-29 25 0.578142 43 33 0.539985 61 
30-34 33 0.447276 74 36 0.376416 96 
35-39 35 0.339477 103 32 0.24576 130 
40-44 35 0.261082 134 17 0.151837 112 
45-49 26 0.216264 120 12 0.102336 117 
50-54 34 0.194131 175 12 0.100002 120 
55-59 21 0.184077 114 11 0.127203 86 
60-64 17 0.179281 95 16 0.161136 99 
65-69 16 0.17492 91 19 0.179138 106 
70-74 14 0.161693 87 19 0.16585 115 
75-79 10 0.131549 76 11 0.132758 83 
Over 80 7 0.105524 66 14 0.102926 136 
Total 342 0.27 1268 278 0.21 1319 
Prevalence 19.8   73.3 15.1   71.7 
No: number of observed prevalent cases    Nt: number of total prevalent cases  
R: completeness index    





Figure 4- 20 Age-specific observed and total prevalence of Hodgkin lymphoma 
for males and females (per 100,000) 
 
 
4.3.3 Dependence of R on registry and validation of R 
 
To analyse the sensitivity and validation of R, a set of parameters was chosen, and 
R computed varying one parameter (length of the registry) at a time, taking the 
remaining ones as fixed. Hodgkin lymphoma was chosen as the example in this 
section (reasons were described in Section 3.4.9.1). To avoid repetitive 
computation, Hodgkin lymphoma for males was chosen as the standard value in 
this section and extrapolated to the past (because there is a male predominance for 
most subtypes, and the incidence and survival patterns of Hodgkin lymphoma are 
similar for males and females [Section 4.3.2]). Hodgkin lymphoma had a good 
prognosis, so the value of completeness index would vary greatly according to the 





































4.3.3.1 Dependence of completeness index on the registry 
 
Figure 4- 21 showed the R-L (completeness index- length of follow-up) curve 
family obtained by varying the age at diagnosis. The lowest curve was the one 
used in the previous section to calculate total prevalence for Hodgkin lymphoma 
when the registry (HMRN) is 7 years old. Other R (completeness index) was 
computed varying the parameter L (the length of the registry), taking the 
remaining ones (incidence, survival, and general mortality) as fixed.  
 
As expected, the incompleteness bias decreased with the length of follow- up. For 
any certain age, the values of R increase with the length of the registry. If the 
length of the registry reached 50 years, the observed prevalence would account 
for the majority of prevalent cases. Then, the completeness index adjustment for 
the bias due to the unobserved part would be limited. If the registry time were to 
go on to infinity, observed prevalence should converge to the total prevalence and 





Figure 4- 21 Prevalence completeness index R as a function of age for various 
lengths of registry follow-up (L). (Hodgkin lymphoma for males) 
 
 
The effect of the length of the registry (L) was straightforward. The longer the 
follow-up was, the lower the underestimation bias. Table 4- 11 showed a matrix 
of completeness index for age and length of registry. When 
𝑎𝑔𝑒 ≤ 𝑡𝑕𝑒 𝑙𝑒𝑛𝑔𝑡𝑕 𝑜𝑓 𝑟𝑒𝑔𝑖𝑠𝑡𝑟𝑦, there was no case diagnosed before the start of 
registry and who was still alive on the index date. The value of R was 1, which 
means the observed prevalence was exactly the same as the total prevalence in 



















































































Table 4- 11 Completeness index of Hodgkin lymphoma for men by age group for 
various lengths of registry follow-up (L) 
  Length of registry follow-up (L) 
Age group 
(Years) L=7 L=10 L=20 L=30 L=40 L=50 
0-4 1 1 1 1 1 1 
5-9 1 1 1 1 1 1 
10-14 0.942 0.979 1 1 1 1 
15-19 0.856 0.962 1 1 1 1 
20-24 0.720 0.880 0.999 1 1 1 
25-29 0.578 0.758 0.993 1 1 1 
30-34 0.447 0.620 0.961 1.000 1 1 
35-39 0.339 0.487 0.885 0.998 1 1 
40-44 0.261 0.378 0.770 0.980 1.000 1 
45-49 0.216 0.308 0.641 0.926 0.999 1 
50-54 0.194 0.273 0.536 0.833 0.987 1.000 
55-59 0.184 0.255 0.477 0.725 0.947 0.999 
60-64 0.179 0.242 0.445 0.637 0.872 0.992 
65-69 0.175 0.226 0.405 0.576 0.775 0.960 
70-74 0.162 0.200 0.338 0.511 0.672 0.887 
75-79 0.132 0.157 0.243 0.402 0.568 0.768 
Over 80 0.106 0.123 0.180 0.312 0.495 0.678 
 
 
The results presented above were derived based on certain simplifying 
assumptions on the morbidity modelling. For example, the last column of Table 
4-11 may not reflect the truth, since the survival of Hodgkin lymphoma was much 
poorer 40 years ago (details were in Section 4.4.2). As expected, for the much 
poorer survival in the past, the R curves tended to move towards the top of the 
figure, indicating a lower proportion of prevalent cases were diagnosed before the 
start of the registry. At 50 years follow-up, for example, the higher mortality rate 







4.3.3.2 Validation of the analysis 
 
I. Goodness of fit 
 
Table 4-12 and Figure 4-22 used Hodgkin lymphoma to compare n-year 
prevalence estimated using the method with the actual n-year prevalence for both 
genders. The similar values suggest this is a relatively good fit for the data, and 
Chi square test shows there was no difference between actual and estimated 
prevalence. The longer the period was, the smaller the differences between 
estimated and actual values. For 7-year prevalence, the estimated prevalence was 
exactly the same as the actual one, because the estimation was made using the 
completeness index, which must be 1 in that instance. 
 
Table 4- 12  n-year prevalence estimated using the method and the actual n-year 
prevalence for both genders (Hodgkin lymphoma) 
n-year Period of Estimated Actual   
Prevalence Diagnosis Prevalence Cases Prevalence Cases   
Male             
1-year 2010-2011 3.5 61 3.8 65 
 2-year 2009-2011 6.6 114 7.7 133 
 3-year 2008-2011 9.6 166 11.0 191 χ2 =2.1(df=6) 
4-year 2007-2011 12.3 213 13.5 233 p=0.908 
5-year 2006-2011 14.9 258 16.0 276 
 6-year 2005-2011 17.4 301 17.7 306 
 7-year 2004-2011 19.8 342 19.8 342 
 Female 
      1-year 2010-2011 2.4 44 2.0 37 
 2-year 2009-2011 4.7 87 4.8 88 
 3-year 2008-2011 6.9 127 7.1 131 χ2=1.0(df=6) 
4-year 2007-2011 9.0 166 8.5 156 p=0.986 
5-year 2006-2011 11.1 204 10.6 195 
 6-year 2005-2011 13.1 241 12.5 230 






Figure 4- 22 n-year prevalence estimated using the method and the actual n-year 
prevalence for both genders (Hodgkin lymphoma) 
 
 
II. Predictive power 
 
The method developed in this study was applied to estimate the expected 7-year 
prevalence in order to compare them to the actual values observed in HMRN data. 
Figure 4-23 and Figure 4-24 summarize the information; the plots were 
satisfactory for both sexes (p=0.842 for males and p=0.852 for females). 
Generally, the estimated 7-year prevalent cases followed the age distribution of 
the observed ones. For all age groups combined, the number of estimated cases 
was slightly lower than the number of observed cases with a difference of 2.9% 
for males (332 estimated cases, and 342 observed cases), and 9.0% for females 
(253 estimated cases, and 278 observed cases). The differences for both sexes 
were less than 10% and did not exceed the limit (Gigli, et al., 2004). Thus, the 
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Figure 4- 23 The number of 7-year prevalent cases estimated using the method 






































































Figure 4- 24 The number of 7-year prevalent cases estimated using the method 




4.3.4 Total prevalence of all subtypes of haematological malignancies 
 
Age- specific R-values for every subtype were calculated following the general 
method, and age-specific total prevalence was calculated as the ratio of observed 
prevalence over R. The basic calculation of incidence and survival for all 
subtypes were shown in Appendix A5. Age specific incidence was simply 
estimated using a non-parametric regression spline regardless of the distributions. 
Survival probabilities were estimated using the parametric model. However, the 
effect of age was difficult to model for some subtypes.  Figure 4- 25 shows the 
log relative hazard of age at diagnosis for all subtypes. Age appeared to have an 


































































Most subtypes that occur in adulthood showed an approximate linear age effect 
on hazard. The non-linear effects can be found in subtypes that occur at any age, 
such as acute myeloid leukaemia and acute lymphoblastic leukaemia. For 
Hodgkin lymphoma with bimodal age distribution, age showed more complicated 
effects on survival. Wide confidence interval appeared in the subtypes with small 
numbers of cases, such as hairy cell leukaemia, T-cell leukaemia, and Burkitt 
lymphoma. This indicated that they were too small in numbers to be able to show 
a clear effect therefore the results of prevalence may be not robust. Furthermore, 
for some subtypes, the small number of diagnoses in early age groups usually 
resulted in a wider confidence interval than in older ones. All this may suggest a 






Figure 4- 25 
 
 













































For all subtypes combined, observed prevalence made up about half of the total 
prevalence. Table 4- 13 presents the completeness index, observed prevalence, 
and total prevalence (per 100,000) for all haematological malignancies under 
WHO classification. The five subtypes with the greatest prevalence rate were 
Hodgkin lymphoma, monoclonal gammopathy of undetermined significance, 
myeloproliferative neoplasms, chronic lymphocytic leukaemia, and diffuse large 
B-cell lymphoma, comprising 60% of haematological malignancies survivors in 
HMRN area. They varied in rank order between observed prevalence and total 
prevalence estimates. 
 
The proportion of observed prevalence to total prevalence ranged from 0.2 for 
Hodgkin lymphoma to nearly 0.9 for mantle cell lymphoma. Compared to 
subtypes with typically short survival duration, subtypes of greater survival 
duration tended to have greater difference between observed and total prevalence. 
For example, according to Table 4-2, acute myeloid leukaemia, mantle cell 
lymphoma, chronic myelomonocytic leukaemia, and myelodysplastic syndromes 
were associated with poor survival, and in these data, the completeness indexes 
were higher, with 0.83, 0.90, 0.93, 0.95 respectively. This implied that total 
prevalence included less than 20% of patients diagnosed before the start of the 
registry for those subtypes. By comparison, Hodgkin Lymphoma, chronic 
myelogenous leukaemia, hairy cell leukaemia, and follicular lymphoma had good 
survival and the completeness indexes were 0.24, 0.39, 0.41, 0.48 respectively. 
 
Subtypes with more cases in childhood usually showed greater differences 
between observed and total prevalence. For example, although both Hodgkin 
lymphoma and monoclonal B-cell lymphocytosis had medium incidence (2-5 per 
100, 000) and good survival (5-year survival> 70%) (See Section 4.1.3, Table 4-
2), the completeness index of monoclonal B-cell lymphocytosis was 50% higher 
than that of Hodgkin lymphoma. This is because younger patients of Hodgkin 
lymphoma with good survival resulted in a large amount of cumulative prevalent 
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cases after middle age, whilst there was no monoclonal B-cell lymphocytosis 
diagnosed before the age of 35 years. Likewise, total prevalence included more 
than 60% of patients diagnosed before the start of the registry for Burkitt 
lymphoma and acute lymphoblastic leukaemia. It was also the reason why acute 
myeloid leukaemia had a lower completeness index than myelodysplastic 
syndromes. The completeness index usually increased to some degree, for 
diseases that could transform from more indolent to aggressive subtypes, for 
example follicular lymphoma/ diffuse large B-cell lymphoma (0.48 to 0.57), 
monoclonal B-cell lymphocytosis/ chronic lymphocytic leukaemia (0.50 to0.58), 
and monoclonal gammopathy of undetermined significance / myeloma (0.49 to 
0.79). However, there was a decrease from myelodysplastic syndromes to acute 
myeloid leukaemia (0.95 to 0.83). This may be because the survival of acute 
myeloid leukaemia in childhood was relatively good, whilst the diagnosis of 
myelodysplastic syndromes is rare in younger age groups. 
 
Using these prevalence estimates, the number of prevalent cases in the UK can be 
estimated due to the similar age and gender structures. Table 4- 14  lists the 
observed and total prevalence of the top five most common haematological 
malignancies in the UK. This analysis demonstrated that relying on observed 
prevalence alone would result in a significant underestimation of the relative 
burden of some diseases such as Hodgkin lymphoma. It identified Hodgkin 




 most prevalent of all heamatological 
malignancies amongst men and women in the UK, whereas total prevalence 
calculation in this data would present it as second for both genders. In other words, 
compared with observed prevalence, the relative contribution of Hodgkin 
lymphoma increased when longer prevalence periods were considered. 
Differences  between observed prevalence and total prevalence estimates also 
pushed chronic myelogenous leukemia, acute lymphoblastic leukemia, 
monoclonal B-cell lymphocytosis, and  lymphoproliferative disorder not 
otherwise specified, slightly up in rank. It indicated that observed prevalence only 
cannot show disease burden correctly, whilst total prevalence was a better guide 
to inform population needs.
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Table 4- 13 Observed and total prevalence (per 100 000) for males, females, and total in HMRN on the index date of 31st, August 2011 
  Total Male Female 
  R Observed Total R Observed Total R Observed Total 
Total 0.51 281.9 548.8 0.54 318 587.7 0.48 248.1 512.3 
Leukaemia 0.55 60.9 111.3 0.55 76.6 138.8 0.54 46.2 85.5 
   Chronic myelogenous leukaemia 0.39 5.8 14.7 0.42 7.2 17.1 0.36 4.5 12.5 
   Chronic myelomonocytic leukaemia 0.93 1.8 1.9 0.95 2.1 2.2 0.91 1.5 1.7 
   Acute myeloid leukaemia 0.83 7.9 9.6 0.88 9 10.2 0.77 6.9 9 
   Acute lymphoblastic leukaemia 0.39 5.6 14.5 0.41 6.8 16.5 0.35 4.5 12.6 
   Chronic lymphocytic leukaemia 0.58 35.9 62.1 0.57 46.5 81.3 0.59 25.9 44.1 
   Hairy cell leukaemia 0.41 2 4.9 0.39 3.4 8.6 0.54 0.8 1.5 
   T-cell leukaemia 0.53 1.9 3.6 0.58 1.7 3 0.51 2.1 4.2 
Non-Hodgkin Lymphoma 0.55 74.7 136.9 0.55 81.3 147.4 0.54 68.4 127.1 
   Marginal zone lymphoma 0.59 17.1 28.9 0.59 19 32.1 0.59 15.3 26 
   Follicular lymphoma 0.48 18.5 38.5 0.53 17.6 33.4 0.45 19.3 43.3 
   Mantle cell lymphoma 0.9 2.7 3 0.89 3.9 4.3 0.93 1.6 1.8 
   Diffuse large B-cell lymphoma 0.57 31.5 55.1 0.56 34.5 61.2 0.58 28.7 49.4 
   Burkitt lymphoma 0.29 1.4 4.8 0.26 2.2 8.3 0.41 0.6 1.5 
   T-cell lymphoma 0.54 3.6 6.6 0.53 4.3 8.1 0.56 2.9 5.2 
Hodgkin Lymphoma 0.24 17.3 72.4 0.27 19.8 73.3 0.21 15 71.5 
Myeloma 0.79 23.8 30.1 0.78 29.4 37.5 0.8 18.6 23.1 
   Plasma cell myeloma 0.8 21.3 26.5 0.79 25.7 32.4 0.82 17.2 21 
   Plasmacytoma 0.71 2.5 3.5 0.72 3.7 5.1 0.69 1.4 2.1 
Myelodysplastic syndromes 0.95 9.5 10 0.95 12.4 13 0.94 6.8 7.3 
Other Neoplasms of Uncertain or Unknown Behaviour 0.51 95.7 188.1 0.55 98.5 177.7 0.47 93 197.9 
   Myeloproliferative neoplasms 0.53 35.4 67.2 0.51 32.4 63 0.54 38.2 71.2 
   Monoclonal B-cell Lymphocytosis 0.5 16.5 32.9 0.58 18.2 31.3 0.43 14.9 34.5 
   Monoclonal gammopathy of undetermined significance 0.49 35.1 72 0.59 37.7 63.9 0.41 32.7 79.5 





Table 4- 14 Comparison of observed (7-year) and total prevalence of the top 5 haematological malignancies by gender* 
Observed Total 
Disease Prevalence Disease Prevalence 
Male   Male 
    Chronic lymphocytic leukaemia 13,300    Chronic lymphocytic leukaemia 23,222 
   Monoclonal gammopathy of undetermined significance 10,772    Hodgkin Lymphoma 20,950 
   Diffuse large B-cell lymphoma 9,847    Monoclonal gammopathy of undetermined significance 18,274 
   Myeloproliferative neoplasms 9,268    Myeloproliferative neoplasms 18,007 
   Plasma cell myeloma 7,352    Diffuse large B-cell lymphoma 17,483 
Female   Female 
    Myeloproliferative neoplasms 11,536    Monoclonal gammopathy of undetermined significance 24,020 
   Monoclonal gammopathy of undetermined significance 9,878    Hodgkin Lymphoma 21,608 
   Diffuse large B-cell lymphoma 8,664    Myeloproliferative neoplasms 21,515 
   Chronic lymphocytic leukaemia 7,827    Diffuse large B-cell lymphoma 14,924 
   Follicular lymphoma 5,825    Chronic lymphocytic leukaemia 13,316 




Figure 4- 26 and Figure 4- 27 illustrated the differences in observed prevalence 
(blue bars) and total prevalence (red bars- additional cases added by observed 




Figure 4- 26 Observed and total prevalence cases for males in the UK on 31
st
, 
August 2011  
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Figure 4- 27 Observed and total prevalence cases for females in the UK on 31
st
, 
August 2011  
 
4.4 Total prevalence range 
 
4.4.1 Chronic Myelogenous Leukaemia (CML) 
 
4.4.1.1 Diagnostic characteristics of CML 
 
CML was used as an example to show the calculation process details in this 
section. It is very rare in children, however according to the data in HMRN 
incidence increases with age. Patients diagnosed with CML had a median age of 
59.0 years (range from 15.1 to 94.7 years).  There was a male predominance, and 
men had a higher incidence of CML than women in nearly all age groups (see 
Figure 4-28). Crude incidence of CML by age and gender (per 100,000 
population) was shown in Table 4-15. 
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Figure 4- 28 Incidence of CML per 100,000 for males, females, and total 
 
Table 4- 15 Crude incidence of CML by age and gender (per 100,000 population) 
Age group Total Male Female 
(Years) N Incidence N Incidence N Incidence 
0-4 0 0 0 0 0 0 
05-Sep 0 0 0 0 0 0 
Oct-14 0 0 0 0 0 0 
15-19 4 0.2 1 0.1 3 0.4 
20-24 8 0.5 5 0.7 3 0.4 
25-29 2 0.1 2 0.3 0 0 
30-34 6 0.3 5 0.6 1 0.1 
35-39 16 0.8 12 1.3 4 0.4 
40-44 16 0.9 8 0.9 8 0.9 
45-49 25 1.6 15 1.9 10 1.3 
50-54 29 1.7 20 2.3 9 1 
55-59 26 1.9 19 2.7 7 1 
60-64 30 2.4 16 2.6 14 2.2 
65-69 17 1.5 11 2.1 6 1 
70-74 19 1.9 8 1.8 11 2 
75-79 22 2.6 15 4.3 7 1.4 
Over 80 22 2.1 9 2.7 13 1.8 

















































































The survival of CML is shown in Figure 4-29. There were only 36 deaths and the 
median age at time of death was 74.2 years (range 25.1 to 92.6 years). There were 




Figure 4- 29 Kaplan-Meier survival estimates for CML patients in HMRN by 
gender 
 
4.4.1.2 Choosing “T” for CML 
 
The treatment of CML has experienced dramatic progress in recent years. The 
previous therapies for CML consisted of interferon alpha based treatments (IFN-
α), hemopoietic stem cell transplantation (HSCT), and simple cell reduction 
treatment with hydroxyurea (HU). However, the introduction of tyrosine kinase 
inhibitors (TKIs) has proved to be highly effective in the treatment of CML 
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trial of imatinib (a kind of TKIs) was conducted in CML patients in 1998, and 
was approved by the Food and Drug Administration in 2001. Thereafter it rapidly 
became considered as front-line therapy for CML (Wang, et al., 2010; Wiggins, et 
al., 2010). Recently, two additional novel kinase inhibitors, dasatinib and nilotinib 
have become available as treatment options for patients who have developed 
resistance to, or those who have shown intolerance to imatinib (Hehlmann, 
Hochhaus, and Baccarani, 2007). 
 
 
Figure 4- 30 Development of treatment for CML (Hehlmann, Hochhaus, and 
Baccarani, 2007) 
 
In this study, the registry data began in 2004, which means that all observed cases 
are in the TKIs treatment era. The period of time covered by HMRN data, which 
is used for estimation of survival trends, was not sufficiently adequate to correctly 
estimate the survival trends in the past for CML. So, for CML, T-year prevalence 
is 10-year prevalence ( = 10), since the new treatment TKIs had been used in 





4.4.1.2 Total prevalence range for CML 
 
Figure 4-31 showed in one graph the completeness index R and RT for both ―total 
prevalence‖ and 10-year prevalence. They had a similar decline pattern with age, 
since they were calculated using the same parameters of incidence, survival, and 
general mortality. Generally, RT was higher than R.  
 
 
Figure 4- 31 Completeness index to calculate ―total prevalence‖ and 10-year 
prevalence of CML for men 
 
Total prevalence was 17.1 per 100,000 and 10-year prevalence was 10.0 per 
100,000 for males. The process of calculation was shown in Table 4-16. 
 
The total prevalence range of CML was 10.0-17.1 per 100,000 for males. The real 












































































compared to those diagnosed and actually observed within the registry, one could 
expect that fewer people diagnosed in the old treatment era were alive on the 
index date (since most of patients in the old treatment era may have died under 
the poor survival and prognosis). Thus, the prevalent patients who were diagnosed 
after the application of a new drug account for the majority of prevalent cases, 
and the ―total prevalence‘s‖ adjustment for those who were diagnosed before the 
application of new treatment will be limited. 
 
Table 4- 16  Total prevalence and 10-year prevalence of CML by age group for 





R Nt RT N10 
0-4 0 1 0 1 0 
5-9 0 1 0 1 0 
10-14 0 1 0 1 0 
15-19 1 0.799403 1 0.823032 1 
20-24 3 0.697204 4 0.794594 4 
25-29 3 0.643452 5 0.791698 4 
30-34 2 0.619998 3 0.799097 3 
35-39 7 0.611804 11 0.799761 9 
40-44 9 0.595212 15 0.781837 12 
45-49 10 0.55898 18 0.75344 13 
50-54 15 0.503745 30 0.725226 21 
55-59 17 0.45856 37 0.725046 23 
60-64 12 0.447061 27 0.745082 16 
65-69 16 0.426584 38 0.716842 22 
70-74 8 0.367705 22 0.663847 12 
75-79 8 0.28374 28 0.629169 13 
over 80 13 0.229152 57 0.624437 21 
Total 124 0.42 296 0.72 173 
Prevalence 7.2   17.1   10.0 
No: number of observed prevalent cases      Nt: number of total prevalent cases  
N10: number 10-year prevalent cases 
R: completeness index for ―total prevalence‖  





4.4.2 Total prevalence range of some other subtypes of haematological 
malignancies 
 
In this section, total prevalence ranges of some other subtypes of haematological 
malignancies (myeloma, Hodgkin lymphoma, and ALL) are presented.  
 
Myeloma is a neoplasm of plasma cells. Its survival characteristics and treatments 
have changed and developed in recent decades. Melphalan, introduced in the 
1960s, improved the poor survival (median survival was less than a year) of 
myeloma patients (Alexanian, et al., (1968)). In the 1980s, high dose 
chemotherapy and autologous stem cell transplant (ASCT) was given to patients, 
and it again improved survival. However, the median duration of response after 
ASCT does not exceed 3 years, and relapse of disease is common in patients 
(Attal, et al., 2006). In 1999, the introduction of immunnodulatory drugs 
(thalidomide and lenalidomide) and proteasome inhibitor (bortezomib) 
represented major milestones in the treatment of myeloma (Attal, et al., 2006; 
Kumar, et al., 2008). It is believed that the duration of response is prolonged and 
salvages relapsed disease. The survival changed from the cut-off of year 1999, 
contemporaneous with the availability of the new drug (Attal, et al., 2006; Kumar, 
et al., 2008). 12-year prevalence is used as the lower limit of total prevalence 
range for myeloma.  
 
The use of new more effective therapies such as new types of chemotherapy (such 
as mechlorethamine, vincristine, procarbazine, and prednisone (MOPP); 
doxorubicin, bleomycin, and vinblastine (ABV) [DeVita, Serpick & Carbone, 
1970; Fermé, et al., 2007]) became widespread for Hodgkin lymphoma, and have 
improved survival for the past decades (Capocaccia, et al., 2002). The great 
improvements in treatment took place in the 1960s and 1970s, which decreased 
the mortality of Hodgkin lymphoma by about over two thirds (Swerdlow, et al., 
2001; Levi, et al., 2002; Swerdlow, 2003). Therefore in this study, 40-year 





ALL is shown as an example to demonstrate long period prevalence and total 
prevalence. The survival of ALL changed drastically around 1960 due to the 
introduction of innovative treatments (Mauer and Simone 1976; Simonetti, et al., 
2008). The improvement of treatment was for children and not adult 
(Pui ,Campana, and Evans, 2001; Pui and Evans, 2006; Simonetti et al., 2008). 
Nowadays, the treatment of ALL includes chemotherapy, steroids, radiation 
therapy, and intensive combined treatments (including bone marrow or stem cell 
transplants) (The Mount Sinai Hospital, 2012). 50-year prevalence is calculated 
for ALL, and used as the lower limit of its total prevalence range. Since 50 years 
is a long period that may cover most of the patients alive on the index date, the 
total prevalence range will be narrow. This is because the patients diagnosed 50 
years earlier have a high probability of death before the index date. It worth 
noting that although the improvements of treatment for ALL were only for 
children (Pui ,Campana, and Evans, 2001; Pui and Evans, 2006; Simonetti et al., 
2008), it is considered it had the effects on all age groups. This is because the 
model in this section ignores the differences of the survival improvement among 
different age groups, and fortunately, most of the cases of ALL occur in 
childhood which brings less bias to the estimates. 
 
Table 4-17 shows the estimated total prevalence range for CML, myeloma, 
Hodgkin lymphoma, and ALL, by gender. The survival changed greatly recently 
for CML (10 years before index date) and myeloma (12 years before index date), 
while, much longer ago for Hodgkin lymphoma and ALL (about 40 and 50 years 
respectively before the index date). Amongst them, 40-year prevalence was 
estimated as the lower limit of total prevalence range for Hodgkin lymphoma. 
This was also the reason why the sensitivity analysis based on Hodgkin 
lymphoma (Section 4.3) was only a theoretical analysis. If the length of the 
registry were longer than 40 years, the fixed parameters of the survival model for 
Hodgkin lymphoma could not reflect the truth, and the completeness index might 




Consistent with expectation, the later the new treatment appeared, the wider the 
range was. When the new treatment was introduced more than 50 years ago for 
ALL, the T-year prevalence was being predicted as close to ―total prevalence‖. 
This is because, according to the incidence and survival of ALL, as well as 
general mortality in the population, the probability that a patient diagnosed with 
ALL 50 years ago being still alive was very low. This means that a 50 year period 
may cover nearly all ALL patients who are alive on the index date. However, the 
total prevalence ranges of myeloma are also narrow, although the new treatment 
for myeloma was applied relatively late on (12 years ago). This can be explained 
by its survival. The maintenance treatment thalidomide improved the survival of 
myeloma, but did not make it a ―curable‖ disease that has a good prognosis (Attal, 
et al., 2006; Kumar, et al., 2008). The survival of myeloma shown in Appendix 
A5 indicated the disease duration. The survivor function declined to about 0.25 
within the registry period. It was therefore reasonable to imagine that most 
patients diagnosed earlier than the introduction of thalidomide would not be able 
to live up to the index date, due to even poorer survival in the past.  
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Table 4- 17 Total prevalence and T-year prevalence for chronic myelogenous leukaemia, myeloma, Hodgkin lymphoma, acute lymphoblastic 
leukaemia by gender  
    T(years) "Total"* T-year  Range 
Prevalence (per 100,000)   
    
   Chronic myelogenous leukaemia 
Male 
10 
17.1 10.0 10.0-17.1 
Female 12.5 5.8 5.8-12.5 
   Myeloma 
Male 
12 
37.4 33.4 33.4-37.4 
Female 23.3 21.1 21.1-23.3 
   Hodgkin lymphoma 
Male 
40 
73.3 66.1 66.1-73.3 
Female 71.5 58.7 58.7-71.5 
   Acute lymphoblastic leukaemia 
Male 
50 
16.5 16.3 16.3-16.5 
Female 12.6 11.9 11.9-12.6 
Prevalent cases in the UK   
    
   Chronic myelogenous leukaemia 
Male 
10 
4,887 2,858 2,858-4,887 
Female 3,776 1,752 1,752-3,776 
   Myeloma 
Male 
12 
10,689 9,546 9,546-10,689 
Female 7,039 6,375 6,375-7,039 
   Hodgkin lymphoma 
Male 
40 
20,949 18,892 18,892-20,949 
Female 21,601 17,734 17,734-21,601 
   Acute lymphoblastic leukaemia 
Male 
50 
4,716 4,659 4,659-4,716 
Female 3,807 3,595 3,595-3,807 
 
T: the number of years from the application of new treatment 




Figure 4-32 shows the estimated prevalence range for the subtypes. The complete 
prevalence was shown in the light blue area that is composed of ―total prevalence‖ 
and T –year prevalence. The ranges were wide for CML and Hodgkin lymphoma 
for different reasons: there was a great improvement in survival for CML but a 
larger number of diagnoses for Hodgkin lymphoma. The ranges were also narrow 
for myeloma and ALL for different reasons: a less significant change in survival 
for myeloma but a much earlier appearance of new treatment for ALL.  
 
 
Figure 4- 32 Prevalence range for the subtypes (per 100,000) (CML: chronic 
myelogenous leukaemia, HL: Hodgkin lymphoma, ALL: acute lymphoblastic 
leukaemia, M: males, F: females) 
 
As described above, if one considers that the complete prevalence approaches the 
lower limit of the range, the ranks of subtypes may vary slightly. Figure 4-33 and 
Figure 4-34 show the total prevalent cases for males and females in the UK on 
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, August 2011. The maximum estimates in the figures were obtained using the 
general method, and the minimum estimates were derived from the ―T-year 
prevalence‖. Figures were sorted according to the minimum estimates. Details of 
the values can be found in Table 4-18, which showed the estimated counts of 
observed and total prevalence/ total prevalence ranges, ranking in order of 
descending total prevalence/ total prevalence range for both genders combined. 
Compared to the results in section 4.3, the ranks were pushed down a little for the 
subtypes with survival changed greatly in the past. For example, the rank of 
Hodgkin lymphoma (for the two genders combined) dropped from first to third 














Figure 4- 33 Total prevalent cases for males in the UK on 31
st
, August 2011 (the 
maximum estimates were obtained using the general method, and the minimum 




Figure 4- 34 Total prevalent cases for females in the UK on 31
st
, August 2011 
(the maximum estimates were obtained using the general method, and the 
minimum estimates were derived from ―T-year prevalence‖) sorted according to 
the minimum estimates
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Table 4- 18 The estimated counts of observed and total prevalence /range in the UK on 31
st
, August 2011, ranked in order of descending total 
prevalence for both genders. 
  Total Male Female 
  Observed Total/Range Observed Total/Range Observed Total/Range 
   Monoclonal gammopathy of undetermined significance 20,645 42,310 10,772 18,274 9,878 24,020 
   Myeloproliferative neoplasms 20,810 39,530 9,268 18,007 11,536 21,515 
   Hodgkin Lymphoma 10,191 36,626-42,550 5,650 18,892-20,949 4,545 17,734-21,601 
   Chronic lymphocytic leukaemia 21,106 36,500 13,300 23,222 7,827 13,316 
   Diffuse large B-cell lymphoma 18,505 32,396 9,847 17,483 8,664 14,924 
   Follicular lymphoma 10,849 22,641 5,022 9,549 5,825 13,082 
   Monoclonal B-cell Lymphocytosis 9,713 19,364 5,204 8,937 4,513 10,424 
   Marginal zone lymphoma 10,043 17,018 5,419 9,178 4,627 7,847 
   Myeloma 14,005 15,921-17,728 8,404 9,546-10,689 5,612 6,375-7,039 
   Lymphoproliferative disorder not otherwise specified 5,087 9,380 2,908 5,568 2,182 3,819 
   Acute lymphoblastic leukaemia 3,276 8,254-8,523 1,933 4,659-4,716 1,346 3,595-3,807 
   Myelodysplastic syndromes 5,598 5,904 3,536 3,704 2,068 2,205 
   Acute myeloid leukaemia 4,643 5,617 2,561 2,901 2,084 2,716 
   Chronic myelogenous leukaemia 3,391 4,610-8,663 2,049 2,858-4,887 1,346 1,752-3,776 
   T-cell lymphoma 2,091 3,866 1,223 2,307 870 1,562 
   Hairy cell leukaemia 1,202 2,903 958 2,462 246 448 
   Burkitt lymphoma 807 2,813 628 2,378 181 442 
   T-cell leukaemia 1,136 2,124 496 858 640 1,265 
   Mantle cell lymphoma 1,597 1,768 1,107 1,240 492 530 
   Chronic myelomonocytic leukaemia 1,054 1,132 595 627 459 505 
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Chapter 5 Discussion  
 
5.1 Conclusion and main findings 
 
5.1.1 Key findings and conclusion 
 
This thesis is the first time that prevalence for haematological malignancies has 
been calculated using current disease classification (ICD-O-3). The methods used 
estimated that around 19,700 people in HMRN region are living with a prior 
diagnosis of a haematological malignancy; this equates to about 327,800 people 
in the UK. After calculating total prevalence, the top five prevalent subtypes, 
monoclonal gammopathy of undetermined significance, myeloproliferative 
neoplasms, Hodgkin lymphoma, chronic lymphocytic leukaemia, and diffuse 
large B-cell lymphoma were found to comprise about 60% of prevalent 
haematological malignancies in HMRN area. 
 
The importance of estimating ―total‖ prevalence instead of observed prevalence 
was evident for some subtypes. In this thesis using HMRN data provided an 
estimate of haematological malignancy prevalence that is about 95% (with 
completeness index of 0.51) greater than observed prevalence for all subtypes 
combined. Out of all the diagnoses, about 9,600 cases were diagnosed before the 
establishment of HMRN registry.  
 
The relative burden presented by each subtype does not parallel that of observed 
prevalence. Consistent with expectations, the greatest differences between total 
prevalence and observed prevalence estimates were typically seen in less fatal 
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cancers that are commonly diagnosed at a younger age. For example, Hodgkin 
lymphoma typically has a good survival, and total prevalence estimates exceed 
those of observed prevalence greatly, whilst the difference between observed 
prevalence and total prevalence is slight for mantle cell lymphoma which has a 
short survival duration. Subtypes that occurred at an early age also lead to more 
accumulative prevalent cases. For example, ALL has an incidence peak under the 
age of five years old, and its completeness index was estimated as low as 0.38.  
However, this pattern may not be suitable to be applied to those cancers that have 
experienced a great improvement in treatment. This is because the survival 
observed in the registry cannot reflect the poor survival rate before the new 
treatment was introduced. In this study, HMRN started to accrue cases in 2004, 
therefore changes in treatment that have led to a change in survival cannot be 
extrapolated from observed data. Total prevalence ranges can help to give some 
information about those conditions. For CML, for example, the total prevalence 
range indicated that at least 1,752 units of health resource were needed (such as 
hospital beds, medicine for diseases, and doctors dedicated to a clinic), and no 
more than 3,776 units. Therefore the higher limit and lower limit avoided the 
chance of a resource shortage and surplus for CML. Thus, to some degree, the 
ranges are instructive for society to meet the population‘s needs. 
 
5.1.2 Importance of HMRN data 
 
HMRN provides high quality data as described in Chapter Three. The advantages 
of HMRN can be summarised into three aspects: (1) the confirmation of diagnosis 
of haematological malignancies, (2) the completeness of data, and (3) the 
percentage of lost- to- follow- up. Firstly, all cases are ascertained by a centralised 
laboratory (HMDS) that contains all relevant expertise and technologies to 
provide an integrated diagnostic service including histology, cytology, 
immunophenotyping and molecular cytogenetics. This provides the integrated 
confirmation of diagnosis of haematological malignancies in HMRN. Secondly, a 
list of newly diagnosed patients is downloaded on a weekly basis, and a group of 
trained nurses in ECSG abstract clinical data from patients‘ medical records. They 
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collect relevant information that includes demographic details, prognostic factors, 
and treatment and response to treatment for all patients. These data extracted by 
the ECSG are input into HILIS linking patients‘ diagnostic information with their 
clinical data, which makes high completeness of data. The nurses also confirm 
from the notes that the patients are newly diagnosed, so the diagnosis is truly an 
incident case. Lastly, like National cancer registries (UKACR, 2013), all cases in 
HMRN are flagged by the NHS Central Register, so it is known the status of 
patients, survival or died. With the high quality data in HMRN, prevalence of 
haematological malignancies can be calculated under WHO classification in this 
work rather than broad categories. Furthermore, it is not necessary to make 
adjustment for those lost-to-follow-up, since its percentage is small and can be 
ignored (Gigli et al., 2006). All in all, high quality data in HMRN is the 
foundation to estimate more accurate prevalence of haematological malignancies 
than other previous report (Ferlay, et al., 2010; NORDCAN, 2010; NCIN, 2012; 
SEER; 2012). 
 
5.1.3 Importance of estimates of prevalence 
 
The basic importance of prevalence estimates is to gain a better understanding of 
the size of the survivor population who received a diagnosis of a certain disease. 
The survivors may require treatment, monitoring for recurrence, and screening for 
other cancers (Capocaccia, et al., 2002). So the estimates of prevalence should be 
useful to agencies charged with planning for health care, such as the treatment, 
medical consultation, and long term counselling and support. It helps doctors and 
cancer care providers to know the cost of diseases management, and aid health 
resources allocation by governments to improve the quality of life for people with 
cancer who survive. For haematological malignancies, some previous sporadic 
reports of prevalence in the literature have not proved to be very useful due to 
data limitations and the lack of completeness, old broad classification, or a 
standard methodology (Capocaccia and De Angelis, 1997; Merrill, et al., 2000; 
Capocaccia, et al., 2002; Verdecchia, et al., 2002; Forman, et al., 2003; Lutz, et al., 
2003; Möller, et al., 2003; Gigli, et al., 2006). This work is to develop a flexible 
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method to estimate prevalence of haematological malignancies under WHO 
classification using data from HMRN, and show their disease burden in HMRN 
area and the UK. In fact, it can be also applied to other defined populations to 
estimate prevalence. For example, health insurance coverage for survivors in the 
US (Carpenter et al., 2011) can be estimated using total prevalence ranges when 
the exact total prevalence in unavailable.  
 
5.2 Methods in this thesis and the possible shortcomings 
 
5.2.1 Model and calculation of prevalence  
 
One of the main purposes of this work was to develop a suitable method to 
estimate total prevalence for haematological malignancies. Besides age, 
prevalence is also related to the time period of observation. Within registry data, 
only a limited number of years of observation data are available for prevalence 
calculation. Factors influencing the number of years of follow- up to capture the 
majority of prevalent cases include the age at which the disease is common and 
the survival of the disease. For example, the registration period was essentially 
sufficient for mantle cell lymphoma because it only occurs in later adulthood and 
the survival is relatively poor. On the other hand, for acute lymphoblastic 
leukaemia where the diagnosis is generally made at a young age and survival is 
generally good, many more years of follow- up are required to capture prevalence. 
In general, females need more years of follow- up than males. This may be 
because of better survival and longer life expectancy in females than in males. 
 
Haematological malignancies have the characteristic ability to transform (Davies 
et al., 2007; Kyle et al., 2010; Landgren et al., 2009; Lossos et al., 2002; Shanafelt 
et al., 2010; Shi et al., 2004), so the effects of multiple cancers cannot be ignored.  
One single patient may suffer from more than one cancer; prevalence can either 
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count the number of patients or refer to the number of cancers in the population. 
Previous studies of prevalence estimation only included the first primary cancer 
diagnosed in each person (Capocaccia, et al., 2002). Such studies only count a 
person once, which is useful if the reader would like to summarise various 
prevalence estimates across cancer sites without double counting individuals (i.e., 
the prevalence of specific cancer sites adds up to the prevalence of all cancers 
combined) (SEER, 2012). However, the ability to transform and process in 
haematological malignancy determines that diagnosis prevalence is more 
appropriate in this study. 
 
Amongst the 14,901 patients in HMRN diagnosed from 2004 to 2011, there were 
821 (5.5%) cases who had a second diagnosis, and 88 (<1%) cases who had a 
third diagnosis, resulting in 15,810 diagnoses in this study. Many followed the 
expected pattern, with either a precursor disease or a more indolent diagnosis 
progressing to one that is considered a more aggressive diagnosis (this has been 
described in Chapter One) (Bagguley et al., 2012;  Davies et al., 2007; Landgren 
et al., 2009; Lossos et al., 2002; Shanafelt et al., 2010;  Shi et al., 2004). For 
example, 12% of MDS cases had progressed to AML. 17.5% of MBL cases had 
transformed to CLL, 7.8% of follicular lymphoma had transformed to DLBCL, 
and 4.1% of MGUS to myeloma.  
. 
HMRN also solves the problems associated with classification of haematological 
malignancies. It provides unbiased ascertainment and accurate capture of detailed 
diagnostic data (HMDS, 2011) and provides a solid foundation for research into 
haematological malignancies in the area covered by HMRN (HMRN, 2011; Smith 
et al., 2010). The high quality functional data makes the calculation easy to move 
to the next step to estimate total prevalence. 
 
A flexible analytical model was developed for use in estimating the total 
prevalence of haematological malignancies. The analytical framework presented 
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is an adaption and an extension of the method used by Capocaccia and De 
Angelis (1997), which involves a mathematical model and statistical estimation.  
 
To estimate total prevalence, the method is presented by fitting data from the 
population-based cancer registry, HMRN. 
 
I. Completeness index (R) 
 
R is calculated using age, and it varies according to age group. Adults who were 
diagnosed in childhood may not be registered within the registry. The older age 
groups have more probability that the patients diagnosed in the younger age 
before the start of the registry and do not have records. For younger age groups, 
born closer to the time of the establishment of the registry, the likelihood of 
having had a diagnosis before the start of the registry is smaller. For the first age 
group, the value of R must be 1, since all of them were born after the start of the 
registry and are registered in HMRN.  
 
II. Validation of the method 
 
There is no gold standard for measuring or estimating cancer prevalence 
(Carpenter et al., 2011). Therefore it is impossible to validate the estimates of 
total prevalence against the actual proportion of the population living with a 
haematological malignancy. The validation analysis used in this study was 
conducted according to two aspects; the goodness of fit of the data was checked, 
along with the predictive power of the method. Both of them provided assurance 
for the methods and results in this thesis. As the length of the registry was limited, 
this work could only use the data in the last five years to estimate 7-year 
prevalence. When the registry becomes more mature, the validation analysis may 
show better results (for example, use 15 years data to estimate 25-year prevalence) 




As more information about survivor populations continues to become available, R 
becomes more robust with respect to the estimation of parameters. When the 
period of registration is long, the difference between total prevalence and 
observed prevalence decreases. As the registry time tends to increase, observed 
prevalence should converge to the total prevalence, which means the 
observational time is long enough to use observed prevalence instead of total 
prevalence to show the burden of cancer patients in a population. As HMRN 
continues to add new cases, increased duration of haematological malignancies 
registration will allow continued examination of the validity of this method and 
stability of these estimates over longer year periods. The limitations of this 
method are described in the later sections. 
 
III. Using AML and Hodgkin lymphoma as examples 
 
AML and Hodgkin lymphoma were chosen as examples to show the calculation 
process in this work, while for other subtypes, the results of total prevalence and 
completeness index were shown directly. This is because AML and Hodgkin 
lymphoma represented two typical diseases with different incidence and survival 
characteristics. AML is an easy example to show the calculation details, as there 
have been no significant changes in incidence and survival in the past years. It can 
occur at any age, and the survival is relatively poor (See Appendix A5). On the 
contrary, the survival of Hodgkin lymphoma is good, which means there may be 
more cases of Hodgkin lymphoma who were diagnosed before the start of HMRN 
and still alive on the index date than AML. Furthermore, Hodgkin lymphoma has 
an unusual age distribution for incidence and is therefore, a good example to 
show the requirement for a more flexible model, since the model in the literature 
may fail to fit the data (See Section 4.3.2). 
 
Hodgkin lymphoma was chosen as an example to demonstrate the validation 
analysis. First, Hodgkin lymphoma can provide a better view of a trend due to its 
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good prognosis compared to AML (See Section4.3.3). Second, there is a 
relatively good sample size to support the estimation. The most important reason 
is that if the method is flexible enough for Hodgkin lymphoma (with its unusual 
age distribution for incidence), it will be fine for other subtypes with common age 
distributions on incidence and survival. 
 
IV. Comparability of HMRN and UK 
 
The prevalence estimated using HMRN data was generalised to the whole of the 
UK. This is because HMRN region population structure mirrors that of the UK in 
terms of age and sex (See Section 3.1.3). The prevalence rates were applied on the 
population of UK without age adjustment. In this estimation, ethnicity was not 
included since it was not available in data. In fact, different ethnic composition 
may bring bias to the results. According to literature (National Cancer 
Intelligence Network and Cancer Research UK, 2009; SEER, 2012), incidence of 
Hodgkin lymphoma and non- and Hodgkin lymphoma in the black ethnic group 
was not significantly different from the white ethnic group, and the incidence of 
leukaemia is slightly higher in white than black (the ethnic comparisons were 
only available for broad categories but not for subtypes in literature). However, it 
should be noting that myeloma has much lower incidence in white than black 
(National Cancer Intelligence Network and Cancer Research UK, 2009; SEER, 
2012). So, if there are more black people in some areas such as London than 
HMRN region (Office for National Statistics, 2012), the generalization in this 
work may underestimate the prevalence counts in the UK for myeloma due to its 
higher incidence in black than white. 
 
V. Total prevalence range 
 
For those subtypes with a change in survival, a range of estimates of total 
prevalence were made, based on the maximum estimates calculated using the 
general method; the minimum estimates were derived from ―T-year prevalence‖.  
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This is consistent with the aim of this study—estimating prevalence of 
haematological malignancies using data from HMRN, and avoids borrowing 
complementary information from other datasets. Total prevalence range 
estimation is a practical method to show the burden of disease, and to our 
knowledge, there has been no similar report made up to this point. . 
 
In the literature, limited duration prevalence is usually used to substitute for 
estimating total prevalence in this situation (Capocaccia, et al., 2002; Forman, et 
al., 2003). However, when the length of the registry is short (seven years in this 
study), the surrogate—observed prevalence, does not appear reasonable. As 
described above, complete prevalence in the real world is difficult to estimate 
until the registration period becomes very long. Total prevalence is only an 
estimate for it. When the exact figures are difficult to estimate, finding a range for 
total prevalence seems a convenient way to show a reasonable result for a certain 
subtype.  
 
5.2.2 Improvements and differences from previous methods 
 
This method is an adaption of the ―completeness index method‖ to estimate total 
prevalence from limited duration prevalence (Capocaccia and De Angelis 1997; 
Gigli, et al., 2006).  However, unlike the methods used in the literature, in this 
thesis some adaptations were used for haematological malignancy according to its 
characteristics of incidence and survival.   
 
5.2.2.1 Parametric and non-parametric 
 
Capocaccia and De Angelis (1997) used a parametric model to estimate incidence 
and survival. In this thesis, however, the incidence model is a non-parametric 
model. To accommodate variation over time of a predictor‘s effect on incidence, 
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regression splines were used to model the incidence rate as a flexible function of 
age, without having to specify a particular functional form.  
 
As described in Section 4.3, the predictions of this incidence function in the 
literature (Capocaccia and De Angelis, 1997; Merrill, et al., 2000; Gigli, et al., 
2006) could potentially bias the results. However, the regression spline showed a 
much better fit for incidence. This is because the log linear model used in the 
literature for incidence was designed mainly for common cancers, which occur 
after adulthood. Their incidence can be simply described by exponential shape. 
However, for some subtypes of haematological malignancy, they can occur at any 
age or have unusual age distributions. The log linear model could not fit the data 
for them. However, regression spline is a non- parametric method, so it can 
describe the data regardless of the distributions. Section 4.3 in Chapter Four took 
incidence of AML and Hodgkin lymphoma as the examples to compare the 
incidence models and to show the benefit of regression spline method in this 
study. 
 
If the unusual incidence patterns of Hodgkin lymphoma are ignored, for example, 
there will be an underestimation of total prevalence using the log linear model as 
the model will not describe the bimodal incidence curve, leading to an 
underestimation of incidence before the age 35 (See Figure 4- 16). The survival 
before the age of 35 is relatively good, therefore the prevalent cases on the index 
date may be underestimated due to the incorrect incidence description. 
 
For survival, a parametric model was used. Survival probability depends on both 
the duration of disease (years since diagnosis) and age at diagnosis. Non-
parametric models can provide a better fit for the data. However, observed 
survival in a short- lived registry cannot model the whole life of patients. In this 
instance, a parametric model provides a best guess to extrapolate beyond the 
survival observed in the sample data. A Weibull model has been applied 
previously and successfully for cancer survival (Capocaccia and De Angelis, 1997; 
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Merrill, et al., 2000; Capocaccia, et al., 2002; Verdecchia, et al., 2002; Forman, et 
al., 2003; Lutz, et al., 2003; Möller, et al., 2003; Gigli, et al., 2006). However, the 
age effect on survival of haematological malignancies is difficult to describe, and 
does not follow the linear assumptions used in previous studies for some subtypes 
(see Figure 4- 24). For some subtypes that can occur at any age, the survival 
pattern may be different in children and adult. The survival of AML, for example, 
increases with age in childhood and then decreases after adulthood (See Section 
4.3.1, Figure 4-11). The survival model in the literature (Capocaccia and De 
Angelis, 1997; Gigli, et al., 2006) could not be used on this non-monotonic trend. 
In this study it was described using splines. They are a useful tool for analysing 
survival especially for subtypes which can occur at any age (Becher, et al., 2009). 
The 3D survival curves estimated using this method are shown in Figure 4-10 and 
Figure 4-17, using AML and Hodgkin lymphoma as examples. All in all, this 
study used more appropriate statistical methods to fit the data (details about the 
comparisons were shown in Chapter Four).  
 
5.2.2.2 Continuous and discrete model 
 
Compared to Capocaccia and De Angelis‘s (1997) method, the method in this 
thesis was formulated using discrete time instead of continuous time as used in 
previous studies. This was mainly because practical applications usually deal with 
discrete data (Verdecchia, et al., 2007). 
 
 Capocaccia and De Angelis (1997) framed their method in continuous time, and 
modelled the incidence and survival functions parametrically to facilitate the 
necessary integrations. However, the quantities that were available to this 
research were quite naturally framed in terms of discrete time. Therefore it made 
sense to look for the discrete version of the fundamental equations and to perform 
the calculations on them numerically. More attention should be paid in building 
models using a discrete version. Some approximation is necessarily involved in 
the model even when one-year age classes are in use. This is because, for example, 
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if a patient was diagnosed and died within the same year, it is difficult to show the 
survival time in a discrete version. In Chapter Three, assumptions were made in 
the first section to help build the model. Diagnoses were assumed to have been 
made at the beginning of the age groups, whilst deaths were all assumed to have 
occurred at the end of the age groups. In addition this approach led to discrete 
survival times. This assumption avoided the zero survival time in some special 
cases (events which occurred at the same age), however there were overestimates 
of survival time. Fortunately the overestimation in this method could be mitigated, 
by calculating the proportion of observed prevalence over total prevalence.  
 
The model relating prevalence, incidence, mortality, and survival was developed 
in a discrete- time version in Chapter Three. However it should be noted that the 
method stands as a mixed approach, since the equations were given in discrete 
form, whilst incidence and survival were modelled before being included in the 
calculation. Ideally it would have been good to use incidence and survival data 
directly, however presumably sample sizes are too small to avoid noisy estimates 
due to sample variation. Errors can occur when abstracting corresponding values 
at single ages or integer disease durations from incidence and survival models. 
Both incidence and survival models provide smooth curves, therefore there may 
be underestimations and overestimations for incidence at certain ages and survival 
probability of certain survival time. However these uncertainties are likely to be 
small and would not affect the results greatly. 
 
5.3 Limitations and weaknesses of the study 
 
Despite the improvements of the method in this study, estimates may be still 
affected by the method chosen, since not all the characteristics of subtypes can be 
captured using the modelling techniques employed here. Inaccuracies in 
estimation may have also occurred due to data limitations and assumptions 
employed to model prevalence estimates. A general limitation of prevalence 
estimation is the incompleteness bias from the limited length of the registry. 
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Therefore in this study, the prevalence was estimated using age-specific 
incidences that were relatively current and survival that was observed only for 
seven years. However, current prevalence is not only based on current incidence 
and survival, but also on past values as well; this is lacking in this thesis due to 
the assumption of constant probabilities with calendar years. The assumptions of 
stable incidence and survival may inaccurately estimate prevalence, because both 
measures increased over time (Cancer Research, UK 2011). Using the incidence 
rate from 2004 to 2011 for all years prior to 2004 would overestimate the total 
prevalence. In addition, owing to the improvement of survival and increasing life 
expectancy, there may be overestimations of the true complete prevalence. Briefly, 
in the model, if there is an increase in incidence and survival, the model will 
overestimate the prevalence. These uncertainties from calendar years may be 
weakened by calculating proportions of observed prevalence over total prevalence. 
 
The incidence that can be observed from these seven years was used, and 
considered as the constant incidence for the past years. This was not only because 
it was not reliable to estimate the trend of incidence from seven years of data, but 
also due to the purpose of the work. For the purpose of estimating, the most 
appealing choice was not to try to adopt the best hypothesis that can be taken, but 
to provide a plausible calculation of estimated probabilities (Verdecchia, et al., 
2002). Therefore the assumption about constant probabilities in this study was the 
most convenient way to build the model. Although there was an assumption that 
the survival under Weibull distribution and the hazard function would change 
monotonically over time, year at diagnosis was not included in the function. 
General mortality rates were taken from the most recent available life table.  The 
London School of Hygiene and Tropical Medicine (LSHTM, 2012) offers life 
table from 1971 to 2009. Although it changes over these 38 years, this work only 
used the latest one (2009) and considered it to be constant with years. All in all, to 
simplify the calculation for total prevalence, the calendar year component was not 




 A further limitation may be the restriction of the length of the registry. HMRN 
has an advantage in providing high quality data, yet also has an obvious 
disadvantage in its limited length. The estimates of prevalence dated to 2011, 
suffer from a delay (it is 2013 this year) that may limit its use for making 
decisions for health resource planning. This is because estimations were made 
based on data from a cancer registry, and it should be stressed that preparations of 
several years are needed to fit criteria of completeness and accuracy of data. 
Additionally, for some subtypes with small numbers of cases in the registry, the 
estimations may be not reliable and robust enough to show total prevalence. 
Sample size is an important feature of the study in which the goal was to make 
estimations of prevalence from the observed incidence and survival. Generally, 
larger sample sizes lead to increased precision when estimating unknown 
parameters. The numbers of observations are quite different for each subtype. 
Therefore the precision is higher in those diseases with more cases in the registry, 
whilst there is inevitable inaccuracy for subtypes with fewer cases. The method is 
not recommended for diseases with small number of cases. For example it does 
not perform very well for rare subtypes (RARECARE, 2013) such as hairy cell 
leukaemia, T-cell leukaemia, Burkitt lymphoma, and T-cell lymphoma. The 
results for those subtypes can only provide a suggestion, but are not sensitive 
enough to show the real burdens. In the calculation, in fact, there may be 
diversities within one subtype. For example acute promyelocytic myeloid 
leukaemia (APML) shows better survival than other AML due to the introduction 
of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in its treatment, 
which turns acute promyelocytic myeloid leukaemia from being highly fatal to 
having a good prognosis (Wang and Chen, 2008). It seems reasonable to exclude 
APML from AML for prevalence estimates. However, being different from the 
descriptive analyses, the main purpose of this study was to make estimations, for 
which sample size is an important factor. Therefore APML was not estimated 





5.4 Comparisons with other published knowledge 
 
Prevalence for most of subtypes cannot be compared with other reports in the 
literature, because data are not coded in the same way. Fortunately, as described 
in section 3.2.1 in Chapter Three, it can be confirmed that the prevalence 
estimates for the conditions in which the bridge coding can provide a reasonable 
approximation. For example, although for haematological malignancies (all 
subtypes combined), n-year prevalence are not in line with expectations as 
compared with national program (NCIN, 2006), the estimates of total survivors of 
Hodgkin lymphomas in the U.S. using my prevalence rates are broadly similar to 
the most recent reports by SEER (SEER, 2012). 
 
The appropriate classification for the disease is important for haematological 
malignancy epidemiological research (Smith, et al., 2009). However, many 
prevalence reports about haematological malignancy have aggregated their data 
into broad groups (Ferlay, et al., 2010; NORDCAN, 2010; NCIN, 2012; SEER; 
2012). The results in Table 4-5 showed that both overall 1-year prevalence and 5-
year prevalence estimates were not consistent with the national published figures 
(NCIN, 2006).  They doubled the frequencies in the UK reported in 2006 (35,679 
vs.16, 432 for 1-year prevalence, and 133,565 vs. 61,755 for 5-year prevalence), 
which were shown in broad categories. The double counting of patients due to 
multiple cancers increased the estimates in this study. A more meaningful reason 
may be the different way of coding, that not all of the subtypes in Table 4-5, such 
as myelodysplastic syndromes, were uniformly compiled (Smith, et al., 2009). 
The national figures do not include conditions such as MGUS, MBL, MDS and 
MPNs, which account for a large proportion of prevalent cases. However, for 
Hodgkin lymphoma alone, the comparison shows a more reasonable result: a 
slight in increase for both 1-year prevalence and 5-year prevalence (1681 vs.1437 




Prevalence estimated in this study can be extrapolated not only to the UK as a 
whole, but also to other populations, by making certain assumptions. If one 
assumes that incidence, survival and general mortality in HMRN area are similar 
in the target population, the number of prevalent cases can be generated from my 
data with adjustment for age structure (applying age- specific rates on the target 
population). For example, it is estimated that in the U.S., the number of prevalent 
cases of Hodgkin lymphoma ranged from 88,147 to 96,040 for males, and 82,932 
to 97,778 for females, based on age-specific prevalence rates in HMRN and 
populations in the U.S. (the population was obtained from IARC [IARC, 2013b]). 
This is consistent with the SEER reports (SEER, 2012) in the U.S. (93,890 for 
males and 88,038 for females). However, the estimates for myeloma were lower 
than their reports. In fact, after making adjustments for age, the incidence rate of 
myeloma in HMRN was slightly lower than in U.S., which leads to 
underestimations of total prevalence. This may be because of the different ethnic 
composition, since for myeloma the incidence in the black population (14.4 per 
100, 000 for males and 10.2 per100, 000 for females) is much higher than in the 
white population (7.1 per 100, 000 for males and 4.2 per 100, 000 for females) 
(SEER, 2012).  
 
Another example is the comparison to prevalence rates of Hodgkin lymphoma 
reported in Denmark. NORDCAN showed the prevalence in Denmark from 1963 
to 2011 (Engholm, et al., 2013), which may be long enough to cover all live 
patients in the country. The age-adjusted incidences were estimated to be 3.5 and 
2.5 per 100, 000 for males and females respectively, which were higher than the 
reports in NORDCAN (2.8 and 2.1 per 100, 000 for males and females). Thus, as 
might have been expected, the total prevalence estimated in HMRN (66.1 to 73.3 
and 58.7 to 71.5 per 100, 000 for males and females respectively) was much 
higher than in the NORDCAN reports (53.8 and 40.9 per 100, 000 for males and 
females in 2011). This indicates the Hodgkin lymphoma prevalence rate estimated 
in HMRN cannot reasonably be applied to the Danish population. However, my 
estimates of the ratio of total prevalence to incidence (P: I) were reasonably 
consistent with those observed in NORDCAN. The P: I estimated in HMRN for 
Hodgkin lymphoma was 18.9 to 20.9 in males, which includes the value reported 
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in the NORDCAN reports (19.2), and 22.6-27.5 in females, which is slightly 
higher than in the NORDCAN reports (19.5). This comparison is not only an 
explanation of the assumption (similar incidence and survival between local 
population and target population), but also reassuring validation of the method in 




Total prevalence entails much more than just a measure of the percentage of the 
population still alive following a diagnosis of disease, frequently represented as a 
single statistic reflecting the proportion of the population alive in n-year (usually 
1-year or 5-year) post-diagnosis. Rather, total prevalence includes all patients 
diagnosed in the past and still alive, and related issues of getting health care and 
follow-up treatment, late effects of treatment, and quality of life. It is therefore 
necessary to produce methods and statistics to inform those comprehensive cancer 
programs, for ensuring aspects such as health insurance coverage for survivor 
needs, facilitating basic healthy behaviours, and informing plans for long-term 
care. One important goal of estimating prevalence is to develop a more complete 
and accurate characterization of the survivor population, and to provide better 
estimates of their burden. That allows cancer networks and countries to better 
meet a population‘s needs all along the survivorship spectrum.  
 
The prevalence in this work was calculated under WHO classification. It avoids 
high level of clinical diversity among the subtypes contained within each of the 
traditional groupings, and has better value for epidemiological (Smith et al., 2010). 
This is the first time to estimate prevalence of haematological malignancies under 
WHO classification. The estimates of survivors in the UK in this study 
demonstrate the importance of understanding the details of the prevalent 
haematological malignancies population when prioritizing survivorship services 
for each subtype. For example, Hodgkin lymphoma changed largely in rank order 





third for two sexes combined). The results in this study (see Figure 4-34 and 
Figure 4-35) may provide not only a ranking and corresponding prioritization of 
haematological malignancies of prevalence for the UK health system, but also an 
estimate of the number of individuals with a history of each subtypes of 
haematological malignancies under new WHO classification. The contributions of 
this study can be summarized into as follows: 
 
I. Adapted and developed a more flexible model to estimate prevalence   
II. Estimated prevalence of haematological malignancies under WHO 
classification, which previously has not been reported. 
III. Estimated national prevalence counts and provided rank and periodization 
for subtypes. 
IV. Showed prevalence ranges for subtypes whose patterns of survival had 
changed greatly in the past due to new treatment for the first time. 
 




In the calculations, all haematological malignancy patients are included, from 
diagnosis to the end of life. In other words, recovery and cure are not considered 
in this method. In fact, even if a cancer patient becomes a long-term survivor after 
treatment, he or she usually still needs extra medical care due to the psychological 
and physical consequences of the disease (Simonetti, et al., 2008). Sometimes, the 
risk of subsequent cancers can increase because of the aggressiveness of the 
treatment (Simonetti, et al., 2008). Furthermore, the patient may suffer disability 
and impairments arising from the cancer treatment and may make more demands 
on health resources than the age-matched general population (Verdecchia, et al., 
2002). From this perspective, the method and the estimates in this study could 




In fact, the conception of recovery and cure requires careful definition (Gras et al., 
2006). The purest definition of recovery should be based on the complete 
eradication of the disease in the individual. However, for cancers, it is not always 
possible to determine this, since people who appear to be ―cured‖ according to 
clinical criteria often have recurrences (Gras et al., 2006). Therefore, in some 
previous calculations, there was an assumption that the disease is irreversible (see 
Chapter Two). That means, the disease, once diagnosed, is irreversible and both 
fatal cases and ―cured (long-term survivors)‖ contribute to prevalence estimates.  
 
After 5-year disease free survival a patient is often considered cured (Hoffbrand, 
et al., 2006; Howard and Hamilton, 2007; Hughes-Jones, et al., 2008). Although 
the ―cure‖ time is not considered in the model, one can also show a proportion of 
those with ―high consumption of health resources‖ by the differences between 
total prevalence and 5-year prevalence (Möller et al., 2003). The details of the 
results are shown in Appendix A6. However, the definition of ―cure‖ of 
haematological malignancies and the involvement of remission rates in the 
models needs further research.  
 
5.6.2 Prevalence in the future 
 
In the future, prevalence may increase. This can be caused by many factors. 
Firstly, the better the cancer registration is, the higher the prevalence might be. 
This can to some degree explain the higher prevalence in developed countries 
than in developing countries (Pisani, Bray and Parkin, 2002). Secondly, 
increasing incidence and better survival (due to lead- time bias in screening 
detected cancer and earlier diagnosis of cancer as well as the improved treatment 
being available to patients [Möller, et al., 2003]) lead to increasing prevalence. In 
these cases, the prevalence will inevitably markedly increase. Thirdly, increasing 
life expectancy will cause an increase in prevalence (Möller, et al., 2003). In a 
Swedish study, from 1961 to 1995, it was estimated that of the increase in 
prevalence, 40-47% could be attributed to population dynamics (ageing and 
234 
 
growth), and 30% and 23-29% to better survival and increasing incidence 
respectively (Stenbeck, et al., 1999). 
 
For HMRN, there is only seven years data available now, so it is impossible to 
obtain robust estimates of the trend of incidence and survival to calculate 
prevalence in the future with such limited data. When the registry is more mature 
and more cases registered in HMRN, calendar year can be added into the model, 
and the robust trends of probabilities with time may be abstracted from data, 




In this work, for the first time, the prevalence of haematological malignancies has 
been estimated for clinically meaningful diagnostic groups. Whilst additional 
research is necessary to continue improving prevalence measures and validating 
them, this study demonstrates the value of understanding total prevalence, as it 
allows more informed planning for health services and resource allocation in both 
HMRN area and in the UK. It illustrates the use of this method for converting 
observed prevalence to total prevalence using limited length of data from HMRN 
rather than based on other registries and their populations. Furthermore, it 
provides total prevalence rates under WHO classification, which can be 
extrapolated to the national or even worldwide level to estimate the number of 





Appendix A1 Cancer Network 
 
Table A- 1 Cancer Networks and their codes in the UK 
Codes Cancer Network 
N01 Lancashire and South Cumbria Cancer Network 
N02 Greater Manchester and Cheshire Cancer Network 
N03 Merseyside and Cheshire Cancer Network 
N06 Yorkshire Cancer Network 
N07 Humber and Yorkshire Coast Cancer Network 
N08 North Trent Cancer Network 
N11 Pan Birmingham Cancer Network 
N12 Arden Cancer Network 
N20 Mount Vernon Cancer Network 
N21 West London Cancer Network 
N22 North London Cancer Network 
N23 North East London Cancer Network 
N24 South East London Cancer Network 
N25 South West London Cancer Network 
N26 Peninsula Cancer Network 
N27 Dorset Cancer Network 
N28 Avon, Somerset and Wiltshire Cancer Network 
N29 3 Counties Cancer Network 
N30 Thames Valley Cancer Network 
N31 Central South Coast Cancer Network 
N32 Surrey, West Sussex and Hampshire Cancer Network 
N33 Sussex Cancer Network 
N34 Kent and Medway Cancer Network 
N35 The Greater Midlands Cancer Network 
N36 North of England Cancer Network 
N37 Anglia Cancer Network 
N38 Essex Cancer Network 
N39 East Midlands Cancer Network 
N96 North Wales Cancer Network 
N97 South West Wales Cancer Network 









Appendix A2 General Mortality by Age and Gender in England in 2009  
Table A- 2 Life table in England (2009) (LSHTM, 2012)  
Age Male Female Age Male Female Age Male Female Age Male Female 
0 0.004902 0.004014 25 0.000621 0.000277 50 0.003744 0.002338 75 0.039341 0.025064 
1 0.000326 0.000314 26 0.000638 0.000296 51 0.004076 0.002578 76 0.043715 0.028205 
2 0.000165 0.000154 27 0.000659 0.000317 52 0.004431 0.002845 77 0.048552 0.031759 
3 0.000141 0.000124 28 0.000683 0.000339 53 0.004814 0.003145 78 0.053891 0.035773 
4 0.000123 0.000106 29 0.000713 0.000364 54 0.005229 0.003485 79 0.059767 0.040297 
5 0.000109 0.0000945 30 0.000747 0.000391 55 0.005678 0.003871 80 0.066216 0.045381 
6 0.0000993 0.0000882 31 0.000787 0.000421 56 0.006168 0.004296 81 0.073274 0.051078 
7 0.0000931 0.0000854 32 0.000832 0.000453 57 0.006703 0.004688 82 0.080972 0.057440 
8 0.0000902 0.0000855 33 0.000885 0.000489 58 0.007295 0.004987 83 0.089337 0.064518 
9 0.0000905 0.0000879 34 0.000944 0.000529 59 0.007954 0.005300 84 0.098393 0.072362 
10 0.0000945 0.0000925 35 0.001012 0.000573 60 0.008688 0.005665 85 0.108156 0.081016 
11 0.000103 0.000099 36 0.001089 0.000622 61 0.009510 0.006088 86 0.118633 0.090516 
12 0.000117 0.000107 37 0.001176 0.000677 62 0.010430 0.006577 87 0.129823 0.100888 
13 0.000140 0.000117 38 0.001275 0.000738 63 0.011464 0.007139 88 0.141712 0.112146 
14 0.000174 0.000128 39 0.001386 0.000807 64 0.012625 0.007786 89 0.154270 0.124287 
15 0.000220 0.000140 40 0.001511 0.000885 65 0.013928 0.008527 90 0.167456 0.137287 
16 0.000278 0.000152 41 0.001651 0.000971 66 0.015389 0.009376 91 0.181208 0.151100 
17 0.000349 0.000164 42 0.001807 0.001067 67 0.017028 0.010348 92 0.195447 0.165653 
18 0.000428 0.000176 43 0.001980 0.001175 68 0.018864 0.011459 93 0.210075 0.180840 
19 0.000503 0.000188 44 0.002171 0.001294 69 0.020919 0.012728 94 0.224973 0.196527 
20 0.000559 0.000201 45 0.002382 0.001428 70 0.023217 0.014177 95 0.240034 0.212543 
21 0.000585 0.000214 46 0.002613 0.001575 71 0.025785 0.015829 96 0.255289 0.228734 
22 0.000592 0.000228 47 0.002865 0.001739 72 0.028650 0.017712 97 0.270832 0.245153 
23 0.000598 0.000243 48 0.003138 0.001920 73 0.031843 0.019857 98 0.286793 0.261954 
24 0.000608 0.000259 49 0.003431 0.002119 74 0.035396 0.022295 99 0.303338 0.279351 
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Appendix A3 Incidence and 5-year Survival for Subtypes of Haematological Malignancies (details for Table 4-2) 
 Table A- 3 Incidence and 5-year survival for subtypes 
  Incidence (per 100,000) 5-year Survival 
   Chronic myelogenous leukaemia 1.0 78.4% 
   Chronic myelomonocytic leukaemia 0.7 19.9% 
   Acute myeloid leukaemia 4.2 19.7% 
   Acute lymphoblastic leukaemia 1.2 60.8% 
   Chronic lymphocytic leukaemia 6.9 65.3% 
   Hairy cell leukaemia 0.3 88.4% 
   T-cell leukaemia 0.4 62.7% 
   Marginal zone lymphoma 3.4 62.5% 
   Follicular lymphoma 3.2 75.9% 
   Mantle cell lymphoma 0.9 23.7% 
   Diffuse large B-cell lymphoma 8.3 48.2% 
   Burkitt lymphoma 0.3 54.1% 
   T-cell lymphoma 1.0 42.9% 
   Hodgkin Lymphoma 3.0 78.8% 
   Plasma cell myeloma 6.6 34.1% 
   Plasmacytoma 0.6 51.1% 
   Myelodysplastic syndromes 3.8 21.4% 
   Myeloproliferative neoplasms 6.2 74.6% 
   Monoclonal B-cell Lymphocytosis 2.8 82.3% 
   Monoclonal gammopathy of undetermined significance 6.6 69.4% 




Appendix A4 Observed and Total Prevalence in the UK 
Table A- 4 Observed and total prevalence cases in the UK on 31
st
, August 2011, ranked in order of descending total prevalence for both genders. 
  Male Female Total 
  Observed Total Observed Total Observed Total 
   Hodgkin Lymphoma 5,650 20,950 4,545 21,608 10,191 42,556 
   Monoclonal gammopathy of undetermined significance 10,772 18,274 9,878 24,020 20,645 42,310 
   Myeloproliferative neoplasms 9,268 18,007 11,536 21,515 20,810 39,530 
   Chronic lymphocytic leukaemia 13,300 23,222 7,827 13,316 21,106 36,500 
   Diffuse large B-cell lymphoma 9,847 17,483 8,664 14,924 18,505 32,396 
   Follicular lymphoma 5,022 9,549 5,825 13,082 10,849 22,641 
   Monoclonal B-cell Lymphocytosis 5,204 8,937 4,513 10,424 9,713 19,364 
   Plasma cell myeloma 7,352 10473 5,185 8066 12,528 18530 
   Marginal zone lymphoma 5,419 9,178 4,627 7,847 10,043 17,018 
   Lymphoproliferative disorder not otherwise specified 2,908 5,568 2,182 3,819 5,087 9,380 
   Chronic myelogenous leukaemia 2,049 4,887 1,346 3,775 3,391 8,657 
   Acute lymphoblastic leukaemia 1,933 4,711 1,346 3,794 3,276 8,501 
   Myelodysplastic syndromes 3,536 3,704 2,068 2,205 5,598 5,904 
   Acute myeloid leukaemia 2,561 2,901 2,084 2,716 4,643 5,617 
   T-cell lymphoma 1,223 2,303 870 2,106 2,091 4,407 
   T-cell leukaemia 496 1,277 640 2,014 1,136 3,294 
   Burkitt lymphoma 628 2,139 181 1,096 807 3,231 
   Hairy cell leukaemia 958 2,497 246 431 1,202 2,920 
   Plasmacytoma 1,052 1,376 427 635 1,476 2,008 
   Mantle cell lymphoma 1,107 1,408 492 517 1,597 1,922 
   Chronic myelomonocytic leukaemia 595 627 459 505 1,054 1,132 
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Appendix A5 Age- specific Incidence and Survival of Subtypes of 
Haematological Malignancy  
 
1 Chronic Myelogenous Leukaemia 
 
Table A- 5 Crude incidence of chronic myelogenous leukaemia by age and gender 
(per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 4 0.2 1 0.1 3 0.4 
20-24 8 0.5 5 0.7 3 0.4 
25-29 2 0.1 2 0.3 0 0.0 
30-34 6 0.3 5 0.6 1 0.1 
35-39 16 0.8 12 1.3 4 0.4 
40-44 16 0.9 8 0.9 8 0.9 
45-49 25 1.6 15 1.9 10 1.3 
50-54 29 1.7 20 2.3 9 1.0 
55-59 26 1.9 19 2.7 7 1.0 
60-64 30 2.4 16 2.6 14 2.2 
65-69 17 1.5 11 2.1 6 1.0 
70-74 19 1.9 8 1.8 11 2.0 
75-79 22 2.6 15 4.3 7 1.4 
Over 80 22 2.1 9 2.7 13 1.8 






Figure A- 2 Incidence of chronic myelogenous leukaemia per 100,000 for males 
females, and total 
 
 
Figure A- 3 Kaplan-Meier survival estimates for chronic myelogenous leukaemia 







































































































2 Chronic Myelomonocytic-Leukaemi 
 
Table A- 6 Crude incidence of chronic myelomonocytic leukaemia by age and 
gender (per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 3 0.2 1 0.1 2 0.3 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 0 0.0 0 0.0 0 0.0 
25-29 0 0.0 0 0.0 0 0.0 
30-34 0 0.0 0 0.0 0 0.0 
35-39 1 0.1 0 0.0 1 0.1 
40-44 1 0.1 1 0.1 0 0.0 
45-49 3 0.2 2 0.3 1 0.1 
50-54 4 0.2 3 0.3 1 0.1 
55-59 5 0.4 4 0.6 1 0.1 
60-64 5 0.4 5 0.8 0 0.0 
65-69 23 2.1 14 2.6 9 1.5 
70-74 25 2.5 15 3.4 10 1.8 
75-79 33 3.9 25 7.1 8 1.6 
Over 80 70 6.7 38 11.4 32 4.5 










Figure A- 4 Incidence of chronic myelomonocytic leukaemia per 100,000 for 
males, females, and total 
 
 
Figure A- 5 Kaplan-Meier survival estimates for chronic myelomonocytic 









































































































3 Acute Myeloid-Leukaemia  
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 18 1.2 10 1.3 8 1.1 
5-9 5 0.3 3 0.4 2 0.3 
10-14 9 0.5 5 0.6 4 0.5 
15-19 15 0.9 11 1.3 4 0.5 
20-24 21 1.4 9 1.2 12 1.5 
25-29 18 1.2 8 1.1 10 1.2 
30-34 24 1.3 13 1.4 11 1.2 
35-39 27 1.4 13 1.4 14 1.4 
40-44 33 1.9 22 2.5 11 1.3 
45-49 32 2.0 18 2.3 14 1.8 
50-54 48 2.7 25 2.9 23 2.6 
55-59 69 5.0 39 5.6 30 4.3 
60-64 96 7.8 59 9.8 37 5.9 
65-69 103 9.2 56 10.6 47 8.0 
70-74 151 15.1 86 19.3 65 11.7 
75-79 163 19.3 89 25.3 74 15.0 
Over 80 229 21.9 110 33.0 119 16.8 










Figure A- 6 Incidence of acute myeloid leukaemia per 100,000 for males, females, 
and total 
 
Figure A- 7 Kaplan-Meier survival estimates for acute myeloid leukaemia 












































































































4   Acute Lymphoblastic Leukaemia 
 
Table A- 8 Crude incidence of acute lymphoblastic leukaemia by age and gender 
(per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 72 4.9 40 5.3 32 4.4 
5-9 47 2.9 24 2.9 23 2.9 
10-14 29 1.7 16 1.8 13 1.5 
15-19 31 1.9 22 2.7 9 1.1 
20-24 12 0.8 9 1.2 3 0.4 
25-29 7 0.4 1 0.1 6 0.7 
30-34 11 0.6 9 1.0 2 0.2 
35-39 11 0.6 5 0.5 6 0.6 
40-44 7 0.4 3 0.3 4 0.5 
45-49 12 0.8 7 0.9 5 0.6 
50-54 7 0.4 5 0.6 2 0.2 
55-59 13 0.9 7 1.0 6 0.9 
60-64 11 0.9 5 0.8 6 1.0 
65-69 16 1.4 13 2.5 3 0.5 
70-74 5 0.5 3 0.7 2 0.4 
75-79 6 0.7 4 1.1 2 0.4 
Over 80 8 0.8 2 0.6 6 0.8 











Figure A- 8 Incidence of acute lymphoblastic leukaemia per 100,000 for males 
females, and total 
 
 
Figure A- 9 Kaplan-Meier survival estimates for acute lymphoblastic leukaemia 









































































































5 Chronic Lymphocytic Leukaemia 
 
Table A- 9 Crude incidence of chronic lymphocytic leukaemia by age and gender 
(per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 0 0.0 0 0.0 0 0.0 
25-29 2 0.1 1 0.1 1 0.1 
30-34 1 0.1 0 0.0 1 0.1 
35-39 13 0.7 10 1.1 3 0.3 
40-44 22 1.3 15 1.7 7 0.8 
45-49 32 2.0 23 2.9 9 1.1 
50-54 84 4.8 58 6.6 26 3.0 
55-59 160 11.5 108 15.5 52 7.5 
60-64 237 19.2 169 27.9 68 10.8 
65-69 225 20.1 161 30.4 64 10.9 
70-74 273 27.2 174 39.0 99 17.8 
75-79 305 36.1 177 50.4 128 25.9 
Over 80 367 35.2 181 54.3 186 26.2 










Figure A- 10 Incidence of chronic lymphocytic leukaemia per 100,000 for males 
females, and total 
 
 
Figure A- 11 Kaplan-Meier survival estimates for chronic lymphocytic leukaemia 










































































































6 Hairy Cell Leukaemia 
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 0 0.0 0 0.0 0 0.0 
25-29 2 0.1 2 0.3 0 0.0 
30-34 0 0.0 0 0.0 0 0.0 
35-39 1 0.1 1 0.1 0 0.0 
40-44 3 0.2 3 0.3 0 0.0 
45-49 6 0.4 4 0.5 2 0.3 
50-54 3 0.2 3 0.3 0 0.0 
55-59 11 0.8 11 1.6 0 0.0 
60-64 11 0.9 10 1.7 1 0.2 
65-69 10 0.9 8 1.5 2 0.3 
70-74 16 1.6 12 2.7 4 0.7 
75-79 10 1.2 6 1.7 4 0.8 
Over 80 8 0.8 5 1.5 3 0.4 












Figure A- 12 Incidence of hairy cell leukaemia per 100,000 for males, females, 
and total 
 








































































































7 T-cell Leukaemia 
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 1 0.1 1 0.1 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 1 0.1 1 0.1 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 0 0.0 0 0.0 0 0.0 
25-29 0 0.0 0 0.0 0 0.0 
30-34 1 0.1 0 0.0 1 0.1 
35-39 2 0.1 1 0.1 1 0.1 
40-44 1 0.1 1 0.1 0 0.0 
45-49 2 0.1 1 0.1 1 0.1 
50-54 8 0.5 5 0.6 3 0.3 
55-59 4 0.3 0 0.0 4 0.6 
60-64 12 1.0 4 0.7 8 1.3 
65-69 6 0.5 2 0.4 4 0.7 
70-74 16 1.6 7 1.6 9 1.6 
75-79 20 2.4 12 3.4 8 1.6 
Over 80 26 2.5 11 3.3 15 2.1 












Figure A- 14 Incidence of T-cell leukaemia per 100,000 for males, females, and 
total 
 









































































































8 Marginal Zone Lymphoma 
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 4 0.3 2 0.3 2 0.3 
25-29 2 0.1 1 0.1 1 0.1 
30-34 2 0.1 2 0.2 0 0.0 
35-39 6 0.3 4 0.4 2 0.2 
40-44 10 0.6 3 0.3 7 0.8 
45-49 25 1.6 13 1.6 12 1.5 
50-54 40 2.3 20 2.3 20 2.3 
55-59 63 4.5 36 5.2 27 3.9 
60-64 89 7.2 56 9.3 33 5.2 
65-69 115 10.3 69 13.0 46 7.8 
70-74 139 13.9 81 18.2 58 10.4 
75-79 161 19.1 79 22.5 82 16.6 
Over 80 183 17.5 90 27.0 93 13.1 











Figure A- 16 Incidence of marginal zone lymphoma per 100,000 for males, 
females, and total 
 
Figure A- 17 Kaplan-Meier survival estimates for marginal zone lymphoma 










































































































 9 Follicular Lymphoma 
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 1 0.1 1 0.1 0 0.0 
20-24 1 0.1 1 0.1 0 0.0 
25-29 3 0.2 2 0.3 1 0.1 
30-34 7 0.4 5 0.6 2 0.2 
35-39 19 1.0 11 1.2 8 0.8 
40-44 36 2.1 21 2.4 15 1.7 
45-49 50 3.1 25 3.2 26 3.3 
50-54 74 4.2 30 3.4 45 5.1 
55-59 87 6.2 46 6.6 46 6.6 
60-64 121 9.8 63 10.4 64 10.1 
65-69 104 9.3 42 7.9 67 11.4 
70-74 108 10.8 53 11.9 60 10.8 
75-79 74 8.8 37 10.5 46 9.3 
Over 80 87 8.3 27 8.1 60 8.4 











Figure A- 18 Incidence of follicular lymphoma per 100,000 for males, females, 
and total 
 










































































































10 Mantle Cell Lymphoma 
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 0 0.0 0 0.0 0 0.0 
25-29 0 0.0 0 0.0 0 0.0 
30-34 0 0.0 0 0.0 0 0.0 
35-39 2 0.1 2 0.2 0 0.0 
40-44 1 0.1 1 0.1 0 0.0 
45-49 4 0.3 4 0.5 0 0.0 
50-54 9 0.5 6 0.7 3 0.3 
55-59 19 1.4 17 2.4 2 0.3 
60-64 21 1.7 12 2.0 9 1.4 
65-69 33 3.0 23 4.3 10 1.7 
70-74 33 3.3 19 4.3 14 2.5 
75-79 40 4.7 25 7.1 15 3.0 
Over 80 57 5.5 32 9.6 25 3.5 












Figure A- 20 Incidence of mantle cell lymphoma per 100,000 for males, females, 
and total 
 











































































































11 Diffuse Large B-cell Lymphoma 
 
Table A- 15 Crude incidence of diffuse large B-cell lymphoma by age and gender 
(per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 3 0.2 3 0.4 0 0.0 
5-9 2 0.1 2 0.2 0 0.0 
10-14 8 0.5 4 0.5 4 0.5 
15-19 8 0.5 5 0.6 3 0.4 
20-24 13 0.9 8 1.1 5 0.6 
25-29 20 1.3 13 1.7 7 0.9 
30-34 26 1.4 16 1.8 10 1.1 
35-39 40 2.1 20 2.1 20 2.1 
40-44 70 4.0 43 5.0 27 3.1 
45-49 78 4.9 47 5.9 31 3.9 
50-54 116 6.6 66 7.6 50 5.7 
55-59 168 12.1 103 14.8 65 9.3 
60-64 210 17.0 99 16.4 111 17.6 
65-69 280 25.1 156 29.4 124 21.1 
70-74 312 31.1 165 37.0 147 26.4 
75-79 313 37.1 164 46.7 149 30.2 
Over 80 399 38.2 166 49.8 233 32.8 









Figure A- 22 Incidence of diffuse large B-cell lymphoma per 100,000 for males, 
females, and total 
 
Figure A- 23 Kaplan-Meier survival estimates for diffuse large B-cell lymphoma 














































































































12 Burkitt Lymphoma 
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 8 0.5 5 0.7 3 0.4 
5-9 6 0.4 6 0.7 0 0.0 
10-14 8 0.5 8 0.9 0 0.0 
15-19 2 0.1 2 0.2 0 0.0 
20-24 6 0.4 5 0.7 1 0.1 
25-29 3 0.2 3 0.4 0 0.0 
30-34 3 0.2 3 0.3 0 0.0 
35-39 3 0.2 1 0.1 2 0.2 
40-44 1 0.1 1 0.1 0 0.0 
45-49 2 0.1 1 0.1 1 0.1 
50-54 5 0.3 3 0.3 2 0.2 
55-59 8 0.6 5 0.7 3 0.4 
60-64 11 0.9 7 1.2 4 0.6 
65-69 4 0.4 3 0.6 1 0.2 
70-74 6 0.6 3 0.7 3 0.5 
75-79 8 0.9 7 2.0 1 0.2 
Over 80 3 0.3 2 0.6 1 0.1 












Figure A- 24 Incidence of Burkitt lymphoma per 100,000 for males, females, and 
total 
 










































































































13 T-cell Lymphoma 
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 2 0.1 1 0.1 1 0.1 
5-9 0 0.0 0 0.0 0 0.0 
10-14 2 0.1 1 0.1 1 0.1 
15-19 3 0.2 1 0.1 2 0.2 
20-24 1 0.1 0 0.0 1 0.1 
25-29 8 0.5 6 0.8 2 0.2 
30-34 3 0.2 3 0.3 0 0.0 
35-39 10 0.5 6 0.6 4 0.4 
40-44 20 1.1 14 1.6 6 0.7 
45-49 13 0.8 8 1.0 5 0.6 
50-54 18 1.0 9 1.0 9 1.0 
55-59 21 1.5 14 2.0 7 1.0 
60-64 28 2.3 16 2.6 12 1.9 
65-69 27 2.4 18 3.4 9 1.5 
70-74 37 3.7 22 4.9 15 2.7 
75-79 27 3.2 14 4.0 13 2.6 
Over 80 36 3.5 15 4.5 21 3.0 











Figure A- 26 Incidence of T-cell lymphoma per 100,000 for males, females, and 
total 
 










































































































14 Hodgkin Lymphoma 
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 2 0.1 2 0.3 0 0.0 
5-9 4 0.2 3 0.4 1 0.1 
10-14 23 1.3 11 1.3 12 1.4 
15-19 59 3.6 32 3.9 27 3.4 
20-24 71 4.7 42 5.6 29 3.7 
25-29 76 4.9 35 4.6 41 5.1 
30-34 68 3.7 37 4.1 31 3.3 
35-39 64 3.4 38 4.1 26 2.7 
40-44 45 2.6 32 3.7 13 1.5 
45-49 40 2.5 29 3.7 11 1.4 
50-54 42 2.4 30 3.4 12 1.4 
55-59 43 3.1 23 3.3 20 2.9 
60-64 42 3.4 27 4.5 15 2.4 
65-69 51 4.6 22 4.2 29 4.9 
70-74 53 5.3 27 6.1 26 4.7 
75-79 39 4.6 22 6.3 17 3.4 
Over 80 32 3.1 13 3.9 19 2.7 










Figure A- 28 Incidence of Hodgkin lymphoma per 100,000 for males, females, 
and total 
 








































































































15 Plasma Cell Myeloma 
 




Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 0 0.0 0 0.0 0 0.0 
25-29 0 0.0 0 0.0 0 0.0 
30-34 3 0.2 3 0.3 0 0.0 
35-39 10 0.5 6 0.6 4 0.4 
40-44 12 0.7 6 0.7 6 0.7 
45-49 50 3.1 36 4.5 14 1.8 
50-54 85 4.8 54 6.2 31 3.5 
55-59 117 8.4 68 9.8 49 7.0 
60-64 183 14.8 126 20.8 57 9.0 
65-69 204 18.3 115 21.7 89 15.1 
70-74 284 28.3 152 34.1 132 23.7 
75-79 277 32.8 164 46.7 113 22.9 
Over 80 421 40.3 219 65.7 202 28.4 










Figure A- 30 Incidence of plasma cell myeloma per 100,000 for males, females, 
and total 
 



















































































































Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 0 0.0 0 0.0 0 0.0 
25-29 0 0.0 0 0.0 0 0.0 
30-34 0 0.0 0 0.0 0 0.0 
35-39 2 0.1 1 0.1 1 0.1 
40-44 4 0.2 2 0.2 2 0.2 
45-49 11 0.7 7 0.9 4 0.5 
50-54 4 0.2 2 0.2 2 0.2 
55-59 16 1.1 13 1.9 3 0.4 
60-64 23 1.9 18 3.0 5 0.8 
65-69 22 2.0 17 3.2 5 0.9 
70-74 26 2.6 17 3.8 9 1.6 
75-79 24 2.8 18 5.1 6 1.2 
Over 80 16 1.5 7 2.1 9 1.3 











Figure A- 32 Incidence of plasmacytoma per 100,000 for males, females, and 
total 
 









































































































17 Myelodysplastic Syndromes 
 
Table A- 21 Crude incidence of myelodysplastic syndromes by age and gender 
(per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 1 0.1 0 0.0 1 0.1 
5-9 1 0.1 0 0.0 1 0.1 
10-14 2 0.1 1 0.1 1 0.1 
15-19 1 0.1 0 0.0 1 0.1 
20-24 0 0.0 0 0.0 0 0.0 
25-29 3 0.2 0 0.0 3 0.4 
30-34 7 0.4 5 0.6 2 0.2 
35-39 3 0.2 2 0.2 1 0.1 
40-44 10 0.6 3 0.3 7 0.8 
45-49 9 0.6 6 0.8 3 0.4 
50-54 24 1.4 15 1.7 9 1.0 
55-59 37 2.7 26 3.7 11 1.6 
60-64 72 5.8 50 8.3 22 3.5 
65-69 106 9.5 73 13.8 33 5.6 
70-74 172 17.2 117 26.2 55 9.9 
75-79 185 21.9 137 39.0 48 9.7 
Over 80 311 29.8 192 57.6 119 16.8 











Figure A- 34 Incidence of myelodysplastic syndromes per 100,000 for males, 
females, and total 
 
Figure A- 35 Kaplan-Meier survival estimates for myelodysplastic syndromes 










































































































18 Myeloproliferative Neoplasms 
 
Table A- 22 Crude incidence of myeloproliferative neoplasms by age and gender 
(per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 1 0.1 1 0.1 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 5 0.3 3 0.4 2 0.2 
20-24 7 0.5 4 0.5 3 0.4 
25-29 19 1.2 5 0.7 14 1.7 
30-34 19 1.0 7 0.8 12 1.3 
35-39 34 1.8 16 1.7 18 1.9 
40-44 36 2.1 16 1.8 20 2.3 
45-49 71 4.5 33 4.2 38 4.8 
50-54 65 3.7 31 3.6 34 3.9 
55-59 122 8.8 66 9.5 56 8.0 
60-64 155 12.5 90 14.9 65 10.3 
65-69 182 16.3 97 18.3 85 14.5 
70-74 231 23.1 102 22.9 129 23.2 
75-79 238 28.2 98 27.9 140 28.4 
Over 80 368 35.3 143 42.9 225 31.7 











Figure A- 36 Incidence of myeloproliferative neoplasms per 100,000 for males 
females, and total 
 
Figure A- 37 Kaplan-Meier survival estimates for myeloproliferative neoplasms 












































































































19 Monoclonal B-cell Lymphocytosis 
 
Table A- 23 Crude incidence of monoclonal B-cell Lymphocytosis by age and 
gender (per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 0 0.0 0 0.0 0 0.0 
25-29 0 0.0 0 0.0 0 0.0 
30-34 0 0.0 0 0.0 0 0.0 
35-39 1 0.1 0 0.0 1 0.1 
40-44 3 0.2 3 0.3 0 0.0 
45-49 15 0.9 11 1.4 4 0.5 
50-54 32 1.8 16 1.8 16 1.8 
55-59 53 3.8 32 4.6 21 3.0 
60-64 99 8.0 57 9.4 42 6.7 
65-69 95 8.5 55 10.4 40 6.8 
70-74 118 11.8 61 13.7 57 10.3 
75-79 114 13.5 55 15.6 59 12.0 
Over 80 160 15.3 86 25.8 74 10.4 












Figure A- 38 Incidence of monoclonal B-cell Lymphocytosis per 100,000 for 
males, females, and total 
 
Figure A- 39 Kaplan-Meier survival estimates for monoclonal B-cell 













































































































20 Monoclonal Gammopathy of Undetermined Significance 
 
Table A- 24 Crude incidence of monoclonal gammopathy of undetermined 
significance by age and gender (per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 0 0.0 0 0.0 0 0.0 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 0 0.0 0 0.0 0 0.0 
25-29 2 0.1 1 0.1 1 0.1 
30-34 5 0.3 2 0.2 3 0.3 
35-39 11 0.6 3 0.3 8 0.8 
40-44 36 2.1 17 2.0 19 2.2 
45-49 52 3.3 30 3.8 22 2.8 
50-54 75 4.3 35 4.0 40 4.5 
55-59 132 9.5 62 8.9 70 10.0 
60-64 181 14.6 108 17.8 73 11.6 
65-69 198 17.7 124 23.4 74 12.6 
70-74 279 27.8 161 36.1 118 21.2 
75-79 307 36.3 169 48.1 138 28.0 
Over 80 366 35.1 191 57.3 175 24.6 











Figure A- 40 Incidence of monoclonal gammopathy of undetermined significance 
per 100,000 for males, females, and total 
 
Figure A- 41 Kaplan-Meier survival estimates for monoclonal gammopathy of 










































































































21 Lymphoproliferative Disorder Not Otherwise Specified 
 
Table A- 25 Crude incidence of lymphoproliferative disorder not otherwise 
specified by age and gender (per 100,000 population) 
Age group 
(Years) 
Total Male Female 
N Incidence N Incidence N Incidence 
0-4 1 0.1 0 0.0 1 0.1 
5-9 0 0.0 0 0.0 0 0.0 
10-14 0 0.0 0 0.0 0 0.0 
15-19 0 0.0 0 0.0 0 0.0 
20-24 1 0.1 1 0.1 0 0.0 
25-29 0 0.0 0 0.0 0 0.0 
30-34 1 0.1 1 0.1 0 0.0 
35-39 1 0.1 1 0.1 0 0.0 
40-44 1 0.1 1 0.1 0 0.0 
45-49 6 0.4 6 0.8 0 0.0 
50-54 7 0.4 4 0.5 3 0.3 
55-59 28 2.0 16 2.3 12 1.7 
60-64 52 4.2 35 5.8 17 2.7 
65-69 60 5.4 39 7.4 21 3.6 
70-74 60 6.0 34 7.6 26 4.7 
75-79 86 10.2 41 11.7 45 9.1 
Over 80 173 16.6 79 23.7 94 13.2 











Figure A- 42 Incidence of lymphoproliferative disorder not otherwise specified 
per 100,000 for males, females, and total 
 
Figure A- 43 Kaplan-Meier survival estimates for lymphoproliferative disorder 













































































































Appendix A6 The Notion of ―Cure‖ 
 
If five years is considered as the ―period of maximum consumption of health 
resources‖ (Colonna, et al., 2000), and if the patients that survive with cancer 
longer than five years are considered to be ―cured‖ patients, the proportion of 
prevalent subjects who are considered to be cured can be computed as the 
difference between total prevalence (estimated in Chapter Six) and observed 5-
year prevalence on the index date (calculated in Chapter Four): 
 
    𝑃𝑐𝑢𝑟𝑒𝑑 = 𝑃𝑡𝑜𝑡𝑎𝑙 − 𝑃5− 𝑒𝑎𝑟         (A. 1) 
 
The results are shown in Table A-26. These cured prevalent patients may require 
fewer health resources compared to patients who have been diagnosed recently. 
More than half of the patients diagnosed with haematological malignancies have 
survived for over five years on the index date. However, for different subtypes, 
these percentages vary due to the varying prognoses of these diseases. For 
example, 81.7% of Hodgkin lymphoma patients live for longer than five years, 




Table A- 26 5-year, total, ―cured‖ prevalence (per 100,000) for males and females in HMRN on the index date 31st, August 2011 








  Prevalence % Prevalence % Prevalence % 
Total 227.1 550.9 323.8 58.8 259.1 591.9 332.8 56.2 196.9 512.3 315.4 61.6 
Leukaemia 48.9 111.3 62.3 56 61.4 138.8 77.3 55.7 37.2 85.5 48.3 56.5 
   Chronic myelogenous leukaemia 4.7 14.7 10 67.9 5.9 17.1 11.2 65.5 3.6 12.5 8.9 70.9 
   Chronic myelomonocytic leukaemia 1.7 1.9 0.3 14.2 2 2.2 0.2 10.5 1.4 1.7 0.3 18.8 
   Acute myeloid leukaemia 6.4 9.6 3.1 32.9 7.5 10.2 2.7 26.5 5.4 9 3.6 39.6 
   Acute lymphoblastic leukaemia 4.1 14.5 10.3 71.5 5 16.5 11.5 69.8 3.3 12.6 9.2 73.6 
   Chronic lymphocytic leukaemia 29 62.1 33.1 53.3 37.2 81.3 44 54.2 21.2 44.1 22.8 51.8 
   Hairy cell leukaemia 1.6 4.9 3.4 68.2 2.5 8.6 6.1 70.5 0.7 1.5 0.8 56 
   T-cell leukaemia 1.5 3.6 2.1 58.9 1.4 3 1.6 53.8 1.6 4.2 2.6 62.4 
Non-Hodgkin Lymphoma 60.2 136.9 76.7 56.1 66.2 147.4 81.2 55.1 54.5 127.1 72.5 57.1 
   Marginal zone lymphoma 14.4 28.9 14.6 50.4 15.9 32.1 16.2 50.5 12.9 26 13 50.2 
   Follicular lymphoma 14.2 38.5 24.3 63.1 14.1 33.4 19.3 57.8 14.3 43.3 29 66.9 
   Mantle cell lymphoma 2.6 3 0.4 14.3 3.6 4.3 0.7 16 1.6 1.8 0.2 10.3 
   Diffuse large B-cell lymphoma 25.4 55.1 29.7 54 27.8 61.2 33.4 54.5 23.1 49.4 26.3 53.3 
   Burkitt lymphoma 1 4.8 3.7 78.3 1.6 8.3 6.7 80.5 0.5 1.5 1 66.6 
   T-cell lymphoma 2.6 6.6 4 60.4 3.1 8.1 4.9 61.3 2.1 5.2 3.1 59 
Hodgkin Lymphoma 13.2 72.4 59.2 81.7 16 73.3 57.3 78.2 10.6 71.5 60.9 85.1 
Myeloma 20.6 32.1 11.5 35.8 25.3 41.7 16.4 39.3 16.2 23.1 6.9 29.9 
   Plasma cell myeloma 18.5 28.6 10.1 35.4 22.1 36.6 14.6 39.7 15.1 21 5.9 28.2 
   Plasmacytoma 2.1 3.5 1.4 39.6 3.2 5.1 1.9 36.4 1.1 2.1 1 47.1 
Myelodysplastic syndromes 8.6 10 1.4 14.1 11.1 13 1.9 14.4 6.3 7.3 1 13.7 
Other Neoplasms of Uncertain or Unknown Behaviour 75.5 188.1 112.6 59.9 79.1 177.7 98.6 55.5 72.1 197.9 125.8 63.6 
   Myeloproliferative neoplasms 29.4 67.2 37.9 56.3 27.9 63 35.1 55.8 30.8 71.2 40.4 56.8 
   Monoclonal B-cell Lymphocytosis 12.6 32.9 20.3 61.7 14 31.3 17.2 55.1 11.2 34.5 23.3 67.4 
   Monoclonal gammopathy of undetermined significance 27 72 45 62.5 29.3 63.9 34.6 54.2 24.8 79.5 54.7 68.8 




Appendix A7 R Code for Calculating Total Prevalence 
 
The data is available in STATA format. Calculations are performed in R version 
3.0.1. The ―foreign‖ R library is used to read STATA format data. Calculations of 
observed prevalence and estimates of total prevalence for all subtypes in this 
study are then calculated in R.  
N.B. the words after ―#‖ are comments on the code: 
 
library(foreign) 
d <- read.dta("hmrn.dta")   
#We use the example of AML 
 
 
##1 Prediction of incidences by spline regression 











# population of females in five years age group 
 
################################################### 
# Population comes from census in the UK  












# number of cases in every age group 
i <- ((e/7)/M)*100000  












# 1.2 regression spline 
 
library(splines) 
es.sm <- lm(i ~ bs(age1, df=6)) 
summary(es.sm <- lm(i ~ bs(age1, df=6))) 
 
Inc<-function(c,modsp=es.sm){ 
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 predict(modsp, newdata=data.frame(age1=c)) 
 } 
 
plot(Inc(2:82),type='l', ylab='Incidence (per 
100,000)',xlab="Age", col=4, lwd=2) 
points(age1, i,type="p", lwd=1, col=3, pch=19) 
 
################################################## 
#incidence cannot be below 0 





           (Inc(t)>0)*Inc(t) 
}                      
# avoid the incidence under 0 after estimation 
 
 







#Kaplan Meier by age groups  






    legend=c("0-10", "10-20", "20-30","30-40","40-
50","50-60","60-70","70-80","over 80"), 
    col=c(1:9)) 
s <- survreg(Surv(d$time, d$status) ~ 




# Function to return the scale parameter of the Weibull distribution from a fitted 
model 
scale <- function(t){ 
       return(exp(predict(s, 
newdata=data.frame(AgeDiagnosis=t),type="lp"))) 
       } 
# Shape parameter from a fitted Weibull regression 
p <- 1/s$scale 
 
# Survival function from a fitted Weibull regression 
  
S<- function(duration,t) 
  (exp(-(duration)/scale(t))^p)  
 
 
## 3 Calculate N and R 
 
# 3.1 read data from *.txt file: general mortality; 
Mort<-read.table('PE.txt', header=T) 
# (1-mortality) data is saved in advance 
 
 
# 3.2 calculate completeness index 
288 
 
N <- function(x, upper) { 
    tmp=c() 
   for (t in 0:upper) { 
  tmp[t]=I(t)* survival(x+1-t, t) / 
prod(mort$M[t:x]) } 
sum(tmp) 
 }               
 #change as ―prod(mort$F[t:x])‖ for females 
 
 

















# show the number of observed prevalent cases 
 
Nt<-No/r  
Nt   
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# show the number of total prevalent cases 
preobs<-sum(No)/sum(M)*100000  
# calculate for observed prevalence for males 
pretot<-sum(Nt)/sum(M)*100000  
# calculate for total prevalence for males 
# change as ―sum(F)‖for females  
ratio<-preobs/pretot 
preobs  
# show observed prevalence (per 100,000) 
pretot   
# show total prevalence (per 100,1000) 
ratio  
# show the ratio of observed prevalence over total prevalence
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Appendix A8 Abbreviations used in this thesis 
 
Table A- 27 Abbreviations in this study 





Australasian Association of Cancer Registries 
Australian Institute of Health and Welfare 
The Italian Association of Cancer Registries 
Acute leukaemia 




Acute myeloid leukaemia  
The Association of the Nordic Cancer Registries 
Acute promyelocytic myeloid leukaemia 
ASP 
CCR 
Age standardized proportion 
Canadian Cancer Registry 
CHILDPREV Childhood Prevalence 
CLL Chronic lymphocytic leukaemia  
CML Chronic myelogenous leukaemia  
CMML Chronic myelomonocytic leukaemia  
CTR The Connecticut Tumour Registry 
DCO Death certificate only  
DisMod Disease model 
DLBCL Diffuse large B-cell lymphoma  
ECSG Epidemiology & Cancer Statistics Group 




French, American, and British Cooperative Group 
IACR International Association of Cancer Registries 
IARC International Agency for Research on Cancer  
ICD The International Classification of Diseases  
ICD-O-3 
ILSG 
International Classification of Disease for Oncology, 3rd Edition 
International Lymphoma Study Group 
IPM Incidence, prevalence, and mortality 
HILIS HMDS Integrated Laboratory Information System 
HIV Human immunodeficiency virus 
HL Hodgkin lymphoma 
HM Haematological malignancy 
HMDS Haematological Malignancy Diagnostic Service 
HMRN Haematological Malignancy Research Network  
LPDs NOS Lymphoproliferative disorder not otherwise specified  
MBL Monoclonal B-cell Lymphocytosis  
MCL Mantle cell lymphoma  
MENA Middle East and Northern Africa 




Table A- 27 continued 








Monoclonal gammopathy of undetermined significance 
Mortality Incidence Analysis Model 
Multiple myeloma 
Myeloproliferative neoplasms 
Marginal zone lymphoma  
NA Not Available 
NCCCR North Carolina Central Cancer Registry 
NCIN National Cancer Intelligence Network 




National Health Service 
PIAMOD 
REAL 
Prevalence Incidence Analysis Model 
Revised European- American Lymphoma 






Transition rate method 
United Kingdom 
United States of America 







Adami, H.O. et al., (1989). The prevalence of cancer in Sweden 1984. Acta 
Oncologica (Stockholm, Sweden), 28(4), 463–470. 
AIHW, (2012). Cancer survival and prevalence in Australia: period estimates 
from 1982 to 2010. [pdf]. Available at: 
http://www.aihw.gov.au/publication-detail/?id=10737422720  [Accessed 
July 29, 2013]. 
Alexanian, R., et al., (1968). Melphalan therapy for plasma cell myeloma. Blood, 
31(1), 1-10. 
Armitage, J.O., (2010). Early-stage Hodgkin‘s lymphoma. The New England 
Journal of Medicine, 363(7), 653–662. 
Attal, M. et al., (2006). Maintenance therapy with thalidomide improves survival 
in patients with multiple myeloma. Blood, 108(10), 3289–3294. 
Auvinen, A. et al., (2002). Lead-time in prostate cancer screening (Finland). 
Cancer Causes & Control: CCC, 13(3), 279–285. 
Bagguley T. et al., (2012). Hematological malignancies & cancer registration in 
England (2004-2008). [pdf] NCIN. Available at: 
www.ncin.org.uk/view rid 1725  [Accessed May 18, 2013]. 
Barlogie, B. et al., (2004). Treatment of multiple myeloma. Blood, 103(1), 20–32. 
Becher, H., et al., (2009). Using Penalized Splines to Model Age‐and Season‐of‐
Birth‐Dependent Effects of Childhood Mortality Risk Factors in Rural 
Burkina Faso. Biometrical Journal, 51(1), 110-122. 
Bennett, J. M., et al., (1976). Proposals for the Classification of the Acute 
Leukaemias French‐American‐British (FAB) Co‐operative Group. British 
Journal of Haematology, 33(4), 451-458. 
293 
 
Brameld, K.J. et al., (2002). Increasing ‗active prevalence‘ of cancer in Western 
Australia and its implications for health services. Australian and New 
Zealand Journal of Public Health, 26(2), 164–169. 
Bray, F., et al., (2013). Global estimates of cancer prevalence for 27 sites in the 
adult population in 2008. International Journal of Cancer, 132(5), 1133-
1145. 
Byrne, J., Kessler, L.G. and Devesa, S.S., (1992). The prevalence of cancer 
among adults in the United States: 1987. Cancer, 69(8), 2154–2159. 
Cancer Research UK, (2011). Cancer incidence for all cancers combined. 
[Online]. Available at: 
http://info.cancerresearchuk.org/cancerstats/incidence/all-cancers-
combined/ [Accessed November 12, 2011]. 
Cancer Research UK, (2013). Different types of non-Hodgkin lymphoma. 
[Online]. Available at: http://www.cancerresearchuk.org/cancer-
help/type/non-hodgkins-lymphoma/about/types/the-most-common-types-
of-non-hodgkins-lymphoma/ [Accessed April 12, 2013]. 
Capocaccia, R. and De Angelis, R., (1997). Estimating the completeness of 
prevalence based on cancer registry data. Statistics in Medicine, 16(4), 
425–440. 
Capocaccia, R. et al., (2002). Measuring cancer prevalence in Europe: the 
EUROPREVAL project. Annals of Oncology: Official Journal of the 
European Society for Medical Oncology / ESMO, 13(6), 831–839. 
Carpenter, W.R. et al., (2011). Getting cancer prevalence right: using state cancer 
registry data to estimate cancer survivors. Cancer Causes & Control : 
CCC, 22(5), 765–773. 
CCR, (2012). Canadian Cancer Registry. [Online]. Available at 
http://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3
207&Item_Id=1633&lang=en[Accessed July 29, 2013] 
294 
 
Census Dissemination Unit, (2001). Census Dissemination Unit. [Online].  
Available at http://cdu.mimas.ac.uk/[Accessed October 13, 2011]  
Cleves, M. et al., (2010). An Introduction to Survival Analysis Using Stata, Third 
Edition 3rd ed., Stata Press. 
Colonna, M. et al., (2000). National cancer prevalence estimation in France. 
International Journal of Cancer. Journal International du Cancer, 87(2), 
301–304. 
Crocetti, E., et al. (2013). Cancer prevalence in United States, Nordic Countries, 
Italy, Australia, and France: an analysis of geographic variability. British 
Journal of Cancer. (109), 219-228 
Cronin, K.A. et al., (2006). Additional common inputs for analyzing impact of 
adjuvant therapy and mammography on U.S. mortality. Journal of the 
National Cancer Institute. Monographs, (36), 26–29. 
Curado,M.P. et al, (2007). Cancer Incidence in Five Continents Vol. IX. Lyon: 
IARC Scientific Publication No. 160. 
Cutler, J. and Ederer, F. (1958). Maximum utilization of the life table in analyzing 
survival. Journal of Chronic Diseases 8, 699-712. 
Davies, A. J., et al., (2007). Transformation of follicular lymphoma to diffuse 
large B‐cell lymphoma proceeds by distinct oncogenic mechanisms. 
British journal of haematology, 136(2), 286-293. 
De Angelis, G. et al., (1994). MIAMOD: a computer package to estimate chronic 
disease morbidity using mortality and survival data. Computer Methods 
and Programs in Biomedicine, 44(2), 99–107. 
De Angelis, R. et al., (2007). Cancer prevalence estimates in Italy from 1970 to 
2010. Tumori, 93(4), 392–397. 
DeVita, V. T., Serpick, A. A., & Carbone, P. P. (1970). Combination 
chemotherapy in the treatment of advanced Hodgkin's disease. Annals of 
Internal Medicine, 73(6), 881-895. 
295 
 
Ederer, F., Axtell, L.M. and Cuter, S.J., (1961). The relative survival rate: a 
statistical methodology. National Cancer Institute Monograph, 6, 101–
121. 
Ellison, L. F., and Wilkins, K. (2009). Cancer prevalence in the Canadian 
population. Health Rep, 20(1), 7-14. 
Engholm G., et al., (2013). NORDCAN: Cancer Incidence, Mortality, Prevalence 
and Survival in the Nordic Countries, Version 5.3. Association of the 
Nordic Cancer Registries. Danish Cancer Society. [Online] Available 
from http://www.ancr.nu, [Accessed July 15, 2013] 
Esna-Ashari, F., et al., (2012). Colorectal Cancer Prevalence According to 
Survival Data in Iran-2007. Iranian Journal of Cancer Prevention, 2(1), 
15–18. 
Estève, J., Benhamou, E. and Raymond, L., (1994). Statistical Methods in Cancer 
Research. Volume IV. Descriptive Epidemiology. IARC Scientific 
Publications, (128), 1–302. 
Eurocare, (2011). MIAMOD and PIAMOD Software. [Online]. Available at: 
http://www.eurocare.it/MiamodPiamod/tabid/60/Default.aspx [Accessed 
August 3, 2012]. 
Feldman, A.R. et al., (1986). The prevalence of cancer. Estimates based on the 
Connecticut Tumor Registry. The New England Journal of Medicine, 
315(22), 1394–1397. 
Ferlay, J et al., (2010). Estimates of worldwide burden of cancer in 2008: 
GLOBOCAN 2008. International Journal of Cancer, 127(12), 2893–2917. 
Fermé, C., et al., (2007). Chemotherapy plus involved-field radiation in early-
stage Hodgkin's disease. New England Journal of Medicine, 357(19), 
1916-1927. 
Fiorentino, F., et al. (2011). Modelling to estimate future trends in cancer 
prevalence. Health Care Management Science, 14(3), 262-266. 
296 
 
Forman, D. et al., (2003). Cancer prevalence in the UK: results from the 
EUROPREVAL study. Annals of Oncology: Official Journal of the 
European Society for Medical Oncology / ESMO, 14(4), 648–654. 
Fritz, A., (2000). International Classification of Diseases for Oncology: ICD-O, 
3rd edn 3rd ed., Geneva: World Health Organization. 
Gail, M.H. et al., (1999). Two approaches for estimating disease prevalence from 
population-based registries of incidence and total mortality. Biometrics, 
55(4), 1137–1144. 
Gambacorti-Passerini, C. et al., (2011). Multicenter independent assessment of 
outcomes in chronic myeloid leukemia patients treated with imatinib. 
Journal of the National Cancer Institute, 103(7), 553–561. 
Gatta, G., et al. (2011). Rare cancers are not so rare: The rare cancer burden in 
Europe. European Journal of Cancer, 47(17), 2493-2511. 
Gigli, A., Simonetti, A. and Capocaccia, R., (2004). Validation of complete 
prevalence by age groups. Working Paper IRPPS, 1/2004 
Gigli, A. et al., (2006). Estimating the variance of cancer prevalence from 
population-based registries. Statistical Methods in Medical Research, 
15(3), 235–253. 
Gjerstorff M. L. (2011). The Danish cancer registry. Scandinavian journal of 
public health, 39(7 suppl), 42-45. 
GLOBOCAN, (2008). Estimated cancer Incidence, Mortality, Prevalence and 
Disability-adjusted life years (DALYs) Worldwide in 2008. [Online]. 
Available at: http://globocan.iarc.fr/ [Accessed July 29, 2013] 
Golestan, B. et al., (2009). An estimation of the chronic rejection of kidney 
transplant using an eternal Weibull regression: a historical cohort study. 
Archives of Iranian Medicine, 12(4), 341–346. 
Gras, C., Daurès, J.P. and Tretarre, B., (2006). Three approaches for estimating 
prevalence of cancer with reversibility. Application to colorectal cancer. 
297 
 
In M. Nikulin, D. Commenges, and C. Huber, eds. Probability, Statistics 
and Modelling in Public Health. Springer US, 169–186. [pdf] Available at: 
link.springer.com/content/pdf/10.1007%2F0-387-26023-4_12.pdf 
[Accessed January 4, 2013]. 
Guzzinati, S., et al. (2012). Cancer prevalence in Italy: an analysis of geographic 
variability. Cancer Causes & Control, 23(9), 1497-1510. 
Haberland, J. et al., (2010). German cancer statistics 2004. BMC Cancer, 10, 52. 
Hakama, M. et al., (1975). Incidence, mortality or prevalence as indicators of the 
cancer problem. Cancer, 36(6), 2227–2231. 
Harris, N. L., et al. (2000 a). Lymphoma classification–from controversy to 
consensus: the REAL and WHO Classification of lymphoid neoplasms. 
Annals of Oncology, 11(suppl 1), S3-S10. 
Harris, N.L. et al., (2000 b). The World Health Organization Classification of 
Hematological Malignancies Report of the Clinical Advisory Committee 
Meeting, Airlie House, Virginia, November 1997. Modern Pathology, 
13(2), 193–207. 
Hehlmann, R., Hochhaus, A. and Baccarani, M., (2007). Chronic myeloid 
leukaemia. The Lancet, 370(9584), 342–350. 
Herrmann, C., et al. (2013). Cancer survivors in Switzerland: a rapidly growing 
population to care for. BMC Cancer, 13(1), 287. 
Hewitt, M., Breen, N. and Devesa, S., (1999). Cancer Prevalence and 
Survivorship Issues: Analyses of the 1992 National Health Interview 
Survey. Journal of the National Cancer Institute, 91(17), 1480–1486. 
HMDS, (2011). Haematological Malignancy Diagnostic Service. [Online]. 
Available at: http://www.hmds.info/ [Accessed August 3, 2012]. 
HMRN, (2011). Haematological Malignancy Research Network. [Online]. 
Available at: http://www.hmrn.org/ [Accessed August 3, 2012]. 
298 
 
Hoffbrand, V., Moss, P. and Pettit, J., (2006). Essential Haematology 5th ed., 
Wiley-Blackwell. 
Hoogenveen, R.T. and Gijsen, R., (2000). Dutch DisMod for Several Types of 
Cancer. [pdf]. Rijksinstituut voor Volksgezondheid en Milieu. [pdf] 
Available at: 
https://rivm.openrepository.com/rivm/bitstream/10029/.../260751004.pdf 
[Accessed June 8, 2012]. 
Horning, S. J., and Rosenberg, S. A., (1984). The natural history of initially 
untreated low-grade non-Hodgkin's lymphomas. New England Journal of 
Medicine, 311(23), 1471-1475. 
Howard, M.R. and Hamilton, P.J., (2007). Haematology: An Illustrated Colour 
Text 3rd ed., London: Churchill Livingstone. 
Hughes-Jones, N., Wickramasinghe, S.N. and Hatton, P.C., (2008). Haematology 
8th ed., Wiley-Blackwell. 
IARC, (2012).Cancer Statistics (International Agency for Research on Cancer). 
[Online]. Available at: http://www-dep.iarc.fr/ [Accessed May 21, 2012]. 
IARC, (2013 a). Global initiative for cancer registry development in low- and 
midlle-income countries. [Online]. Available at: 
http://gicr.iarc.fr/en/whatwedo-where.php [Accessed June 8, 2013]. 
IARC, (2013 b). Population pyramid. [Online].  Available at: http://www-
dep.iarc.fr/WHOdb/graph5_sel.asp [Accessed July 2, 2013]. 
Jensen OM. et al, (1991). Cancer registration principles and methods. Lyon: 
Scientific Publication No. 95. 
Krogh, V. and Micheli, A., (1996). Measure of cancer prevalence with a 




Kruijshaar, M.E., Barendregt, J.J. and Hoeymans, N., (2002). The use of models 
in the estimation of disease epidemiology. Bulletin of the World Health 
Organization, 80(8), 622–628. 
Kumar, S.K. et al., (2008). Improved survival in multiple myeloma and the 
impact of novel therapies. Blood, 111(5), 2516–2520. 
Kyle, R. A., et al.,(2010). Monoclonal gammopathy of undetermined significance 
(MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG 
consensus perspectives risk factors for progression and guidelines for 
monitoring and management. Leukemia, 24(6), 1121-1127. 
Landgren, O., et al., (2009). Monoclonal gammopathy of undetermined 
significance (MGUS) consistently precedes multiple myeloma: a 
prospective study. Blood, 113(22), 5412-5417. 
Leon  G. (2008). Epidemiology, 4
th
 Edition. Philadelphia: Sauders Elsevier. 
Levi, F. et al., (2002). Trends in mortality from Hodgkin‘s disease in western and 
eastern Europe. British Journal of Cancer, 87(3), 291–293. 
Lennert K., (1978). Malignant Lymphomas Other Than Hodgkin's Disease. New 
York: Springer-Verlag. 
Lossos, I. S., et al., (2002). Transformation of follicular lymphoma to diffuse 
large-cell lymphoma: alternative patterns with increased or decreased 
expression of c-myc and its regulated genes. Proceedings of the National 
Academy of Sciences, 99(13), 8886-8891. 
Louchini, R. et al., (2006). Trends in cancer prevalence in Quebec. Chronic 
Diseases in Canada, 27(3), 110–119. 
LSHTM, (2012). Tools for Cancer Survival Analysis | London School of Hygiene 
& Tropical Medicine. [Online]. Available at: 
http://www.lshtm.ac.uk/eph/ncde/cancersurvival/tools/ [Accessed 
December 4, 2012]. 
300 
 
Ludwig, H. et al., (2010). Current Multiple Myeloma Treatment Strategies with 
Novel Agents: A European Perspective. The Oncologist, 15(1), 6–25. 
Lutz, J.M. et al., (2003). Cancer prevalence in Central Europe: the 
EUROPREVAL Study. Annals of oncology: official journal of the 
European Society for Medical Oncology / ESMO, 14(2), 313–322. 
Maddams, J., Utley, M., and Møller, H. (2012). Projections of cancer prevalence 
in the United Kingdom, 2010–2040. British Journal of Cancer.107, 1195-
1020 
Marcos-Gragera, R., et al. (2011). Survival of European patients diagnosed with 
lymphoid neoplasms in 2000–2002: results of the HAEMACARE project. 
Haematologica, 96(5), 720-728. 
Mariotto, A. et al., (1999). Cancer prevalence in Italian regions with local cancer 
registries. Tumori, 85(5), 400–407. 
Mariotto, A.B. et al., (2006). Projecting the number of patients with colorectal 
carcinoma by phases of care in the US: 2000-2020. Cancer Causes & 
Control: CCC, 17(10), 1215–1226. 
Mariotto, A. B. et al., (2009). Long-term survivors of childhood cancers in the 
United States. Cancer Epidemiology Biomarkers & Prevention, 18(4), 
1033-1040. 
Mariotto, A. B., et al., (2011). Projections of the cost of cancer care in the United 
States: 2010–2020. Journal of the National Cancer Institute, 103(2), 117-
128. 
Marti, G. E., et al., (2005). Diagnostic criteria for monoclonal B‐cell 
lymphocytosis. British journal of haematology, 130(3), 325-332. 
Marti, G.E., (2009). The changing definition of CLL. Blood, 113(18), 4130–4131. 
Mauer, A.M. and Simone, J.V., (1976). The current status of the treatment of 




Maynadié, M., et al. (2013). Survival of European patients diagnosed with 
myeloid malignancies: a HAEMACARE study. Haematologica, 98(2), 
230-238. 
Mehrabian, A.A. et al., (2010). Gastric Cancer Prevalence, According To Survival 
Data in Iran (National Study-2007). Iranian J Public Health, 39(3), 20–26. 
Merrill, R.M. et al., (2000). Cancer prevalence estimates based on tumour registry 
data in the Surveillance, Epidemiology, and End Results (SEER) Program. 
International Journal of Epidemiology, 29(2), 197–207. 
Micheli, A. et al., (1999). Cancer prevalence in Italian cancer registry areas: the 
ITAPREVAL study. ITAPREVAL Working Group. Tumori, 85(5), 309–
369. 
Micheli , A. et al., (2002 a). Cancer prevalence in European registry areas. Annals 
of Oncology: Official Journal of the European Society for Medical 
Oncology / ESMO, 13(6), 840–865. 
Micheli, et al., (2002 b). Contrasts in cancer prevalence in Connecticut, Iowa, and 
Utah. Cancer, 95(2), 430–439. 
Miguel, JF S, Creixenti, J.B. and Garcia-Sanz, R., (1999). Treatment of multiple 
myeloma. Haematologica, 84(1), 36–58. 
Möller, T., et al., (2003). Cancer prevalence in Northern Europe: the 
EUROPREVAL study. Annals of Oncology: Official Journal of the 
European Society for Medical Oncology / ESMO, 14(6), 946–957. 
Morton L M., et al., (2007). Proposed classification of lymphoid neoplasms for 
epidemiologic research from the Pathology Working Group of the 
International Lymphoma Epidemiology Consortium (InterLymph). Blood, 
110(2): 695-708. 
National Cancer Institute, (2012). SEER*Stat Software. [Online]. Available at: 
http://seer.cancer.gov/seerstat/ [Accessed August 3, 2012]. 
302 
 
National Cancer Intelligence Network and Cancer Research UK, (2009). Cancer 
Incidence and Survival by Major Ethnic Group, England 2002-2006. 
National Cancer Intelligence Network (NCIN), (2010). One, Five and Ten-year 
Cancer Prevalence, National Cancer Intelligence Network. [pdf]. NCIN 
Available at: www.ncin.org.uk/view?rid=76 [Accessed August 2, 2012]. 
NCIN, (2012). National Cancer Intelligence Network. [Online].  Available at: 
http://www.ncin.org.uk/home.aspx [Accessed November 28, 2012]. 
NHS, (2011). Cancer Networks | NCAT. [Online]. Available at: 
http://www.ncat.nhs.uk/what-is-ncat/cancer-networks [Accessed October 
12, 2011]. 
NORDCAN, (2010). NORDCAN. [Online]. Available at: http://www-
dep.iarc.fr/nordcan/English/frame.asp [Accessed October 12, 2011]. 
Office for National Statistics, (2001). Census: Aggregate data. UK Data Service 
Census Support. [Online]. Available at: http://casweb.mimas.ac.uk/  
[Accessed August 3, 2012]. 
Office for National Statistics, (2008). Postcode directories. Office for National 
Statistics. [Online]. Available at: http://www.ons.gov.uk/ons/guide-
method/geography/products/postcode-directories/index.html [Accessed 
August 3, 2012]. 
Office for National Statistics, (2012). Ethnicity and National Identity in England 
and Wales 2011. [Online]. Available at: 
http://www.ons.gov.uk/ons/rel/census/2011-census/key-statistics-for-
local-authorities-in-england-and-wales/rpt-ethnicity.html [Accessed April 
13, 2014]. 
Parker, S. L., et al., (1996). Cancer statistics, 1996. CA: a cancer journal for 
clinicians, 46(1), 5-27 
303 
 
Parkin, D M. et al., (2001). Estimating the world cancer burden: Globocan 2000. 
International Journal of Cancer. Journal International du Cancer, 94(2), 
153–156. 
Parkin, D M., (2006). The evolution of the population-based cancer registry. 
Nature Reviews. Cancer, 6(8), 603–612. 
Pisani, P., Bray, F. and Parkin, D. M., (2002). Estimates of the world-wide 
prevalence of cancer for 25 sites in the adult population. International 
Journal of Cancer, 97(1), 72–81. 
Polednak, A.P., (1997). Estimating the prevalence of cancer in the United States. 
Cancer, 80(1), 136–141. 
Racine, J.S., (2011). A Primer on Regression Splines. [pdf]. Available at: cran.r-
project.org/web/packages/crs/vignettes/spline_primer.pdf. [Accessed May 
8, 2013] 
Rappaport. H., (1966). Tumors of the hematopoietic system. Atlas of Tumor 
Pathology. Vol. Section III. Washington, Washington, DC: Armed Forces 
Institute of Pathology.  
RARECARE, (2013). Surveillance of Rare Cancer in Europe. [Online]. Available 
at: http://www.rarecare.eu/default.asp  [Accessed May 12, 2014]  
Rawstron, A. C., et al., (2008). Monoclonal B-cell lymphocytosis and chronic 
lymphocytic leukemia. New England Journal of Medicine, 359(6), 575-
583. 
Roman, E. and Smith, A., (2011). Epidemiology of lymphomas. Histopathology, 
58(1), 4–14. 
Rosenberg S.A., et al., (1982). National Cancer Institutesponsored study of 
classification of non Hodgkin‘s lymphoma:summary and description of 
Working Formulation for clinicalusage. The non Hodgkin‘s lymphoma 
classification project. Cancer, 49(21), 12–35. 
304 
 
Pui, C. H., Campana, D., & Evans, W. E. (2001). Childhood acute lymphoblastic 
leukaemia–current status and future perspectives. The lancet oncology, 
2(10), 597-607. 
Pui, C. H., & Evans, W. E. (2006). Treatment of acute lymphoblastic leukemia. 
New England Journal of Medicine, 354(2), 166-178. 
Salles, G.A., (2007). Clinical Features, Prognosis and Treatment of Follicular 
Lymphoma. ASH Education Program Book, 2007(1), 216–225. 
Salomon, J. A, Gakidou, E. and Murray, C.J.L., (1999). Methods for modeling the 
HIV/AIDS epidemic in sub-Saharan Africa. [pdf]. Available at: 
www.who.int/healthinfo/paper03.pdf [Accessed May 28, 2012]. 
Salomon, J. A. and Murray, C.J., (2001). Modelling HIV/AIDS epidemics in sub-
Saharan Africa using seroprevalence data from antenatal clinics. Bulletin 
of the World Health Organization, 79(7), pp.596–607. 
Sant, M., et al. (2009). EUROCARE-4. Survival of cancer patients diagnosed in 
1995–1999. Results and commentary. European Journal of Cancer, 45(6), 
931-991. 
Sant, M., et al. (2010). Incidence of hematologic malignancies in Europe by 
morphologic subtype: results of the HAEMACARE project. Blood, 
116(19), 3724-3734. 
Schrijvers, C.T.M. et al., (1994). Validation of Cancer Prevalence Data from a 
Postal Survey by Comparison with Cancer Registry Records. American 
Journal of Epidemiology, 139(4), 408–414. 
SEER, (2012). Surveillance Epidemiology and End Results Program. [Online]. 
Available at: http://www.seer.cancer.gov/ [Accessed November 28, 2012]. 
Sehn, L. H., et al., (2005). Introduction of combined CHOP plus rituximab 
therapy dramatically improved outcome of diffuse large B-cell lymphoma 
in British Columbia. Journal of Clinical Oncology, 23(22), 5027-5033. 
305 
 
Shanafelt, T. D.,et al., (2010). Monoclonal B-cell lymphocytosis (MBL): biology, 
natural history and clinical management. Leukemia, 24(3), 512-520. 
Shi, J., et al.,. (2004). Transformation of myelodysplastic syndromes into acute 
myeloid leukemias. Chinese medical journal, 117(7), 963-967. 
Silva, I., (1999). Cancer Epidemiology: Principles and Methods 2nd Revised 
edition., Lyon: World Health Organization. 
Simonetti, A. et al., (2008). Estimating complete prevalence of cancers diagnosed 
in childhood. Statistics in Medicine, 27(7), 990–1007. 
Skjelbakken, T., Løchen, M.-L. and Dahl, I.M.S., (2002). Haematological 
malignancies in a general population, based on information collected from 
a population study, hospital records, and the Cancer Registry of Norway: 
the Tromsø Study. European Journal of Haematology, 69(2), 67–75. 
Smith, A. et al., (2010). The Haematological Malignancy Research Network 
(HMRN): a new information strategy for population based epidemiology 
and health service research. British Journal of Haematology, 148(5), 739–
753. 
Stenbeck, M., Rosén, M. and Sparén, P., (1999). Causes of increasing cancer 
prevalence in Sweden. Lancet, 354(9184), 1093–1094. 
Swerdlow, A., Silva, I.D.S. and Doll, R., (2001). Cancer Incidence and Mortality 
in England and Wales: Trends and Risk Factors, Oxford: Oxford 
University Press. 
Swerdlow, A.J., (2003). Epidemiology of Hodgkin‘s disease and non-Hodgkin‘s 
lymphoma. European Journal of Nuclear Medicine and Molecular 
Imaging, 30(1), S3–S12. 
Swerdlow, S.H. and Cancer International Agency for Research, (2008). WHO 
Classification of Tumours of Haematopoietic and Lymphoid Tissues: 




Tabata, N. et al., (2008). Partial cancer prevalence in Japan up to 2020: estimates 
based on incidence and survival data from population-based cancer 
registries. Japanese Journal of Clinical Oncology, 38(2), 146–157. 
The Mount Sinai Hospital, (2012). Acute Lymphoblastic Leukemia Information. 
The Mount Sinai Hospital. [Online]. Available at: 
http://www.mountsinai.org/patient-care/health-library/diseases-and-
conditions/acute-lymphoblastic-leukemia [Accessed December 18, 2012]. 
UKACR (2013). United Kingdom Association of Cancer Registries. 
[Online].Available at: http://www.ukacr.org/[Accessed December 20, 
2013]  
Verdecchia, A. et al., (1989). A method for the estimation of chronic disease 
morbidity and trends from mortality data. Statistics in Medicine, 8(2), 
201–216. 
Verdecchia, A et al., (2001). Incidence and prevalence of all cancerous diseases in 
Italy: trends and implications. European Journal of Cancer (Oxford, 
England: 1990), 37(9), 1149–1157. 
Verdecchia, A, De Angelis, G. and Capocaccia, R., (2002). Estimation and 
projections of cancer prevalence from cancer registry data. Statistics in 
Medicine, 21(22), pp.3511–3526. 
Verdecchia, A et al., (2002). A comparative analysis of cancer prevalence in 
cancer registry areas of France, Italy and Spain. Annals of Oncology: 
Official Journal of the European Society for Medical Oncology / ESMO, 
13(7), 1128–1139. 
Verdecchia, A. et al., (2007). Methodology for estimation of cancer incidence, 
survival and prevalence in Italian regions. Tumori, 93(4), 337–344. 
Visser, O., et al. (2012). Incidence, survival and prevalence of myeloid 
malignancies in Europe. European Journal of Cancer. 48, 3257-3266. 
307 
 
Wang, Z. Y., and Chen, Z. (2008). Acute promyelocytic leukemia: from highly 
fatal to highly curable. Blood. 111(5), 2505-2515. 
Wang, A.-H. et al., (2010). Summary of 615 patients of chronic myeloid 
leukaemia in Shanghai from 2001 to 2006. Journal of Experimental & 
Clinical Cancer Research: CR, 29, 20. 
WHO, (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid 
Tissues. Lyon: International Agency for Research on Cancer. 
WHO, (1994). International Statistical Classification of Disease and Related 
Health Problems, ICD -10. Vol. 3, Alphabetical index. Geneva: World 
Health Organization.  
Wiggins, C.L. et al., (2010). Age disparity in the dissemination of imatinib for 
treating chronic myeloid leukemia. The American Journal of 
Medicine, .123(8), 764.e1–9. 
Wobker, S., Yeh, W. and Carpenter, W., (2010). Focus on Survivorship: Refining 
Complete Prevalence Estimates Using Local Cancer Registry Data. 
Cancer Epidemiology Biomarkers & Prevention, 19(3), 897–897. 
Youlden, D., Health, Q.G.-Q. and Baade, P.D., (2005). Cancer Prevelence in 
Queensland 2002. [pdf] Queensland Government - Queensland Health. 
Available at: www.health.qld.gov.au/hic/reports/cancer prev.pdf 
[Accessed June 10, 2012]. 
Zanetti, R. et al., (1999). The prevalence of cancer: a review of the available data. 
Tumori, 85(5), 408–413. 
 
